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Self-assembling and shear-responsive biomaterials possess favorable rheological and viscoelastic 
properties to be injectable and facilitate minimally invasive surgery. The current thesis work 
describes the evaluation of malleable colloidal gel scaffolding technology for the regeneration of 
bone tissue in non-load bearing critical-sized defects. This represents the first attempt to form 
colloids exclusively from biomaterials found in the microenvironment of healing bone fractures 
including hyaluronic acid (HA), hydroxyapatite (HAP), bone and cartilage extracellular matrix 
(ECM). Work in the current thesis evaluated preliminary in vitro and in vivo efficacy of several 
injectable colloids. Specifically, HA-HAP colloids exhibiting desirable rheological, viscoelastic, 
and swelling properties for surgical placement and defect site retention were identified from an 
array of formulations. Subsequent formulation refinement incorporated micronized decellularized 
cartilage (DCC) and demineralized bone matrix (DBM) particles into HA-HAP colloids, which 
did not result in any significant decreases in measured fluid properties. Coupling ECM 
microparticles within a colloidal fluid carrier was hypothesized to enhance the regenerative 
capacity of HA-HAP colloidal formulations. In vitro studies demonstrated evidence of temporal 
chondrogenic, hypertrophic, and osteogenic gene expression in response to changes in colloidal 
composition. More specifically, the inclusion of DCC led to hypertrophic chondrogenesis while 
both HAP and demineralized bone matrix DBM colloidal formulations appeared to direct cell 
lineage down an osteogenic pathway in a temporal manner similar to expression profiles observed 
in native bone fracture healing. In vivo studies demonstrated the feasibility and efficacy of colloidal 
scaffolds in critical-sized rat calvarial defects. Although no significant differences in regenerated 
bone were observed in defects treated with colloidal formulations compared to negative control, 
the presence of endochondral (EC) derived ossification foci were only observed in HA-HAP and 
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HA-HAP-ECM treated defects. Thus, definite advantages of using colloidal gel technology were 
observed in these preliminary studies, but future iterations of the implant formulation design may 
yield enhanced bone tissue regeneration. Ultimately, the idea of colloidal-based tissue implants 
has been taken from concept to practice, produced promising results for the treatment of non-load 
bearing bone defects, and has given rise to numerous areas of tangential research to refine the 
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CHAPTER 1: Introduction to Thesis 
The overall objective of this thesis was to characterize a novel, native biomaterial based 
colloidal gel scaffold with self-assembling and shear-responsive rheological behavior for bone 
tissue regeneration. The overall progression was to first develop malleable colloidal gels to 
facilitate minimally invasive surgical repair, refine colloidal gel formulations to incorporate native 
extracellular matrix (ECM) biomaterials with potential to enhance bone regeneration via 
endochondral (EC) ossification, and finally evaluate preliminary in vitro and in vivo performance. 
Therefore, characterization of the colloidal gel scaffold design incorporated three specific aims: 
(1) synthesize and characterize novel colloidal gels with modulated rheological properties, (2) 
engineer and refine colloidal gels with incorporated native ECM substrates relevant to EC 
ossification, and (3) determine the efficacy of colloidal gel formulations in vitro and in vivo.  
The first aim was designed to evaluate the importance of various rheological properties 
including yield stress, flow-behavior and consistency index as well as swelling and viscoelastic 
properties of glycosaminoglycan (GAG) and hydroxyapatite (HAP) colloidal gel composites for 
minimally invasive surgical delivery. The second aim elucidated the feasibility of incorporating 
native ECM biomaterials, including decellularized cartilage (DCC) and demineralized bone matrix 
(DBM), into refined colloidal gel formulations. This would facilitate the inclusion of both 
physically conductive and chemically inductive signaling moieties for bone regeneration into 
colloidal gel scaffolds. The third and final aim tested the performance of colloidal gels and ECM 
biomaterials in vitro and in rat calvarial defect models. The subsequent chapters reflect 
chronological progression of these aims, which provided essential information that directed later 
phases of the work. The organization of these chapters is as follows:    
2 
 
Chapter 2 gives historical context on the development of non-setting tissue fillers within 
the confines of tissue engineering and regenerative medicine and provides a framework for 
colloidal gel technology to impact and potentially obviate existing scaffolding paradigms in the 
field. This chapter additionally addresses the first aim and provides experimental evidence to 
suggest the use of these colloidal gel formulations in subsequent chapters involving in vitro and in 
vivo designs. Chapter 2 thus introduces the central motif for this thesis: colloidal gels for enhancing 
bone regeneration.           
Chapter 3 addresses the other central motif for this thesis, which is the application of native 
ECM biomaterials to enhance EC ossification in bone regeneration. This chapter highlights the 
key differences that distinguish marginally successful bone tissue engineering strategies, which 
focus on mimicking the composition of late reparative stage ECM in bone fracture repair (i.e. 
‘hard’ or ‘bony’ callus), with underexplored alternatives that focus on developmental engineering 
strategies and mimic the composition of early reparative phase ECM in natural bone repair (i.e., 
‘pro-’ or ‘soft’ callus). Chapter 3 thus provides a framework for subsequent colloidal gel 
refinement, aim 2, with regard to bone regeneration applications.        
Chapter 4 addresses the second aim by discussing subsequent iterations of colloidal gel 
formulations for the purpose of regenerating bone in non-load bearing defects. Initially, the effect 
of GAG polymer molecular weight on rheological performance of colloidal gels was evaluated. In 
addition, chapter 4 builds on engineering principles discussed in chapter 3 by incorporating native 
ECM biomaterials, specifically micronized DCC and DBM, into colloidal formulations and 
evaluating rheological performance. These studies suggested that the initial colloidal formulations 
discussed in chapter 2 could be adjusted and beneficially loaded with native ECM biomaterials 
without compromising rheological performance.           
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Chapter 5 addresses the third aim and final aim by investigating the efficacy of colloidal 
formulations in vitro and in vivo. Studies combined colloidal gels with isolated rat bone 
mesenchymal stem cells (rBMSCs) for up to 3 weeks. Preliminary cell viability and gene 
expression results suggested that the incorporation of DCC may be beneficial for eliciting EC 
ossification in tissue engineered constructs. Several pilot in vivo studies in 8-mm rat calvarial 
defect models were conducted to further investigate bone regenerative capacity of colloidal gel 
formulations. Micro computed tomography (MicroCT), histology, and gross anatomy of implants 
were evaluated 8 weeks following surgical placement. These studies suggested that the native 
ECM colloidal formulations discussed in chapter 4 could be retained in the defect space over the 
span of the study and more importantly could elicit bone regeneration in the defect space. Evidence 
of EC ossification foci were observed in animals treated with colloidal gels, but minimal 
differences in the extent of ossification were observed between treated animals and negative sham 
control. Future studies will aim to reformulate colloidal gels to improve retention of implant 
material and enhance bone regeneration in the defect space.   
 Chapter 6 addresses concluding remarks for this thesis. It provides a summary of key 
internal findings along with global perspective on the impact of colloidal gels in the field of bone 
tissue engineering and regenerative medicine. Recommendations for worthwhile future 
experimental directions are discussed, which attempt to address limitations in current colloidal gel 
designs. 
 Overall, the work conducted within this thesis proposes potential solutions for treating 
irregularly shaped, critical-sized bone defects. Current technologies in the non-setting bone paste 
market may inadequately meet the needs of minimally invasive surgery, which include limited 
injectability due to high viscosity and poor wound site retention due to poor viscoelastic recovery 
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following shear. Furthermore, current bone regeneration products focus primarily on mimicking 
the complex composition and signals present in late reparative stage fracture healing environment, 
or bony callus, which may be obviated by tissue engineered constructs that alternatively mimic the 
procallus ECM and native bone healing process.  
Autologous bone grafting (ABG) remains the gold standard of treatment for bone 
regeneration in critical size defects due to its inherent osteoconductive, osteoinductive, and 
osteogenic capabilities; however, concerns remain regarding donor site pain and morbidity, 
increased risk of infection, and graft resorption.1-3 Substantial efforts with synthetic (e.g. Ostim®; 
Heraeus Kulzer)4 and allograft (e.g. DBX®; MTF-Synthes)5 biomaterial products have attempted 
to replace ABG technology, yet they still rely on direct intramembranous (IM) ossification, which 
may limit bone regenerative capacity in critical-sized, avascular bone defects compared to the EC 
ossification pathway. The advantages of the colloidal gel technology proposed within this thesis 
center on improving delivery and retention of non-setting bone pastes while simultaneously 
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Malleable biomaterials such as Herschel-Bulkley (H-B) fluids possess shear responsive 
rheological properties and are capable of self-assembly and viscoelastic recovery following 
mechanical disruption (e.g., surgical placement via injection or spreading). This study 
demonstrated that the addition of moderate molecular weight glycosaminoglycans (GAGs) such 
as chondroitin sulfate (CS) (Mw = 15-30 kDa) and hyaluronic acid (HA) (Mw = 20-41 kDa) can be 
used to modify several rheological properties including consistency index (K), flow-behavior 
index (n), and Yield Stress (τy) of sub-micron hydroxyapatite (HAP) particle (Davg ≤ 200 nm) 
colloidal gels. GAG-HAP colloidal mixtures exhibited substantial polymer-particle synergism, 
likely due to ‘bridging’ flocculation, which led to a synergistic increase in consistency index 
(KGAG-HAP ≥ KGAG + KHAP) without compromising shear-thinning behavior (n < 1) of the gel. In 
addition, GAG-HAP colloids containing high concentrations of HAP (60-80% w/v) exhibited 
substantial yield stress (τy ≥ 100 Pa) and viscoelastic recovery properties (G′recovery ≥ 64%). While 
rheological differences were observed between CS-HAP and HA-HAP colloidal gels, both CS and 
HA represent feasible options for future studies involving bone defect filling. Overall, this study 
identified mixture regions where rheological properties in CS-HAP and HA-HAP colloidal gels 
aligned with desired properties to facilitate surgical placement in non-load bearing tissue filling 





Developing malleable biomaterials for filling tissue defects is desirable for minimally invasive 
surgical repair and potential regeneration of bone defects.6-8 Minimally invasive surgery reduces 
the risk of infection and scar formation while also decreasing patient discomfort and cost of 
treatment.6-9 Malleable biomaterials with shear responsive rheological properties, such as 
Herschel-Bulkley (H-B) fluids which possess favorable yield stress and shear-thinning behavior, 
may be injected or extruded to fill irregular shaped bone defects. It may also be necessary for these 
materials to have sufficient viscoelastic recovery kinetics following placement to ensure retention 
at the defect site. An ideal H-B fluid biomaterial candidate would facilitate surgical placement and 
site retention with desirable shear responsive properties and viscoelastic properties, respectively.      
Many injectable scaffolds exhibit thickening or stiffening after placement via in situ chemical 
crosslinking in the presence of water, heat, light, or other stimuli; however, concerns exist where 
unreacted reagents or catalysts may persist and impose localized cytotoxicity or adversely affect 
encapsulated biomolecules.8, 10, 11 Alternatively, self-assembling biomaterials that rely on physical 
crosslinking may yield or flow in response to variation in external shear stress (i.e., extrusion or 
spreading) during placement.8, 12 Upon removal of shear (i.e., after placement), such materials 
could potentially recover in situ, thus providing local structure and delivery of biological cues in 
non-load bearing tissue sites. 
Colloids are a promising candidate for this application. The cohesive strength of these 
materials is dependent on electrostatic forces, van der Waals attraction, and steric hindrance. These 
forces in combination directly influence the macroscopic material properties.8, 10-12 Of particular 
interest is the colloidal sol-gel transition, which is distinguished by a shift from dispersed solid 
particles at low concentrations to the formation of sample-spanning networks of particle 
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flocculations at higher solid concentrations.13-15 On the macroscopic level, this transition is marked 
by an appreciable increase in the material yield stress and viscosity.13-15 Previous investigations 
have explored leveraging these interactions in oppositely charged poly(lactic-co-glycolic) acid 
nanoparticles10, 11, gelatin nanoparticles16, and dextran microparticles17, 18 to form cohesive 
colloidal gels capable of delivering a variety of therapeutic osteogenic proteins for bone tissue 
engineering. More recently, nanoparticle gelatin colloidal gels were shown to outperform 
microparticle gelatin gels with regard to malleability during injection and as drug delivery vehicles 
in vitro and in vivo.19, 20 The current study aims to expand upon previous work leveraging 
nanoparticle colloidal interactions by using biomolecules found in native human bone including 
hydroxyapatite (HAP) and glycosaminoglycans (GAGs).  
HAP [Ca10(PO4)6(OH)2] is a well-studied calcium orthophosphate bone substitute material 
similar to the mineral component of mammalian bones and is commonly referred to as ‘biological 
apatite.’21, 22 HAP has been studied extensively in bone regeneration, and results indicate HAP 
nanoparticles (e.g., Ostim® and Nanostim®) can be delivered as highly concentrated colloidal 
pastes in injectable bone filler applications.4, 13, 14, 21-26 Phase separation has been observed in some 
HAP nanoparticle suspensions, leading to poor injectability or ‘filter-pressing’4, 27 and poor 
retention at the defect site28 resulting in limited tissue regeneration. Such limitations could be 
improved by incorporating large biomolecular polymers into the suspending fluid phase.12, 26, 29-36 
Polymer solutions exhibit a significant increase in viscosity with concentration due to increased 
entanglements or associations between polymer chains in the solution.37-40 Additionally, 
polyelectrolytes (i.e., charged polymers) may be leveraged in a charged colloidal system to 
improve particle-polymer interactions to induce cohesiveness in the colloidal gel.41 
Naturally occurring polymeric GAGs such as hyaluronic acid (HA) and chondroitin sulfate 
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(CS) are found in extracellular matrix, cartilage, and skin. These GAGs exhibit desirable 
physicochemical properties as scaffolds in tissue engineering.32, 38-40, 42, 43 HA is a linear, high-
molar-mass polysaccharide composed of alternating (14)-β linked D-glucuronic acid and 
(13)-β linked N-acetyl-D-glucosamine residues. CS differs only in the N-acetyl-D-glucosamine 
residue, which is sulfonated at either the 4 or 6 carbon site.39, 40, 43, 44 Due to repeating carboxyl or 
sulfonate moieties along the backbone, HA and CS occur as anionic macromolecules in aqueous 
environments at extracellular pH.39, 40, 43, 44 As a result, these highly charged macromolecules 
possess desirable shear-thinning and viscoelastic properties37-39, 42, 43 and have primarily been used 
as inert carrier fluids in bone tissue engineering applications.5 Emerging efforts, however, aim to 
elicit ‘bridging’ connections within colloidal gels by using particles to act as anchoring points 
between multivalent, adsorbing polymers.12, 26, 29-31, 33-35, 41, 45, 46  
In this study, polyanionic GAG polymers were combined with HAP nanoparticles in various 
concentrations and weight ratios to create cohesive ‘bridging’ colloidal gels as potential scaffolds 
for bone tissue regeneration in irregular bone defects. This study represents the first attempt to 
exclusively combine native tissue components in a particle-polymer colloidal gel mixture with the 
goal of creating H-B fluids. More specifically, this study aims to elucidate the relationship between 
bulk rheological properties as a function of relative HAP nanoparticle and GAG biopolymer 
content. The primary goal of this assessment is to identify GAG-HAP colloidal gel candidates with 
appropriate yield stress, consistency, flow behavior and recovery properties to explore surgical 







Hydroxyapatite was purchased as a powder (Davg ≤ 200 nm (BET Analysis); Sigma-Aldrich).  
Chondroitin sulfate A from bovine trachea (Mw =15-30 kDa) (Sigma Aldrich; St. Louis, MO) and 
hyaluronic acid (Mw =20-41 kDa) (Lifecore Biomedical; Chaska, MN) were purchased as sodium 
salts.  
2.2. Characterization of HAP Nanoparticles 
Size, morphology, and elemental distribution analysis of HAP was observed using a 
combination of transmission and scanning electron microscopy (TEM and SEM) and  energy 
dispersive x-ray spectrometry (EDS) (FEI Tecnai F20 XT Field Emission TEM-EDS and Carl 
Zeiss Leo 1550 Field Emission Scanning). Additional sizing and zeta-potential measurements of 
HAP were conducted using dynamic light scattering (Brookhaven; ZetaPALS).   
Fourier transform infrared (FTIR) spectroscopy (PerkinElmer; Frontier FTIR) was used to 
confirm chemical identity. HAP samples were press formed into a thin disk with KBr crystals. The 
spectrum was collected in the 4000-400 cm-1 range with an average of 256 scans.   
Crystallographic structural analysis of the sample was determined using X-ray diffraction 
(XRD) method (Bruker; D8 Advance). Monochromatic CuKα radiation (λ = 0.15406 nm) was used 
over the 2θ range of 20-45° at a step size of 0.014° per 0.5 s. XRD data was compared with built-
in Bruker software utilizing standard International Center for Diffraction Data (ICDD) for HAP. 
21, 22 
2.3. Preparation of Colloidal Gels 
HA or CS powders were combined with HAP nanoparticles and dispersed in PBS solution (pH 
= 7.4, 150 mM NaCl). CS and HA concentrations in the mixtures were varied between 0-80% 
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(w/v) and 0-40% (w/v), respectively. GAG:HAP weight ratio (w:w) was controlled by the 
incremental addition of HAP particles to GAG solutions at ratios of 2, 1, 0.5, 0.25, and 0.125. 
These mixtures were compared to pure component controls (GAG and HAP), respectively. Overall 
volume fraction of HAP (Φ = VHAP/VMixture) was calculated from particle density and resulting 
mixture volume measurements. Homogeneous colloid mixtures were prepared by manual stirring 
(5 min) at ambient conditions and stored at 4°C. Samples were allowed to equilibrate to ambient 
conditions (2 hr) before testing.    
2.4. Swelling Characterization 
Relative swelling ratios (S) of CS-HAP and HA-HAP colloidal gels were determined by 
placing 1.0 mL of PBS (pH = 7.4, 150 mM NaCl) on top of 0.5 mL of material contained in a 2 
mL Eppendorf tube. Tubes were then constantly agitated (24 hr, 100 rpm, 37°C) in an incubator 
shaker (New Brunswick Scientific; Excella E24). Swelling ratio (S = (M(swollen)-M(before))/M(before)) 
was determined from the initial (M(before)) and final (M(swollen)) mass of the material as described by 
Holland et al.47 The final weight was determined by removing excess PBS from tube and drying 
the surface of gel with evaporative paper.   
2.5. Rheological Characterization 
The rheological properties of the colloidal gels were characterized using a controlled stress 
rheometer (TA Instrument; AR2000). All measurements were performed using a stainless steel 
plate geometry (20 mm diameter) at a gap distance of 500 µm. The shear stress profile of the 
colloidal gels was determined using a stepped flow test (1 min/step) with an increasing shear rate 
(1-1000 s-1). All samples were tested at 37°C.     
Recovery kinetics following temporary disruption of the colloidal gel network were 
determined by measuring viscoelastic properties as described by Ozbas et al.48 Initially, an 
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oscillatory stress sweep (1-1000 Pa) was performed at a constant frequency (1 Hz) to determine 
the linear viscoelastic (LVE) region. Subsequently, the gel viscoelastic properties including 
storage modulus (G′), loss modulus (G″), and loss angle (δ) were determined in a three phase 
oscillatory time sweep at 37°C following pre-shear (1 min, 100 s-1) and equilibration (5 min). Gels 
were oscillated (5 min, low stress in LVE regime, 1 Hz) before and after an intense disruption 
phase (30 s, 1000 Pa, 1 Hz). 
2.6. Rheological Modeling 
Rheological flow property estimations were determined with a three-parameter fit to the H-B 
fluid model (Equation 1): 
𝜏 = 𝜏𝑦 + 𝐾?̇?
𝑛  (Eq. 1) 
where τ was the measured shear stress [Pa] in the sample resulting from the fluid’s yield stress, τy 
[Pa], consistency index, K [Pa•sn], and flow behavior index, n [unitless], at a given shear rate, ?̇? [s-
1]. Optimal fit was determined using curve fitting tool software in MATLAB (The Mathworks, 
Inc.) with a non-linear least squares method. Some GAG-HAP mixtures exhibited localized shear 
banding at low shear rates (< 10 s-1) as described by Möller et al.49 As a result, data points below 
the critical shear rate, determined from the point of minimum shear stress in the sample, were 
excluded from H-B modeling. 95% confidence intervals were reported from triplicate 
measurements for all three parameters in each tested colloidal mixture along with the overall root-
mean-squared error (RMSE) of the fit.  
2.7. Statistical Analysis 
All measurements were performed in triplicate (n = 3) and depicted as average ± standard 
deviation (SD) unless stated otherwise. Statistical analyses of data were performed using one-way 
analysis of variance (ANOVA) and Tukey’s HSD was used post-hoc to compare differences 
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between individual groups. A p-value (p < 0.05) was accepted as statistically significant.  
      
3. RESULTS 
3.1. Characterization of HAP Nanoparticles 
TEM-EDS analysis of HAP (Figure 2.1) revealed spherical particle morphology with 
polydisperse diameters near the supplier’s specified value (Davg ≤ 200 nm (BET); Sigma-Aldrich); 
however, a small fraction of particles were visually observed to exceed this specification. SEM 
analysis of HAP, CS-HAP, and HA-HAP (Figure 2.2A-C) likewise revealed spherical HAP 
particle morphology. Colloidal aggregation was also observed with SEM. However, negligible 
aggregation differences were observed between groups most likely due to the dehydrated state of 
the sample. Contrary to the supplier’s elemental purity analysis (≥ 97% HAP (wt %) (XRF Assay); 
Sigma-Aldrich), elemental distribution analysis (EDS) indicated the presence of calcium deficient 
HAP (Figure 2.3). Atomic composition of HAP samples were (Average atomic % ± SD) Ca (24.58 
± 0.20 %), P (15.91 ± 0.15 %), and O (59.49 ± 0.30 %), yielding a Ca/P ratio of 1.54. Pure 
stoichiometric HAP yields a Ca/P ratio of 1.67, while CDHA has a Ca/P ratio around 1.50-1.67.22 
CDHA has been studied extensively in bone tissue regeneration due to its similar stoichiometry to 
that of ‘biological apatite’.4, 50-52  
Dynamic light scattering was used to measure HAP particle size (nm) and zeta potential (mV) 
(average ± SD; n = 10). Dilute suspensions (0.167 mg/mL) of pure HAP particles where combined 
with either HA or CS in GAG:HAP weight ratios of 1:1 or 10:1, and the changes in size and zeta 
potential were observed (Table 2.1). Only the 10:1 ratio of CS:HAP resulted in a significant 
increase in particle size (p < 0.05) compared to the pure HAP. The inclusion of CS or HA at both 
weight ratios resulted in a significant increase in HAP zeta potential (p < 0.01) compared to the 
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pure HAP suspensions.     
FTIR spectra (Figure 2.4) of HAP revealed the presence of expected bonds in the crystal. 
Strong modes for stretching (1035 cm-1) and bending (564, 604 cm=1) indicated the presence of 
PO4
3-.53, 54 Characteristic stretching (3572 cm-1) of the –OH group was also observed.53, 54 
Additionally, some bands indicating the weak presence of adsorbed water (1635 and 3000-3700 
cm-1) were observed.53, 54       
The XRD pattern (Figure 2.5) revealed expected HAP diffraction peaks at 2θ regions of 26°, 
29°, 32-34°, 40°, and 46-54°, indicating the crystalline nature of the HAP particles when compared 
with the International Center for Diffraction Data (ICDD) for HAP.53, 54  
3.2. Swelling Characterization 
Relative swelling of CS-HAP (Figure 2.6A) and HA-HAP (Figure 2.6B) gels increased with a 
clear dependence on HAP Φ. While sedimentation and swelling tolerances were initially set (-20% 
≤ S ≤ 20%) in an attempt to identify suitable GAG-HAP candidates for retention of material at a 
bone defect surgical site, the most desirable colloidal mixtures exhibited the least amount of 
swelling or sedimentation (S ≈ 0%). Excessive sedimentation (S ≤ -20%) occurred in pure HAP 
mixtures below Φ = 0.25. The addition of CS or HA resulted in increased swelling at a given HAP 
Φ. Furthermore, swelling also exhibited dependence on GAG:HAP ratio (w:w), where mixtures 
with GAG in excess tended to show increased swelling, and mixtures with HAP in excess tended 
to demonstrate swelling behavior of pure HAP. As a result, excessive sedimentation only occurred 
below HAP Φ = 0.12 and Φ = 0.06 for CS-HAP and HA-HAP colloidal mixtures, respectively. 
Excessive swelling (S ≥ +20%) occurred in mixtures containing GAG:HAP ratios in equivalence 
or in GAG excess ([1:1] and [2:1]) above Φ = 0.18. The only mixtures exhibiting excessive 
swelling and favoring HAP content were [1:2] GAG:HAP colloids with HAP concentrations above 
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Φ = 0.37.   
3.3.Rheological Characterization 
3.3.1. Consistency Index 
Measuring shear stress in response to increasing external shear rate yielded flow behavior 
properties which were estimated from a three-parameter H-B Fluid model. An extensive array of 
CS-HAP (Table 2.2) and HA-HAP (Table 2.3) mixtures were tested and compared to pure HAP 
colloids (Table 2.4). Consistency index (K [Pa•sn]) in CS-HAP and HA-HAP gels increased 
exponentially with increasing GAG content (% w/v) and increasing HAP content (% w/v) in the 
mixture, respectively. In addition, GAG-HAP mixtures containing HA had higher K values than 
respective CS mixtures. Plotting K values versus HAP Φ (Figure 2.7A and Figure 2.7B) for 
constant GAG:HAP weight ratios (w:w) yielded a noticeable shift in K values from predominantly 
GAG-like behavior when in polymer excess to HAP-like behavior when in particle excess.        
All tested mixtures, except those exhibiting high yield stress (τy > 500 Pa), exhibited higher K 
values than the addition (KGAG-HAP ≥ KGAG + KHAP) of their respective pure GAG and HAP 
components. Examples of this synergistic K value behavior are seen in shear stress versus shear 
rate plots (Figure 2.8A and Figure 2.8B), where the mixtures of 15% CS – 60% HAP and 15% HA 
– 60% HAP (% w/v) exhibited higher K values than predicted by the summation of their respective 
pure GAG 15% and pure HAP 60% components. Mixtures exhibiting high yield stress (τy ≥ 500 
Pa) were the exception to this trend, where estimated K values were smaller than the addition of 
respective pure components. This likely reflects possible limitations attributed to how the H-B 
constitutive relationship captures τy and K behavior for some GAG-HAP mixtures. At high HAP 
concentrations, the increased apparent viscosity of the material is modeled more by an increase in 
τy and not captured by K (Table 2.2 and Table 2.3). 
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3.3.2. Flow Behavior Index 
Flow behavior index (n [unitless]) of the pure aqueous PBS media was indicative of a 
Newtonian fluid (n = 0.95 ± 0.18). In CS-HAP (Figure 2.7C) and HA-HAP (Figure 2.7D) mixtures, 
n values decreased from unity with the addition of HAP and GAG content, an indication of shear-
thinning behavior (n < 1) in the gels. Further evidence of this was seen in plots containing n values 
versus HAP volume fraction (Φ) (Figure 2.7C and Figure 2.7D) for constant GAG:HAP weight 
ratios (w:w). There was no conclusive evidence to support shear-thinning dependence on the 
concentration of GAG or GAG:HAP ratio in colloidal mixtures.     
Examples elucidating the extent of shear-thinning over the range of shear rates tested (1-1000s-
1) was observed in log-log plots of viscosity versus shear rate for 15% CS – 60% HAP and 15% 
HA – 60% HAP (Figure 2.4C and Figure 2.4D), respectively. While apparent viscosity was nearly 
independent of ?̇? in pure GAG solutions such that n values were near unity (n ≈ 1), GAG-HAP 
colloidal mixture viscosities decreased at least an order of magnitude over the tested shear rate 
range. These GAG-HAP mixtures exhibited high viscosities (µ > 100 Pa•s) at lower shear rates 
and relatively low viscosities (µ < 10 Pa•s) at higher shear rates.   
3.3.3. Yield Stress 
Yield stress (τy [Pa]) estimation from rheological data appeared to only be dependent on HAP 
particle concentration (Figure 2.7E and Figure 2.7F), and an exponential increase in τy was seen 
across the entire range of tested HAP concentrations, 0%-80% (w/v) or 0.00 ≤ Φ ≤ 0.49. For some 
GAG-HAP mixtures H-B fluid modeling resulted in large confidence intervals and negative τy 
values (Table 2.2 and Table 2.3). This likely reflects possible limitations attributed to how the H-
B constitutive relationship captures τy and K behavior for some GAG-HAP mixtures, favoring an 
increase in τy instead of K at high HAP concentrations. Fluids with negative yield values were 
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interpreted to possess no yield. Colloidal mixtures exhibited appreciable τy (≥ 10 Pa) only at the 
highest HAP concentrations 60-80% (w/v), which translated to a volume fraction of Φ = 0.37-
0.49. CS-HAP colloidal mixtures exhibited yield stress across all tested CS concentrations, while 
HA-HAP mixtures only exhibited τy below 20% HA (w/v).  
3.3.4. Rheological and Swelling Summary 
Tested CS-HAP (Figure 2.9A) and HA-HAP (Figure 2.9B) colloidal mixtures were mapped on 
ternary diagrams (weight %). Based off of both swelling (S) and rheological properties (τy, K, and 
n) exhibited by each tested mixture, regions of desirable properties for facilitating surgical delivery 
were identified. Explicitly, a desirable mixture contained swelling or sedimentation within 
tolerance (-20% ≤ S ≤ +20%), identifiable yield stress (τy ≥ 100 Pa), and shear responsive flow 
properties (n < 1). From these criteria, 15% GAG – 60% HAP mixtures were selected due to 
overlapping regions of desirable swelling and flow properties between CS and HA colloidal gels 
(Figure 2.6).  
3.3.5. Viscoelastic Recovery 
Selected colloidal gels were initially subjected to an oscillatory shear stress sweep (1-1000 Pa) at 
a constant frequency (1 Hz) to determine the linear viscoelastic (LVE) regime of the fluid. This 
was determined to be less than 100 Pa for all mixtures. Subsequent viscoelastic time sweeps were 
therefore conducted at an oscillatory shear stress selected to be sufficiently within the LVE regime 
for all samples (10-25 Pa). Viscoelastic properties including storage modulus (G′), loss modulus 
(G″), and phase angle (δ) of GAG-HAP mixtures were measured before, during, and after an 
intense temporary disruption period, which involved a large increase in external oscillatory shear 
stress on the material. 
Based on previous swelling and flow behavior results, 15% GAG – 60% HAP mixtures 
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were selected as desirable candidates for viscoelastic recovery studies (Figure 2.10A and Figure 
2.10B) and then compared to their respective pure components at the same concentration. 
Recovery was assessed 5 minutes after disruption and expressed as a percentage (G′recovery = 
G′(Final)/G′(Initial) •100%) compared to initial G′ in the mixture. Both the CS-HAP and HA-HAP 
mixtures recovered a large portion of their initial viscoelastic behavior within the brief recovery 
period, 64% and 85% respectively. HA-HAP appeared to recover its initial G′ within seconds of 
disruption while the CS-HAP mixture and pure HAP took several minutes. This may favor HA-
HAP mixtures in a surgical application, since rapid self-assembly may improve retention in the 
tissue defect site. Pure HAP recovered a higher percentage, 92%, and pure CS and pure HA both 
recovered 100% of their initial viscoelastic properties almost instantaneously following disruption. 
Furthermore, G′, G″ and δ values measured from GAG-HAP mixtures appeared to exhibit 
intermediate values between pure GAG and pure HAP components. Pure GAG exhibited primarily 
viscous behavior and pure HAP exhibited predominately elastic behavior during periods of low 
oscillatory stress. CS-HAP, HA-HAP, and pure HAP displayed primarily elastic behavior (δ ≤ 14°) 
during the initial low oscillatory stress phase, transitioned to predominately viscous behavior 
during the temporary disruption phase (δ ≥ 84°), and rapidly (< 5 min) returned to primarily elastic 
behavior (δ ≤ 16°) while recovering from disruption at low oscillatory stress (Figure 2.10C and 
Figure 2.10D). HA-HAP exhibited larger G′ and G″ values than CS-HAP at the given GAG-HAP 
ratio.    
 
4. DISCUSSION  
Colloidal sols are suspensions of submicron particles undergoing Brownian motion.8, 12 
Stabilization of these sols relies on the balance of particle-particle interactions such as electrostatic 
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forces, Van der Waals attraction, and steric hindrance.8, 10-12 Stable HAP sols have been created 
with the use of adsorbed polyelectrolytes that act as dispersing agents by forming steric barriers 
around particles.55  However, these stable HAP sols generally possess a small consistency index 
and lack yield stress, which limit their application as bone tissue fillers.  
Destabilized colloidal sols exhibit widespread flocculation across the colloidal mixture. 
When concentrations of particles are high enough, sample-spanning networks of flocculated 
particles are formed creating a colloidal gel.13, 56 In this study, pure HAP particles with spherical 
morphology and sub-micron diameter suspended in PBS media formed destabilized flocculations 
above 40% w/v as evidenced by significant sedimentation (S ≤ -20%) over 24 hrs (Figure 2.6A 
and Figure 2.6B). Inclusion of polyelectrolytes can also induce substantial destabilization in 
colloids, where non-adsorbing polymers can induce depletion flocculation57-59 and adsorbing 
polymers can induce flocculation by bridging.57, 60, 61 In the latter case, particles act as cross-linkers 
between polymer molecules or vice versa. CS and HA contain repeat carboxylic acid moieties 
similar to polyacrylic acid and were hypothesized in this study to adsorb to the surface of the HAP 
particles via a similar mechanism.55, 56 The inclusion of either CS or HA at dilute HAP 
concentrations significantly increased overall zeta potential of HAP particles (Table 2.1), 
supporting the hypothesis that CS and HA adsorb to the particle surface. Although GAGs act to 
increase electrostatic stability at dilute concentrations, it is hypothesized that at high 
concentrations, similar to those tested in rheological experiments, bridging flocculation occurs due 
to multivalent GAG polymers adsorbing simultaneously to multiple HAP particles in close 
proximity.  
The formation of sample spanning networks was observed macroscopically in swelling 
studies with the addition of CS and HA to suspensions of HAP, and the onset of these networks 
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appeared at lower total HAP Φ compared to pure HAP suspensions (Figure 2.6A and Figure 2.6B). 
Swelling of the GAG-HAP mixtures were dependent on absolute GAG and HAP concentrations 
as well as relative GAG:HAP ratio, where mixtures favoring GAG content exhibited higher 
swelling compared to mixtures with HAP in excess. High concentrations of CS and HA exhibited 
undesirable swelling (S ≥ 20%), which may have been due to sodium salt associated with GAGs 
causing an osmotic pressure difference between the mixture and swelling media. The most 
desirable colloidal mixtures exhibited the least amount of swelling or sedimentation (S ≈ 0%), and 
were identified as suitable GAG-HAP candidates for enhancing retention of material at a tissue 
defect surgical site (Figure 2.9). This occurred only in mixtures containing both high 
concentrations of HAP (Φ ≥ 0.36) and GAG:HAP ratios favoring HAP ([1:4] and [1:8]).      
More importantly, this study aimed to associate colloidal microstructure dynamics with 
observed synergistic rheological properties including τy, K, n, and G′recovery. Critical boundaries of 
GAG-HAP colloidal mixtures were mapped with regard to potential tissue defect filling (Figure 
2.9). Presence of τy was desired to improve chances of retention at a bone defect wound site, and 
therefore, a lack of τy (e.g., a liquid or phase-separated suspension) was considered the minimum 
fail point in colloidal mixtures. Although a maximum τy limit was not defined, it was observed that 
mixtures containing more than 80% (w/v) HAP particles failed to reconstitute completely in PBS 
media. Therefore, this practical limit served as the basis for defining a maximum obtainable τy. 
Yield appeared to only be dependent on HAP (Figure 2.7E and Figure 2.7F) within the tested 
concentration range, 0 ≤ Φ ≤ 0.49 (v/v). Furthermore, τy increased exponentially with increasing 
HAP Φ, where appreciable τy (> 10 Pa) was observed only at the highest HAP concentrations 60-
80% (w/v) or Φ = 0.37-0.49, respectively. This observed transition corresponded with computer 
simulations and experiments on monodisperse colloidal hard-spheres.57, 62 Below Φ < 0.49 
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suspensions were reported to be disordered fluids exhibiting random local order; however, these 
networks can be sample-spanning and exhibit small amounts of τy.
57, 62 Above Φ > 0.49, 
suspensions became a mixture of colloidal fluid and colloidal crystals, where particles began 
ordering in macrocrystalline structure of either face-centered cubic or hexagonally close packed 
orientation.57, 62 CS-HAP colloidal mixtures exhibited appreciable τy across all tested CS 
concentrations, but HA-HAP mixtures above 20% HA (w/v) possessed no yield regardless of HAP 
concentration. Since τy in these GAG-HAP mixtures was solely the result of HAP particle 
flocculation, the observed τy differences between CS and HA colloidal gels may have been caused 
by differences in the ability of the two GAGs to sterically hinder particle flocculation.   
In addition to τy, GAG-HAP colloidal mixtures also exhibited significant viscosity changes 
over the range of shear rates tested (1-1000 s-1), and were described by K and n in H-B fluid 
models.  K and n behavior in high solid content HAP particle gels has been described previously13, 
15, 55, 56 and were in agreement with tested pure HAP colloids. As particle concentrations become 
large enough to form sample-spanning flocculation networks, K undergoes a rapid increase due to 
the significant increase in attractive particle interactions.13, 15, 55, 56 Likewise, the K and n behavior 
of pure HA solutions at various molecular weights and concentrations have been observed37, 38, 42 
and appeared to be in agreement with pure HA solutions tested here. As polymer concentrations 
became larger, K values in the solution increased exponentially (Figure 2.7A and Figure 2.7B). 
Previous work has attributed this exponential increase in polymer consistency to increased 
amounts of intermolecular entanglements.37, 38, 42  
GAG-HAP mixtures tested here exhibited a synergistic increase in K compared to 
respective pure GAG and pure HAP components (Figure 2.7A and Figure 2.7B), and this increase 
was seen clearly in the shear stress versus shear rate profiles for GAG 15% - HAP 60% colloidal 
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gels (Figure 2.8A and Figure 2.8B). The nature of this observed synergistic increase was most 
likely due to the GAG polymer chains inducing bridging flocculation between HAP particles.8, 12, 
31, 33, 57, 60, 61, 63 Furthermore, the differences in K values exhibited by CS-HAP and HA-HAP gels 
were most likely a result of inherent K value differences in the respective GAG polymers combined 
with the nature of the particle flocculation induced by the addition of GAG polymer.8, 12, 31, 33, 57, 63  
Meanwhile, shear-thinning (n < 1) in colloidal gels occurs when the applied shear rate is 
high enough to disrupt the particle-particle spacing away from equilibrium.57 Pure HAP and pure 
GAG mixtures exhibited shear-thinning behavior within the tested shear rate range (1-1000 s-s) 
which was concentration dependent (Figure 2.7C and Figure 2.7D). The addition of HAP into 
GAG-HAP mixtures enhanced shear-thinning behavior compared to pure GAG mixtures. Previous 
work with polymer-particle composites has also shown enhanced shear-thinning in these materials 
because shear rates experienced locally by a polymer confined between particles can be much 
larger than the overall external shear rate.57 
Specific tolerance values for K and n were not pre-defined with regards to surgical 
application; however, these properties were shown to be highly tunable with respect to GAG and 
HAP concentrations. In general, higher consistency values were considered favorable since they 
coincided with enhanced shear responsive behavior including enhanced shear-thinning (n < 1) and 
viscoelastic recovery. Flow behavior results indicated a mutually beneficial relationship between 
K and n, where K values increased exponentially while shear-thinning behavior was enhanced with 
respective increase in GAG or HAP concentration. Additionally, it was shown that K was highly 
dependent on the polymer-particle ratio (w:w) in the GAG-HAP mixtures (Figure 2.7A and Figure 
2.7B). At high ratios where GAG was in excess, mixture properties were dominated by the polymer 
component. Likewise, at low ratios where HAP was in excess, mixture properties reflected those 
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of pure HAP particles. Overall, flow experiments revealed that GAG-HAP colloidal mixtures 
could be tuned to exhibit large and synergistic K values without compromising shear-thinning 
behavior, a result that proves promising for surgical delivery purposes.       
While the aforementioned rheological flow properties defined colloidal mixture behavior 
during shear induced disruption (Figure 2.11; Phase 1  2), oscillatory shear experiments 
attempted to elucidate GAG-HAP rheological recovery behavior following disruptive shear 
conditions. In these experiments, the colloidal mixture was allowed to recover initial viscoelastic 
properties following temporary microstructure breakdown (Figure 2.11; Phase 2  Phase 3). A 
malleable material desirable for non-load bearing surgical application would possess a G′ and G″ 
conducive to retention when no external force was present (e.g., primarily elastic behavior; δ < 
45°) and flow when exposed to an external shear (e.g., primarily viscous behavior; δ > 45°). 
Additionally, a material with rapid recovery kinetics on the order of seconds to minutes following 
disruption (e.g., injection) may be desired. Utilizing results from swelling and rheological flow 
studies, colloidal mixtures containing 15% GAG – 60% HAP exhibited the most desirable 
behavior among tested mixtures. Thus, dynamic viscoelastic recoveries of 15% GAG – 60% HAP 
colloidal gels were compared to their pure GAG and HAP components, respectively (Figure 2.10A 
and Figure 2.10B). In terms of G′recovery magnitude, 15% GAG – 60% HAP mixtures recovered 
less extensively compared to pure 60% HAP. This result was expected since return to particle 
spacing equilibrium following microstructure disruption is dependent on the particle diffusivity in 
the suspending fluid.57, 64 However, HA-HAP appeared to recover its initial G′ within seconds of 
disruption while the CS-HAP mixture and pure HAP took several minutes. This may be due to the 
rapid and extensive self-association of HA polymers in the mixture compared to CS.37-39 This may 
favor HA-HAP mixtures in a tissue filler application, since rapid self-assembly may improve 
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retention in the defect site. Overall, the rapid (< 5 min) and extensive (G′recovery ≥ 64%) recovery 
of viscoelastic properties in 15% GAG – 60% HAP colloidal mixtures was encouraging with 
regard to potential surgical applications. 
 
5. CONCLUSION 
Malleable polymer-colloidal gels represent a desirable approach for minimally invasive filling 
of tissue defects and may ultimately facilitate regeneration of non-load bearing bone defects. This 
study demonstrated that the addition of moderate molecular weight GAGs such as CS (Mw = 15-
30 kDa) and HA (Mw = 20-41 kDa) can be used successfully to modify the rheological properties 
of sub-micron HAP (Davg ≤ 200 nm) colloidal gels. GAG-HAP colloidal mixtures appeared to 
exhibit substantial polymer-particle interactions, leading to a synergistic increase in consistency 
index (K) without compromising shear-thinning behavior (n < 1) of the gel. In addition, GAG-
HAP colloids containing high concentrations of HAP exhibited substantial yield stress (τy) and 
viscoelastic recovery properties (G′recovery) which may be desirable for retention of these materials 
at surgical sites. While rheological differences were observed between CS-HAP and HA-HAP 
colloidal gels, both CS and HA represent feasible options for future studies investigating bone 
defect filling. HA is available across a large range of molecular weights (10-1000s kDa) compared 
to CS, which may ultimately yield additional rheological advantages. Overall, this study mapped 
and identified desirable mixture regions (Figure 2.9A and Figure 2.9B) where rheological 
properties of certain CS-HAP and HA-HAP colloidal gels aligned with desired properties to 





6. LIST OF ABBREVIATIONS 
CS, Chondroitin Sulfate; GAG, Glycosaminoglycan; HA, Hyaluronic Acid; HAP, Hydroxyapatite; 
H-B, Herschel-Bulkley Fluid; LVE, Linear Viscoelastic Region  
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Autologous bone grafting (ABG) remains entrenched as the gold standard of treatment in bone 
regenerative surgery. Consequently, many marginally successful bone tissue engineering 
strategies have focused on mimicking portions of ABG’s ‘ideal’ osteoconductive, osteoinductive, 
and osteogenic composition resembling the late reparative stage extracellular matrix (ECM) in 
bone fracture repair, also known as the ‘hard’ or ‘bony’ callus. An alternative, less common 
approach that has emerged in the last decade harnesses endochondral (EC) ossification through 
developmental engineering principles, which acknowledges that the molecular and cellular 
mechanisms involved in developmental skeletogenesis, specifically EC ossification, are closely 
paralleled during native bone healing. EC ossification naturally occurs during the majority of bone 
fractures65-73 and thus can potentially be utilized to enhance bone regeneration for nearly any 
orthopedic indication, especially in avascular critical-sized defects where hypoxic conditions favor 
initial chondrogenesis instead of direct intramembranous (IM) ossification. The body’s native EC 
ossification response, however, is not capable of regenerating critical-sized defects without 
intervention. We propose that an underexplored potential exists to regenerate bone through the 
native EC ossification response by utilizing strategies that mimic the initial inflammatory or 
fibrocartilaginous ECM (i.e., ‘pro-‘ or ‘soft’ callus) observed in the early reparative stage of bone 
fracture repair. To date, the majority of strategies utilizing this approach rely on clinically 
burdensome in vitro cell expansion protocols. This review will focus on the confluence of two 
evolving areas, (i) native ECM biomaterials and (ii) developmental engineering, which will 
attempt to overcome the technical, business and regulatory challenges that persist in the area of 
bone regeneration. Significant attention will be given to native ‘raw’ materials and ECM-based 
designs that provide necessary osteo- and chondro- conductive and inductive features for 
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enhancing EC ossification. Additionally, critical perspectives on existing stem cell based 
therapeutic (SCBT) strategies will be discussed with a focus on their use as an extension of the 
acellular ECM based designs for specific clinical indications. Within this framework, a novel realm 
of unexplored design strategies for bone tissue engineering will be introduced into the collective 







The human body has an extensive capacity to regenerate bone tissue following trauma.  
Disruption of the surrounding vasculature and bone marrow resulting from a bone fracture initially 
facilitates a cascade of coagulation and inflammatory events within the fracture space (Figure 
3.1).65-70, 72, 73 The subsequent bone healing process overlaps with this inflammatory phase spatially 
and temporally via both bone developmental pathways: intramembranous (IM) and endochondral 
(EC) ossification.65-70, 72, 73 Large defects above a ‘critical-size’, however, cannot be restored 
without intervention and often lead to non-union.71, 74 Although current surgical intervention 
strategies, most notably autologous bone grafting (ABG), have yielded favorable bone healing 
outcomes in these situations, it is clear from the past decade’s surge in clinically available tissue 
engineered bone implants, some coupled with stem cell based therapeutics (SCBTs), that 
alternative bone regenerative strategies have gained a significant market share.75  
Clinically, however, ABG remains the gold standard of treatment due to its inherent 
osteoconductivity, osteoinductivity, and thus osteogenic capabilities.1-3, 70 Despite these 
advantages, ABG has key clinical limitations including donor site morbidity and pain, increased 
risk of infection, limited handling capacity, graft resorption problems, and restricted tissue 
availability.1-3, 70 Nearly three decades of bone tissue engineering research have been aimed at 
overcoming these limitations by finding performance competitive alternatives to ABG. As a result, 
many bone regeneration strategies have focused on mimicking portions of the complex 
composition and bioactive signals present in ABG, such as demineralized bone matrix (DBM), 
which resembles the late reparative stage extracellular matrix (ECM) in bone fracture repair (i.e., 
‘hard’ or ‘bony’ callus).65-70, 72, 73 These efforts have yielded dozens of clinical products including 
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synthetic scaffolds, allografts, and xenografts4, 5, yet the majority of orthopedic procedures 
continue to utilize ABG.1-3, 70 
To date, acellular biomaterial-based products have dominated the alternative bone implant 
market at the commercial level.4, 5, 75 A major characteristic of these products is the ability to mimic 
the biological ECM environment specific for bone regeneration. These materials possess both 
conductive scaffold moieties and inductive signaling molecules that have been difficult to match 
with synthetic designs.76-80 Within the realm of bone biomimetics, native ECM based biomaterials 
(e.g., DBM) have been a key protagonist.5 However, there may be underexplored potential to 
enhance the bone regenerative response with native ECM biomaterials that instead mimic the 
initial inflammatory or fibrocartilaginous ECM (i.e., ‘pro-‘ or ‘soft’ callus) observed in the early 
reparative stage of the native bone fracture healing process.  
Addressing this avenue of research is the emerging paradigm of “developmental 
engineering” first introduced in 2009 in two reviews by Lenas et al.81, 82, which offers an innovative 
approach to enhance the regenerative capacity of tissue engineered implants, including bone tissue 
applications, by focusing on path-dependent precursor tissue formation. This new strategy involves 
engineering developmental ‘processes’ in vitro in addition to ‘tissues’, and recognizes that the 
molecular and cellular mechanisms involved in developmental skeletogenesis, specifically EC 
ossification, are closely paralleled during native bone healing.65-70, 72, 73 Primarily, these strategies 
have involved in vitro chondrogenic priming of various adult and embryonic stem cells for 
subsequent implantation and EC ossification in vivo. To date, however, no review has critically 
analyzed these in vitro priming approaches across various stem cell sources as a collective 
endeavor for the purpose of advancing bone regenerative medicine. While these priming strategies 
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have successfully produced EC ossification in several animal models, their clinical translation 
remains tethered to burdensome donor cell expansion protocols.     
The incorporation of donor cells via stem cell based therapeutic (SCBT) strategies may 
provide advantageous osteo- and chondrogenic capabilities to acellular bone implants, which rely 
solely on recruited cells from the peripheral host tissue. These benefits are likely the reason behind 
the increasing saturation of product pipelines (i.e., preclinical and clinical level) with SCBTs 
across the areas of tissue engineering and regenerative medicine.75 As a result, the bone 
regeneration market is likely to see an influx of SCBT products, either as exclusive therapies or 
combined with biomaterial implants, within the next decade. The clinical acceptance of these 
products will primarily depend on achieving (i) improved patient outcomes while at the same time 
reducing procedural (ii) complications and (iii) expenses compared to current standards of 
treatment.75, 83, 84 Key to the success of SCBTs will be the reduction in time and cost consuming 
manufacturing practices (multiple days to weeks) associated with traditional in vitro cell 
expansion. Critical-sized bone defects often require surgical intervention within hours as opposed 
to weeks because delayed bone healing leads to higher risk of non-union.71 Therefore, traditional 
cell expansion procedures represent a non-feasible clinical option in most critical-sized defect 
indications. Advances in intraoperative SCBT strategies offer innovative solutions to overcome 
this challenge by combining cell harvest, isolation, and implantation in one surgical setting without 
compromising progenitor cell and signal efficacy, thus eliminating the prolonged cell expansion 
phase.84 Although SCBT strategies could revolutionize the orthopedic market, basic biomaterial 
designs incorporating the appropriate native ECM components to accompany these SCBTs will be 
crucial in the advancement of bone regenerative medicine.     
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An alternative strategy to reduce or remove the cell expansion step may reside in extending 
developmental engineering principles to in vivo designs (i.e., within the graft or implant), thus 
removing in vitro chondrogenic priming requirements altogether. Inspiration for in vivo 
developmental designs already exists with native ECM biomaterials, specifically acellular DBM 
grafts, which have already been shown to elicit some EC ossification in addition to the IM 
pathway.85-91 However, as mentioned previously, DBM composition reflects the physicochemical 
properties of the late bone reparative stage ECM (Figure 3.1)70, 71, 92, 93 and suggests that designs 
aimed at mimicking the composition of bone ECM may insufficiently elicit an EC ossification 
response inside healing fractures.  
This review will highlight essential design criteria involved in the underexplored 
regenerative area of developmentally engineering bone in vivo (Figure 3.2). Traditional strategies 
have approached tissue-engineered construction through a combination of factors described in the 
tissue engineering triad: cells, signals, and scaffolds. However, the use of ‘raw’ ECM biomaterials 
may serve to bridge the gap between the latter two components of this triad by recognizing their 
integrated contribution to the local ECM79, potentially obviating the need for additional 
incorporation of cells and signaling molecules. Crucial to developmentally engineering the process 
of EC ossification inside an implant will not only be the selection of native biomaterials that mimic 
the relevant tissue’s ECM composition, but also materials that serve to modulate the 
developmental process. The primary focus will be on acellular ECM strategies, where the 
physicochemical cues that native ECM biomaterials possess may sufficiently elicit a bone 
regenerative response. Within this framework, the advantages of incorporating SCBT strategies 




2. Overview of the Natural Bone Healing Process 
As mentioned before, the human body has an extensive capacity to regenerate bone tissue 
following trauma and fracture. The cellular and molecular processes involved in developmental 
skeletogenesis are closely paralleled during native bone healing.65-73 Characterization of the 
complex mechanisms involved in bone healing has been the focus of several extensive reviews65, 
66, 71, 92, and readers interested in further details surrounding this cascade of events should direct 
their attention to these recommended citations.  
 In general, the fracture healing process is most often described in three overlapping phases: 
Inflammatory, Reparative, and Remodeling (Figure 3.1), where each phase represents a complex 
spatiotemporal distribution of cells, ECM, and bioactive signals.65-73 Initially, disrupted 
vasculature and bone marrow during the inflammatory phase facilitates a coagulation cascade 
along with an influx of progenitor cells, including bone mesenchymal stem cells (BMSCs), into 
the fracture space forming a hematoma. Without permanent vasculature, however, the fracture 
space becomes hypoxic, and it remains unclear whether enough of these stem cells survive the 
initial inflammatory phase to play an active role in subsequent tissue regeneration.65-73 Established 
bioactive signaling from the inflammatory phase ECM subsequently recruits progenitor cells from 
both the exposed periosteum and bone marrow that migrate into the fracture space initiating both 
bone developmental pathways: IM and EC ossification.65-70, 72, 73 Primary differences in these 
pathways reside in precursor requirements. While IM requires condensation and proliferation of 
progenitor BMSCs for ossification, EC requires cartilage and fibrous intermediate tissue formation 
before ossification.65-73 EC ossification therefore can further be divided into three generalized 
steps: 1) chondrogenesis, 2) cartilage hypertrophy, and 3) ossification.65-73 Regardless of the 
pathway, however, neo-vascularization and angiogenesis are necessary before ossification can 
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proceed.69, 70, 94-97 In contrast, chondrogenesis predominately occurs in avascular environments 
where oxygen tension is low.98-102 The main consequence of this difference is that IM and EC 
ossification manifest in physiologically distinct regions of the fracture space, where the former 
primarily occurs adjacent to the fracture ends and the latter occurs primarily in the avascular bulk 
of the fracture space.66, 69, 70 Collectively, this early reparative stage climaxes in the formation of a 
spanning fibrocartilaginous callus (i.e., ‘pro-’ or ‘soft’ callus) in the majority of the fracture space 
developing from EC ossification. The procallus serves both a chemical and mechanical function 
and acts as a primed template for subsequent osteoblast infiltration, woven bone ossification (i.e., 
‘hard’ or ‘bony’ callus), and finally bone remodeling to restore healthy lamellar bone 
architecture.65-73       
While the aforementioned process describes successful bone regeneration within the body, 
it is well understood that large defects above a ‘critical-size’ are incapable of completely restoring 
native bone structure without intervention and often lead to non-union.71, 74 It is important to note 
that critical-sized defects are inherently large, avascular spaces that present favorable conditions 
for EC ossification as opposed to IM. This review will outline several studies (Tables 2-4) that 
have leveraged EC ossification and developmental engineering strategies within critical-sized 
defects in various animal models. Collectively, this evidence suggests that enhancing EC 
ossification may be a viable, underexplored strategy for improving bone regeneration.     
 
3. Strategies to Enhance EC Ossification 
3.1  Harnessing the Potential of Developmental Engineering 
Developmental engineering, a term first introduced into the tissue engineering community with 
two reviews in 2009 by Lenas et al.81, 82, involves the engineering of developmental ‘processes’ 
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and ‘tissues’ in vitro, and recognizes that the embryonic and morphological paradigms involved 
in developmental skeletogenesis are closely paralleled during native bone healing.65-70, 72, 73 This 
approach attempts to recapitulate aspects bone regeneration by leveraging several concepts in 
developmental biology including.81, 82   
1) Path-dependence: successive developmental tissue relies on previous tissue formation 
2) Robustness: tissue developmental process resistant to unintended external perturbation     
3) Semi-autonomy: partially self-governed tissue development    
EC ossification is a feasible route to utilize these guiding principles of developmental engineering, 
and the current review will cover advances made over the past decade in engineering EC 
ossification for bone regeneration (Table 3.2-3.4).  
While the Lenas reviews only covered replicating in vivo developmental processes in an in 
vitro environment81, 82, the current review aims to expand their previous concept further to include 
reproduction of developmental processes in an in vivo environment (i.e., within implanted 
grafts/scaffolds). If evidenced to produce similar regenerative outcomes compared to their in vitro 
counterparts, in vivo developmental designs would obviate the need for cost and time-consuming 
cell expansion protocols, which remain a critical challenge in the translation of SCBTs.75, 83, 84. 
However, there remains a deficiency in both fundamental research and translatable products within 
the expansive framework of in vivo developmental designs.    
3.2 Coupling In Vivo Developmental Engineering with Native ECM Biomaterials 
3.2.1 Characterizing the Influence of DBM on Ossification Pathway 
Inspiration for in vivo developmental designs already exists in the form of native ECM 
biomaterials. There is significant evidence that EC ossification occurs in acellular DBM grafts85-
88, which inherently resemble the composition of late reparative stage bone healing ECM.5, 65-70, 72, 
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73 In a critical-sized rat femoral defect model, Oakes et al.85 observed histological evidence of 
increased EC ossification foci in human DBM implants suspended in a hyaluronic acid carrier 
fluid compared to similar DBM implants suspended in a glycerol solution. However, radiographic 
scoring 16 weeks post implantation revealed no significant difference in their mineral content.85 
Although the authors did not further pursue developmental differences between groups, this 
evidence suggests that both EC and IM pathways were utilized within DBM implants. This could 
have been due to differences in carrier fluid. Hyaluronic acid is known to be a major component 
of cartilage ECM68 and therefore could play a regulatory role in both chondrogenesis and EC 
ossification.73  
Regardless, the DBM composition containing conductive and inductive biological agents 
likely influences developmental pathways during bone healing.85-88 DBM composition, however, 
is not uniform throughout the body. There exist compositional differences in bone ECM 
originating from IM sources during fetal development (e.g., cranium) and EC sources (e.g., 
femur).103 Furthermore, DBM originating from IM and EC bone have been shown in a series of 
studies by Rabie et al.87, 89-91 to elicit different healing pathways during regeneration of parietal 
bone defects in New Zealand White Rabbits. The parietal bone is formed by IM ossification during 
fetal development103, suggesting that only implants directed toward IM ossification will possess 
regenerative potential. However, evidence from Rabie et al. 87, 89, 90 showed that IM and EC 
ossification pathways can be utilized, exclusively or in combination, to regenerate parietal defects 
based entirely on the source of DBM. In addition, the amount of bone regeneration was shown to 
be source dependent, where grafts favoring IM ossification displayed a significantly higher degree 
of newly formed bone observed by serial histological sectioning.91 While these studies collectively 
support the ‘same for same’ surgical practice in bone regeneration91, where DBM from IM and EC 
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sources is matched on a developmental basis to the respective bone defect site, the major limitation 
of these studies was the short timeframe of healing (14 days) observed following implantation. 
Since Oakes et al.85 observed no evidence of a difference in bone regeneration 16 weeks post 
implantation, similar longitudinal studies are necessary to determine whether DBM implants from 
EC or IM sources display significant regenerative capacities.  
The differences in regenerative potential and developmental pathways seen in the Rabie 
studies were attributed to varying inductive and conductive ECM factors within DBM.87, 89-91 
Inductive factors such as bone morphogenic proteins (BMPs) have been implicated in bone 
morphogenesis dating back to their initial isolation from DBM, reviewed in chronological detail 
by Gruskin et al.5 Consequently, BMP-2 content, release, and bioactivity has become an important 
guideline in determining efficacy and quality control of commercially available DBM products.5 
BMPs, however, represent only a fraction of the growth factors in the spatiotemporal cascade of 
inductive molecules involved during bone healing, reviewed extensively by Mehta et al.71 
Inductive signaling alone could have been responsible for the regenerative effect seen in DBM as 
well as account for differences seen between DBM from IM and EC sources. However, the 
conductive proteins present in DBM may also provide key regulatory control since it has become 
increasingly evident that structural components of native ECM along with mechanical forces 
acting on the tissue have significant influence on cellular and molecular bioactivity.80, 104      
Collectively, there is significant evidence to suggest that EC ossification can occur within 
native ECM biomaterials in the form of acellular DBM implants. While there has been extensive 
research into the bone regenerative capacity of DBM, an underexplored avenue of research is the 
focus on the developmental pathway’s effect on regenerative capacity of these implants. The 
characterization of DBM’s influence, and perhaps limitation, in stimulating EC ossification should 
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be elucidated in the future to advance the understanding of the bone healing process and potentially 
enhance bone regenerative designs.      
3.2.2 Exploring EC Ossification Potential in ECM Biomaterials  
In general, native ECM refers to both soluble and insoluble biomolecules that may be 
utilized as cell scaffolding and bioactive signaling. Additionally, the effectiveness of autologous, 
allogeneic and xenogeneic ECM biomaterials can be assessed in terms of physical, chemical, and 
mechanical properties of the tissue. While it remains debatable whether native ECM represents 
nature’s ideal biological scaffold, particularly because resident cells exhibit physiologically 
relevant synthesis and maintenance within it, these materials have received significant attention 
for their potential efficacy in the regenerative tissue market.76, 77, 79, 80  
3.2.2.1 Traditional Bone ECM Strategies 
ABG intrinsically involves the grafting of native bone ECM tissue with associated 
autologous cells into bone defects, and it remains the gold standard of treatment in bone 
regeneration due to its inherent osteoconductivity, osteoinductivity, and osteogenic capacity.1-3, 70 
It intuitively followed that designs mimicking the native bone ECM (Figure 3.1) held potential for 
bone regeneration, and as a result, many alternative bone regeneration strategies focused on 
mimicking portions of the complex composition and bioactive signals present in ABG, which 
resembles the late reparative stage ECM in bone fracture repair (i.e., ‘hard’ or ‘bony’ callus).65-70, 
72, 73 Some of these strategies were discussed in the previous DBM characterization section where 
allogeneic tissue was used to elicit bone regeneration. Subsequently, efforts in the bone ECM 
biomimetic area have yielded dozens of commercially available products.4, 5 Two reviews by 
Gruskin et al.5 and Bohner4 compare an extensive number of these products which can be divided 
into two broad categories: 1) organic scaffolds (e.g., allografts, and xenografts) and 2) inorganic 
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scaffolds (e.g., calcium phosphate cements), yet the majority of orthopedic procedures continue to 
utilize ABG.1-3, 70 This is likely due to the fact that bone ECM biomimetic strategies fail to 
sufficiently mimic the complex 3D physical, chemical, and cellular composition of healthy 
autologous bone.1-3, 70    
It is important to note, however, that the functional and structural properties of ECM during 
the bone healing process are spatially and temporally dynamic and do not resemble healthy native 
bone until well into the reparative and remodeling stages of healing (Figure 3.1).70, 71, 92, 93 This 
delay in resemblance suggests that designs aimed at mimicking the composition of bone ECM may 
insufficiently elicit a regenerative response inside healing fractures and could be a worthwhile 
focus of future investigation in bone regeneration.  
3.2.2.2 Alternative ECM Biomaterial Strategies for EC Ossification 
By instead leveraging the concepts of both developmental engineering and the 
spatiotemporal dynamics of ECM in bone healing, there may be potential to enhance the extent 
and quality of EC ossification. Specifically, native ECM biomaterials that mimic the initial 
inflammatory stage ECM or fibrocartilaginous ECM (i.e., ‘pro-’ or ‘soft’ callus) in the early 
reparative stage of bone fracture healing may be selected instead of materials that mimic the 
composition of bone ECM. These scaffolds or grafts based on inflammatory or fibrocartilaginous 
ECM may harness the path-dependent, robust, and semi-autonomous nature of EC ossification, 
potentially leading to extensive bone regeneration.  
Characterization of the complex cascade of signaling events and ECM changes involved 
in bone healing and EC ossification has been the focus of several recent reviews70, 71, 92, 93, and 
readers interested in further multifaceted details surrounding relevant biomolecules should direct 
their attention to these recommended citations. While the characterization of the spatiotemporal 
40 
 
distribution of these molecules may be of value for developmental engineering, few efforts have 
been made to mimic the appropriate array of bioactive scaffolding and signaling molecules with 
native ECM biomaterials that correspond to the early and intermediate stages of native bone 
healing. 
Native ECM biomaterials possess both conductive and inductive potential that are difficult 
to match with synthetic designs (e.g., non-native polymers).76-79 Additionally, it is increasingly 
evident that the structural components of native ECM also provide a regulatory role for key 
processes in cellular development and tissue regeneration.80, 104 These processes include cell 
adhesion, proliferation, differentiation, migration, and survival along with modulating signaling 
activity of soluble bioactive molecules.80, 104 Furthermore, the native ECM’s integrated approach 
to combine the traditional signaling and scaffolding components of the tissue engineering triad 
suggests that acellular designs may obviate the need for burdensome cell expansion protocols and 
additional bioactive signal incorporation which introduce major challenges that threaten 
commercial success in bone regeneration.83, 84  
To date, few studies have attempted to coordinate developmental bone engineering 
strategies with acellular native ECM biomaterials (Figure 3.1 and Figure 3.2). Subsequent sections 
will address key features of existing technology and more importantly focus on worthwhile areas 
of future investigation for the purpose of enhancing EC ossification and bone regeneration.  
3.2.2.3 Inflammatory Stage ECM Strategies for EC Ossification 
Since most tissues primarily rely on broken vasculature to supply damaged areas with 
inflammatory signals and cells, modulating the body’s initial inflammatory response following 
any tissue trauma has been well studied.105, 106 As a result, many regenerative design strategies 
have focused on isolating and concentrating portions of human blood such as platelets and plasma 
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(e.g., platelet rich plasma or PRP) or pro-coagulation molecules (e.g., fibrin sealants) to enhance 
endogenous healing responses.107-113 It remains to be seen whether a scaffold with only 
inflammation-related chemical and mechanical cues can elicit enough of an EC ossification 
response to heal critical-sized bone defects. Pure fibrin scaffolds and PRP alone do not appear to 
exhibit sufficient cartilage107-109, 111 and bone110, 112, 113 regeneration in critical-sized defects, which 
suggests that additional regenerative stimuli such as bioactive molecules and progenitor stem cells 
may be required.   
One strategy to enhance the regenerative response in inflammatory stage ECM strategies 
has been to supply the fracture space with stem cells from bone marrow aspirate since fractured 
bone is supplied with bone marrow intrusion when the inner marrow space is disrupted.65-73 This 
intrusion of marrow allows supplementary signaling molecules and progenitor cells, including 
BMSCs, to infiltrate the fracture space. However, hypoxic conditions within the mechanically 
unstable fracture lead to significant cell mortality, and it remains unclear whether enough of these 
stem cells survive the initial inflammatory phase to actively participate in subsequent tissue 
regeneration.65-73 Jakob et al.84 reviewed some bone engineering strategies that included isolated 
and concentrated bone marrow aspirate to enhance regeneration, but concluded that the fraction of 
BMSCs present in bone marrow (1 in 10,000 nucleated cells) limited the regenerative capacity of 
these designs. Extensive work has also been conducted to additionally isolate, differentiate, and 
expand the BMSCs within bone marrow to enhance the regenerative capacity of engineered bone 
implants, discussed in subsequent sections on SCBT strategies (Tables 2-4). However, the 
expansion of BMSCs requires financially burdensome and time consuming protocols that limit the 
commercial application of these strategies.83, 84 Therefore, cell expansion should likely be 
considered as a contingent reserve to cell recruitment strategies.   
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Coupling the evidence of low progenitor count with poor cell survival rate observed in 
hypoxic bone defects suggests the importance of spatiotemporal cellular recruitment strategies for 
bone regeneration. As the native bone healing process continues into the reparative stages of 
healing, the exposed periosteum and bone marrow continue to serve as reservoirs of progenitor 
cells that subsequently migrate into the fracture space.70, 71, 92, 93 Several important reviews have 
focused on physical (e.g., osmotic gradients and hydrodynamic forces) and chemical (e.g., 
chemokines) cellular recruitment strategies for tissue regeneration.114, 115 Within the realm of 
developmental engineering and native ECM biomaterials, the subsequent differentiation pathway 
should also be emphasized with regard to overall cellular recruitment strategy. Since critical-sized 
defects are primarily avascular and hypoxic66, 69, 70, initial chondrogenesis involved in EC 
ossification may be a more favorable condition to exploit in this lower oxygen tension environment 
compared to direct osteogenesis in IM ossification.98-102  
Collectively, the evidence surrounding the use of inflammatory stage ECM scaffolds, 
signals, and recruited cells indicates that current designs remain insufficient in regenerating bone 
in critical-sized defects. To date, no studies have focused on controlling the recruitment and 
differentiation of BMSCs down the EC ossification pathway within the realm of inflammatory 
stage ECM strategies. This underexplored area may be an advantageous condition to exploit in 
future bone regeneration strategies.    
3.2.2.4 Procallus Stage ECM Strategies for EC Ossification 
An intuitive source for enhancing stimulation of EC ossification is the procallus ECM since 
natural bone healing progresses to this stage early in the regenerative process.65-73 Insight into the 
conductive and inductive biomolecules that control EC ossification have been essential to tissue 
engineering strategies focusing on cartilage formation116, 117, osteochondral defects118, 119, and 
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more recently bone regeneration (Table 3.2-3.4).86, 102, 116, 117, 120-135 While cartilage tissue 
engineering strategies have focused on inducing and maintaining chondrogenic phenotypes, the 
induction and modulation of cartilage hypertrophy is critical to the progression of EC ossification 
in bone regeneration designs.71, 92, 93, 96-102, 131, 136-144 Whereas the key transcription factor involved 
in initial chondrogenesis is SOX9, the primary hypertrophy associated factors are runt-related 
transcription factor 2 (Runx2) and myocyte enhancer factor 2C (MEF2C).92, 93, 100, 137 In this critical 
maturation stage of EC ossification, chondrocytes experience a large increase in volume (~5 to 10 
fold), and downstream proteins activated by Runx2 and MEF2C transcription factors begin to 
remodel the surrounding ECM.92, 93, 100, 137 These targets include MMPs that degrade cartilaginous 
ECM65-70, 72, 73, Indian Hedgehog (Ihh) that induces proliferation of non-hypertrophic 
chondrocytes92, 93, 100, 137, angiogenic factors like vascular endothelial growth factor (VEGF) to 
promote neo-vascularization93, 94, 131, 136, 137 along with collagen type X, alkaline phosphatase 
(ALP), and matrix vesicles for ECM mineralization.145-147 While several in vitro studies have 
shown that external chemical71, 92, 97, 100, 132, 139-144, 148, 149, physical98-101 and mechanical cues100, 104 
stimulated BMSCs to stay locked in a stable cartilage state or progress into a hypertrophic 
phenotype (Table 3.1), it remains to be seen whether acellular procallus ECM designs have the 
potential to elicit similar responses from incorporated or recruited stem cells.    
In summary, the success of in vivo developmental engineering designs for EC ossification 
will likely depend on the incorporation of physiologically relevant bioactive chemical mediators 
along with physical and mechanical cues drawn from these important in vitro studies. Coupling 
these results with the previously discussed evidence regarding DBM’s influence on EC 
ossification85-91 provides a potent array of strategies for future bone regeneration designs. 
Furthermore, it is evident that the selection of appropriate native ECM components is essential for 
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exploiting the advantages of EC ossification. However, strategies to efficiently and feasibly 
incorporate these biomolecules into bone regenerative implant designs require consideration and 
thus will be further discussed below. 
3.3 Isolating, Identifying and Delivering Native ECM for EC Ossification 
3.3.1 Utilizing Step-Wise ECM Strategies 
Strategies to design scaffolds with incorporated native ECM components can be divided 
into two main categories: 1) Bottom-up approach or 2) Top-down approach (i.e., step-wise 
designs) (Figure 3.3). While the former aims to mimic native ECM with complex biomaterial re-
synthesis strategies (e.g., collagen polymerization), the latter step-wise approach attempts to 
process native ECM from autologous, allogeneic, or xenogeneic sources without completely 
compromising tissue structure and function (e.g., decellularization and demineralization). Two 
extensive reviews by Badylak76 and Renth et al.79 provided detailed experimental outcomes and 
current clinical products utilizing ‘raw’ native ECM biomaterials for tissue regeneration, which 
include both bottom-up and step-wise strategies. In general, nearly all step-wise design approaches 
described in these reviews, with the exception of autologous tissue harvesting, require some form 
of processing to avoid immunogenicity with host (i.e., recipient) tissue since allogeneic and 
xenogeneic cellular antigens are recognized as foreign.76-78, 150 To address this immunogenicity, a 
variety of physical, chemical, and enzymatic processing methods have demonstrated the possibility 
of sufficiently devitalizing or decellularizing these tissues to suppress host rejection without 
compromising the conductive, inductive and mechanical components of the ECM.76-78, 150  
In a comprehensive review of current tissue and whole organ decellularization methods by 
Crapo et al.150, it was recognized that all current techniques cause some degree of ECM disruption. 
As manufacturing requirements increase, the complex physical and chemical components of the 
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native ECM tissue decrease along with corresponding mechanical structures and functions.76-80, 150 
At the extreme end of this spectrum, where individual ‘raw’ ECM components are isolated (e.g., 
collagen, glycosaminoglycans, and soluble growth factors)79, designs necessarily require some 
form of bottom-up re-synthesis to regain a portion of the physiologically relevant ECM structure 
and functionality, yet it poorly resembles the initial native ECM tissue (Figure 3.3).76 The main 
advantage of using ‘raw’ biomaterial re-synthesis, however, is that designs can be modular, which 
means that separate elements of the design can be tested independently. As a result, each 
component can be characterized for its contribution to the process as a whole in a full-factorial 
experimental design (e.g., scaffolding protein vs. soluble factor vs. scaffolding protein + soluble 
factor). Nevertheless, the problem with modular re-synthesis based designs is that mimicking 
complex environments, such as the complex cascade of signaling events involved in bone 
healing70, 71, 92, 93, is nearly impossible in addition to  being economically infeasible.151 This is 
compounded by the fact that the characterization of the complex 3D structures and functions of 
native ECM remains incomplete.76, 150 A modular design coupling both conductive and inductive 
biomolecules present in native bone ECM yields nearly infinite permutations, yet this has remained 
entrenched as the primary philosophy of bone tissue engineering over the past three decades.151 
Even with current sophisticated manufacturing technology, including 3D printing, complex 
polymerization and chemical conjugation techniques, artificial re-synthesis of this biological 
material remains physiologically dissimilar compared to its native tissue counterpart in terms of 
relevant physicochemical composition.76-80 Although future technological advances may someday 
improve bottom-up re-synthesis designs, the main consequence is that step-wise design strategies 
may currently represent the more favorable option when attempting to mimic native ECM.150   
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Step-wise designs from both allogeneic and xenogeneic tissue sources have been utilized 
clinically for cartilage and bone tissue engineering along with dermal, vascular, nerve, and 
urogenital tissue.5, 76, 77, 79, 152 Furthermore, previous evidence was presented linking step-wise 
derived DBM to extensive bone regeneration via IM and EC ossification,85-91 attributes which 
likely contribute to its role as a key protagonist in the bone graft substitute market.5 If alternative 
ECM biomaterials are to be used to enhance bone regeneration as proposed in the current review, 
then key technical, regulatory, and commercial features surrounding the use and approval of DBM 
should be utilized as a guiding template for potential success.       
3.3.2 Decellularized Cartilage for Enhancing EC Ossification 
Intuitively, it follows that designs mimicking the native bone or cartilage ECM hold vast 
potential for eliciting ossification and chondrogenesis, respectively. Therefore, it is understandable 
that for many years, bone and cartilage tissue engineering strategies have focused primarily on 
treating these two tissues as separate regenerative endeavors. Although a pivotal review by Singh 
et al.114 established chemical and mechanical based spatial gradients as an advantageous design 
approach in osteochondral interfacial tissue regeneration, these strategies still involve a binary 
differentiation pathway, where the transition zone is only a spatial gradient formed by a gradual 
change in either chondrogenic or osteogenic cues. EC ossification, however, is a spatial and 
temporal transition process where cartilage precursor gradually transitions to bone over extended 
periods of time.65, 66, 71, 92 Thus, the chondrogenic signaling cues initially present in a scaffold may 
be required to transition over time to influence hypertrophy and osteogenesis.  
Previously mentioned in this review was emerging evidence that has shown the potential 
of DBM to prompt EC ossification in vivo85-91, and subsequent sections will discuss evidence that 
in vitro primed cartilage constructs may also prompt EC ossification in vivo (Table 3.2-3.4). 
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Coupling this evidence with motifs in developmental engineering including path-dependence, 
robustness, and semi-autonomy suggests that decellularized cartilage (DCC), which mimics 
portions of the native procallus ECM, may provide extensive potential in prompting EC 
ossification within an implant and could be a worthwhile focus of future investigation in bone 
regeneration.  
DCC, from both allogeneic and xenogeneic sources, is a poorly explored native ECM 
biomaterial. Recently, it has emerged as a source rich in both chondroinductive and 
chondroconductive potential.77, 79, 80, 152-154 Current commercially available products utilizing 
articular cartilage and/or DCC include Biocartilage® (Arthrex), De Novo NT® and ET® Live Graft 
(Zimmer), and Chondrofix® (Zimmer). However, all of these products use cartilage ECM for the 
purpose of regenerating only cartilage tissue. In the framework of developmental engineering, 
DCC provides a source for modulating and enhancing EC ossification, yet there remains an 
extreme deficiency in both fundamental research and translatable products incorporating this 
material. Hyaline cartilage is avascular in nature, which may be advantageous to pursue for critical-
sized bone defects since chondrocytes are better suited for hypoxic environments compared to 
osteoblasts. Moreover, an avascular tissue may minimize potential developmental disturbance 
from unintended external perturbations.65-73, 81, 82 An additional consequence of this isolation is 
that the progression of cartilage to bone during EC ossification is primarily dictated within the 
tissue by intercellular signaling, incorporating semi-autonomous control into the process.65-73, 81, 82 
Furthermore, many forms of cartilage exist in the body including hyaline cartilage (e.g., femoral 
condyles and tibial plateau), fibrocartilage (e.g., temporomandibular joint disc and knee meniscus), 
elastic cartilage (e.g., nose and ear), and even hypertrophic cartilage (e.g., fetal bones and growth 
plates).68 Fibrocartilage may provide an even better procallus mimetic tissue than hyaline cartilage 
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since the procallus is fibrocartilaginous in nature. Additionally, fetal bones undergoing EC 
ossification during skeletogenesis may provide primed hypertrophic cartilage that could facilitate 
rapid ossification in a bone defect. Thus, there exists a range of DCC-derived tissues that may be 
explored in relation to EC ossification.  
3.3.3 Delivery Strategies for Decellularized Tissues 
Crucial to the future success of these ECM materials will be the strategies used to 
incorporate and deliver them within engineered implants. If maximum retention of native 
inductive, conductive, and mechanical potential of ECM is desired, then minimal required 
processing is preferred to keep the microarchitecture of the native tissue intact.76-80 However, this 
severely limits native ECM’s potential to be incorporated within an engineered implant or 
delivered surgically to a defect site. Large sections of native ECM tissue have been broken down 
by various morselization and solubilization strategies, which can be used to enhance 
decellularization efficiency.5, 77-79 However, the effect of particle size on regenerative capacity of 
these materials remains unclear. A recent review of DBM clinical products and procurement by 
Gruskin et al.5, indicated that larger particles of DBM (420-840 µm) might be more osteoinductive 
than smaller particles (<250 µm) but warned readers that the majority of preclinical data regarding 
particle size effects are inconsistent due to varying animal models and subjective outcome 
measures. Furthermore, the authors of the current review are not aware of any studies that analyze 
chondrogenesis as a function of DCC particle size or EC ossification as a function of ECM particle 
size.     
 While morselization strategies most often include some form of mechanical breakdown 
(e.g., pulverization or cyrogrinding), solubilization uses chemical and enzymatic methods (e.g., 
demineralization and collagenase) to breakdown ECM.77, 78 The primary advantage of breaking 
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down native ECM into micron or sub-micron sized particles is an increased relative surface area 
per volume of material. This can be exploited to improve decellularization efficiency, but it may 
also be essential in exposing cellular adhesion proteins, modulating growth factor release, and 
uncovering potential crosslinking moieties to facilitate synthetic reconstruction strategies (e.g., 
polymerization).  
In summary, the extent of native ECM processing required to enhance the regenerative 
capacity of a bone implant will be application specific. These specifications will include issues 
like load-bearing requirements, defect geometry (e.g., irregular vs. machined defects), bone 
architecture (e.g., cortical vs. cancellous), and vulnerable surrounding tissues (e.g., the spinal cord 
in vertebral fusion or brain tissue in calvarial repair). Existing design paradigms already used to 
support DBM particles, such as solid scaffolding or chemically crosslinked hydrogels5 along with 
emerging design paradigms such as shear-responsive and self-assembling colloidal gels8, 10-12, 155, 
will likely yield an extensive array of application specific bone regenerative scaffolds with EC 
ossification potential.              
3.4 Incorporating SCBTs into the Design 
3.4.1 Priming Chondrogenesis in vitro for EC Ossification 
While acellular ECM design strategies possess great conductive and inductive potential for 
eliciting in vivo EC ossification, SCBTs may provide advantageous osteo- and chondrogenic 
capacity within bone implants. Without the incorporation of donor cells, acellular implants such 
as allografts, xenografts, or synthetic scaffolds must rely solely on recruited cells from the 
peripheral host tissue. Recruitment strategies often involve biochemical agents (e.g., chemokines) 
or induced physical migration (e.g., osmotic gradients or hydrodynamic forces), which may be 
insufficient for some indications with limited access to progenitor cell reservoirs in the bone 
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marrow and periosteum. BMSC recruitment also involves successful cellular migration into the 
scaffold, which may be limited by physical constraints within the implant (e.g., small pore size, 
limited pore connectivity).156  By incorporating a donor stem cell population within an implant 
instead, these cellular recruitment challenges may be overcome.      
The bone regeneration community has attempted to harness the advantages of SCBT 
strategies, either as exclusive therapies or combined and encapsulated within biomaterial implants, 
to overcome cell recruitment limitations and to obviate ABG as the standard of treatment for bone 
fractures.157 Gamie et al.157 provided a comprehensive review of various sources of stem cells in 
combination with bone graft substitutes for bone tissue engineering through osteogenic 
differentiation. Sources of these cells range from embryonic stem cells (ESCs) to an array of cells 
from adult mesenchymal origin including umbilical cord stem cells (UMSCs), bone marrow and 
periosteum derived stem cells, adipose derived stem cells (ADSCs), synovium derived stem cells 
(SDSCs), and more recently induced pluripotent stem cells (iPSCs) were shown to lead to 
osteogenesis in vitro and in vivo.100, 157 Cells from these sources possess some degree of 
pluripotency, where differentiation can lead to a number of distinct cell types including osteoblasts 
and chondrocytes.  
 Within the realm of SCBTs for bone regeneration, a majority of strategies have focused on 
stimulating cell populations to undergo direct osteogenesis rather than chondrogenesis. However, 
as previously mentioned, the EC ossification pathway holds key advantages over IM ossification. 
This is especially true in critical-sized defects which are inherently large avascular spaces and 
favor intermediate chondrogenesis of tissue rather than direct ossification.65-73 An emerging group 
of successful research efforts have focused on exploiting this condition over the past decade. These 
recent publications (Table 3.2-3.4) have demonstrated the capacity of cartilage tissue constructs to 
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promote EC ossification in vivo following in vitro priming with seeded BMSCs119, 122, 123, 125, 126, 
131-135, 158-162, ESCs86, 121, 126, 135, ADSCs163, iPSCs164, and articular chondrocytes (ACs)120, 126, 129, 
130, 134. Most of these studies utilized a heterotopic bone formation model in immunocompromised 
animals to provide evidence of osteo- and chondro- conductivity, and inductivity. However, more 
recent studies by Bahney et al.,165 van der Stok et al.,161 Harada et al.,160 and Shoji et al.163 (Table 
3.2) showed critical-size defect regeneration in rat femurs and mice tibias via EC ossification. 
Likewise, studies by Montufar-Solis et al.86 and Doan et al.121 (Table 3.3) showed critical-sized 
defect regeneration in murine calvaria. Collectively, these studies indicated that primed cartilage 
constructs can regenerate bone through EC ossification regardless of fetal developmental origin.      
While the majority of the tissue priming research aimed to establish feasibility from a 
particular cell population (Table 3.2-3.3), several studies compared various cell sources to 
elucidate differences in their capacity to stimulate EC ossification (Table 3.4).126, 134, 135 Most of 
these comparative studies concluded that only certain cell sources, most often ESCs or BMSCs 
were capable of inducing EC ossification in animal models,126, 134-136, 166 yet other studies clearly 
showed significant EC ossification with ADSCs,163 iPSCs,164 and even ACs in vivo.120, 129, 130 The 
only stem cell population that did not exhibit EC ossification were SDSCs, which instead went 
through fibrous degradation and resorption in vivo.134, 136 This contradicting evidence highlights 
the fact that the spatiotemporal control of cell culture priming conditions are essential in 
determining implant fate in vivo. A review by Gawlitta et al.100 focused on the modulation of these 
conditions to optimize the in vitro priming of BMSCs for EC ossification. However, a 
comprehensive overview of modulating EC priming conditions between comparative sources of 
stem cells has not been addressed and could be a worthwhile focus of future investigation in 
enhancing EC ossification and bone regeneration designs.  
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Regardless of the cell source used for priming EC ossification, several generalized 
conclusions from the reviewed primed in vitro stem cell studies (Table 3.2-3.4) can be summarized 
as follows: 
1) Chondrogenic cell priming in vitro was required to elicit EC ossification in vivo. 
2) Cartilage templates were necessary, but not sufficient to elicit EC ossification in vivo 
a. Stable or permanent AC templates did progress through EC ossification. 
3) Osteogenic priming alternatively favored IM over EC ossification 
4) Hypertrophic chondrocyte priming elicited the most extensive EC ossification. 
While the collective evidence from these studies suggested that EC ossification remains 
necessarily tethered to the burden of in vitro cell priming and expansion, previous evidence was 
already presented linking EC ossification to acellular DBM grafts.85-91 This evidence directly 
contradicts the notion that priming is necessary to elicit an EC response (Tables 2-4) and instead 
only represents a sufficient condition that can also be addressed by acellular native ECM 
biomaterials.  
Consequently, this contradictory evidence suggests that an intermediate and underexplored 
strategy for bone regeneration may exist that incorporates advantages exhibited by both DBM 
biomaterials and primed cartilage constructs, such as the enhancement of EC ossification, and 
possibly minimizes their limitations, for example the extensive costs, risks, and time consuming 
manufacturing practices associated with in vitro cell expansion. Extensive supporting evidence has 
been presented previously in this review to suggest that native, acellular ECM biomaterials (e.g., 
DCC) mimicking the procallus healing microenvironment may be a worthwhile focus for future 




3.4.2 Intraoperative SCBT Strategies with Native ECM Biomaterials 
An emerging strategy to streamline SCBTs is to consolidate necessary cell protocols, 
including the harvesting, isolation, stimulation, and implantation of autologous cells, into one 
surgical (i.e., intraoperative) setting. Intraoperative SCBTs usually involve the use of multiple 
surgical sites (e.g., a bone defect site and a bone marrow aspiration site) but obviates the need for 
cell expansion protocols. By definition, ABG falls under the description of an intraoperative SCBT 
since autologous stem cells are harvested and implanted within one surgical setting. Recent 
intraoperative strategies aim at minimizing the limitations associated with traditional stem cell 
expansion protocols and ABG while also maximizing stem cell efficacy. 
To date, however, no intraoperative SCBT approaches using either BMSCs or ADSCs 
derived from the stromal vascular fraction (SVF) have been able to regenerate bone in critical-
sized defects without the inclusion of additional stimulatory factors.84 In a study by Helder et al.,167 
isolated SVF cells failed to generate bone when implanted in a goat intervertebral model. Likewise, 
Follmar et al.168 saw limited angiogenesis and no evidence of ossification in ADSCs loaded fibrin 
glues implanted subcutaneously in rabbits. Muller et al.169 did observe some evidence of combined 
angiogenesis and osteoid structures, identified with histology and immunostaining for bone 
sialoprotein and osteocalcin, in human ADSC loaded fibrin glues combined with beta-tricalcium 
phosphate, hydroxyapatite, and acellular bone xenografts implanted subcutaneously in nude mice. 
However, the authors found no evidence of murine derived bone structures in the implants, 
indicating a lack of osteoinductivity.169 More recent data from the same group indicated that SVF 
combined with 250 ng of BMP-2 and encapsulated in a fibrin and porous calcium phosphate 
composite gel could form heterotropic bone when injected subcutaneously in nude mice.170 
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Overall, this combined evidence suggests that additional inductive stimulation of stem cells within 
the brief surgical time frame may be crucial in improving efficacy of intraoperative designs.  
Emerging evidence in this area suggests that quick stimulation of isolated stem cells (e.g., 
minutes to hours) may improve differentiation and gene expression outcomes compared to 
untreated cells.84, 105, 106, 171 Some strategies for stimulating isolated stem cells include the use of 
inductive and conductive signaling molecules, either in purified form (e.g., BMP-2)169, 170 or from 
extracted endogenous tissue and fluids (e.g., PRP).172 Kitamura et al.172 showed histological and 
mechanical evidence that BMSCs loaded with PRP regenerated bone in a dog mandible defect 
model comparable to autologous bone controls.  
Meanwhile, it should be reiterated and emphasized that native ECM biomaterials from 
allogeneic and xenogeneic sources possess both conductive and inductive biomolecules.76, 77, 79, 80 
These biomaterials alone may have the potential to stimulate stem cells in an intraoperative setting. 
As discussed previously, native ECM representing both the early and late stages of bone repair 
have the ability to induce both chondro- and osteogenesis by seeded stem cells.85-88, 152 A critical 
area of future investigation, therefore, should be devoted to examining the capacity of these 
biomaterials to stimulate stem cell differentiation and gene expression within the time constrained 
intraoperative setting for the purpose of enhancing bone regeneration.        
In summary, establishing the regenerative potential of acellular ECM biomaterial designs 
will help elucidate the additional benefits of incorporating either SCBTs or other purified inductive 
and conductive biomolecules into intraoperative manufacturing strategies for bone tissue 
engineering. Regardless of these future outcomes, it is critical for these intraoperative designs to 
maximize implant efficacy while at the same time reducing cost, time, and complexity of the 




4. DISCUSSION : Converging Framework of EC Ossification in the Future of Bone 
Regeneration 
EC ossification, a process which naturally occurs in almost all bone healing events65-73, can 
be utilized to enhance bone regeneration for nearly any orthopedic indication, especially in 
avascular critical-sized defects where hypoxic conditions favor chondrogenesis instead of direct 
IM ossification. The native EC ossification response, however, remains insufficient in regenerating 
critical-sized defects without intervention but can potentially be enhanced by combining in vivo 
developmental engineering strategies with biomimetic ECM biomaterials. Evidence to support this 
claim of utility reside in two evolving arenas of bone tissue engineering: 1) in vitro primed 
chondrogenic constructs (Tables 2-4) and 2) native DBM allografts and xenografts.85-91 Both 
strategies have been shown to elicit EC ossification in heterotopic animal models and more 
importantly regenerate critical-sized defects in bone which originated during fetal development 
from EC ossification (e.g., femur) and IM ossification (e.g., cranium). This latter evidence gives 
credence to the potential versatility of strategies enhancing EC ossification for a vast array of 
clinical orthopedic indications.  
Currently, however, both in vitro priming and DBM strategies face formidable technical, 
business, and regulatory challenges that limit their feasibility as commercially competitive 
alternatives to the standard of treatment, ABG. While the former approach remains tethered to 
burdensome, costly, and commercially inhibitive in vitro cell expansion protocols, the latter may 
elicit an insufficient EC ossification response due to its primarily osteoinductive and 
osteoconductive ECM cues, which instead favor IM ossification.  
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Additionally, regulatory challenges exist for both strategies.173 The in vitro expansion of 
autologous stem cells inherently involves a high level of manufacturing risk that must meet 
stringent quality assurance and control for approval by the U.S. Food and Drug Association 
(FDA)173, potentially resulting in an expensive pre-market approval (PMA) process for each 
orthopedic indication. Furthermore, off-site facilities may be required to expand cells, which add 
to the associated risks involved in maintaining viability and preventing contamination of cells. 
Meanwhile, native ECM biomaterials also face regulatory approval challenges outlined by the 
FDA and American Association of Tissue Banks (AATB).5 Allogeneic tissue (e.g., DBM or DCC) 
by itself is not considered a medical device by the FDA unless it is combined with a carrier 
material, such as hyaluronic acid (e.g., DBX®; MTF/Synthes), in which case it must go through 
510(k) approval. Instead, these materials (e.g., Puros® DBM; Zimmer) are categorized under the 
heading of human cells, tissues, and cellular and tissue based products (HCT/P). However, the 
majority of orthopedic DBM products have undergone 510(k) approval by the FDA.5 Based on 
this knowledge of the regulatory landscape surrounding these strategies, it is evident that acellular 
ECM biomaterials face fewer challenges than SBCT strategies for approval and therefore may 
represent the more favorable route to clinical translation.              
An alternative, and underexplored, developmental engineering strategy integrates the 
advantages of these two EC ossification approaches with a new class of ECM biomaterials that 
instead resemble the early fibrocartilaginous bone healing microenvironment and may enhance the 
EC ossification response from damaged host tissue. The primary native ECM candidates proposed 
to potentially elicit such a response are decellularized biomaterials originating from articular, 
fibrocartilaginous, or hypertrophic cartilage sources. These tissues inherently possess relevant 
chondroconductive and chondroinductive biomolecules that may potentially modulate EC 
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ossification within an implant. Additionally, decellularized ECM constructs may reduce or remove 
the need for time and cost consuming in vitro cell expansion protocols, expanding the 
developmental engineering paradigm81, 82 to include in vivo design strategies. Likewise, the FDA 
regulatory approval associated with this new class of ECM biomaterials may possibly avoid the 
more costly and time consuming PMA process and instead follow a less stringent 510(k) approval 
process due to its similarity to existing commercially available DBM products.  
Although significant focus was given to acellular ECM strategies, critical perspectives on 
SCBTs were also discussed. While the reviewed chondrogenic priming studies collectively 
concluded that in vitro stimulation was a necessary step to elicit EC ossification, contradicting 
evidence with acellular DBM implants suggests that the inclusion and priming of stem cells is not 
a requirement and may be obviated with the proper inclusion of native ECM components.85-91 
Regardless of this contradiction, SCBT strategies provided evidence that modulating hypertrophic 
signals in bone regenerative implants may lead to a significant enhancement of EC ossification 
(Table 3.2-3.4). Furthermore, SCBTs provide additional chondrogenic and osteogenic potential 
within implants compared to acellular ECM biomaterials that alternatively rely upon stem cell 
recruitment from surrounding host tissue. It is not clear if current orthopedic products in the pre-
clinical and clinical development phase utilize in vitro expansion strategies, but according to 
Jaklenec et al.75, a majority of SCBTs across the entire area of tissue engineering and regenerative 
medicine favor autologous cells (59%) compared to allogeneic (39%) and xenogeneic (2%) cell 
sources. This indicates the industry’s growing interest in developing SCBTs, but it should be 
emphasized that regulatory approval is not a guarantee of commercial success. Intraoperative 
SCBT strategies may address these concerns by reducing or removing the burden of in vitro cell 
expansion without compromising the chondrogenic and osteogenic potential of incorporated stem 
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cells, thus furthering the bone regenerative potential of ECM implants along with overall 
commercial feasibility.  
In summary, native ECM biomaterials inherently possessing ideal conductive, inductive, 
and mechanical properties have yet to be considered with respect to EC ossification and 
developmental engineering principles in general. A variety of ECM biomaterial criteria have been 
reviewed here, which are promising for regenerative investigations spanning bone, cartilage, and 
osteochondral defects. In the future, in vivo comparisons will be necessary to provide substantial 
evidence that native ECM biomaterials mimicking aspects of the reparative procallus 
microenvironment will provide superior performance compared to traditional tissue engineering 
strategies and current standards of treatment.     
 
5. LIST OF ABBREVIATIONS 
AATB – American Association of Tissue Banks; ABG – Autologous Bone Grafting 
AC – Articular Chondrocyte; ADSC – Adipose Derived Stem Cell; ALP – Alkaline Phosphatase; 
BCP – Biphasic Calcium Phosphate; BMSC – Bone Mesenchymal Stem Cell; BMP – Bone 
Morphogenic Protein; β-TCP – Beta Tricalcium Phosphate; DBM – Demineralized Bone Matrix; 
DCC – Decellularized Cartilage; ECM – Extracellular Matrix; EC – Endochondral Ossification; 
ESC – Embryonic Stem Cell; FDA – Food and Drug Association; HAP – Hydroxyapatite; 
HCT/P – Human cells, tissue and cellular and tissue based products; IM – Intramembranous 
Ossification; iPSC – Induced Pluripotent Stem Cell; MEF2C – Myocyte Enhancer Factor 2C; 
MMP – Matrix Metalloproteinase; PMA – Pre Market Approval; PRP – Platelet Rich Plasma; 
Runx2 – Runt Related Transcription Factor 2; SCBT – Stem Cell Based Therapeutic; SDSC – 
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Synovium Derived Stem Cell; SVF – Stromal Vascular Fraction; UMSC – Umbilical Cord Stem 
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Malleable and injectable colloidal gels can be designed to exhibit self-assembling and shear-
response behavior that may facilitate minimally invasive bone tissue filling. This study 
demonstrated that native extracellular matrix (ECM) microparticles, specifically demineralized 
bone matrix (DBM) and decellularized cartilage (DCC), could be formulated as injectable 
viscoelastic colloidal fluids when combined with hyaluronic acid (HA) and hydroxyapatite (HAP). 
An array of HA-ECM microparticle suspensions and HA-HAP-ECM colloidal gels exhibited 
either equivalent or substantially higher storage modulus (G′ ≈ 100-10,000 Pa), yield stress (τy ≈ 
100-1000 Pa), and viscoelastic recovery (G′Recovery ≥ 87%) kinetics compared to control fluids. 
Some rheological differences were observed between respective DBM and DCC formulations, 
especially in HA-HAP-DBM colloids, where both G′ and τy were significantly higher (p < 0.01) 
than corresponding DCC mixtures. However, both DBM and DCC loaded suspensions and 
colloidal gels represent worthwhile options for future studies involving osteo- and chondro- 
regeneration. To date, this represents the first attempt to form composite colloidal gels with native 
ECM microparticles. Overall, this study identified notable HA-ECM and HA-HAP-ECM 
formulations to facilitate surgical placement and implant retention in non-load bearing tissue 
defect applications ranging from cranial and maxillofacial reconstruction to pelvic and 









Self-assembling and shear-responsive biomaterials possess favorable rheological and 
viscoelastic properties for filling bone tissue defects.7, 8, 63 Such materials may be designed to be 
injectable to facilitate minimally invasive surgery that reduces risk of infection, scar formation, 
patient discomfort, and possibly cost of treatment.7, 8, 63 In addition, these malleable biomaterials 
may also be designed to possess viscoelastic recovery following surgical placement to ensure 
sufficient retention of material at the defect site. Although numerous non-setting bone pastes 
already exist in the orthopedic market including DBX® (MTF/Synthes), Dynagraft II (Integra 
Orthobiologics), Grafton® Gel (Osteotech), Puros® DBM (Zimmer), and TricOS (Baxter)5, the 
majority of these products contain suspended microparticles within a viscous carrier fluid. These 
microparticle formulations can be prone to exhibit undesirable phase-separation upon injection 
(e.g., filter-pressing) and following placement in the tissue defect (e.g., sedimentation)4, 27, leading 
to poor retention at the defect site.28 In addition, some ceramic microparticles have also displayed 
poor resorption kinetics in vivo, leading to their undesired persistence in the defect and delaying 
bone healing.174   
Meanwhile, malleable colloidal gels comprised exclusively of nanoparticles have been 
identified as promising viscoelastic fluids for facilitating both surgical placement and wound site 
retention (Chapter 2).10, 11, 175 The macroscopic rheological properties of these materials rely on 
the cohesive strength of physical crosslinking, which depend on electrostatic forces, van der Waals 
attraction, and steric hindrance in the microstructure.8, 11, 12, 175 As a result, self-assembling and 
shear-responsive colloidal fluids may be designed to yield or flow in response to variations in 
external stress (i.e., injection) and rapidly recover these properties following placement. Previous 
investigations have explored leveraging these interactions in nanoparticles composed of 
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poly(lactic-co-glycolic) acid10, 11, gelatin16, 19, 20, dextran17, 18, and hydroxyapatite (HAP)175, 176 to 
form cohesive colloidal gels. While colloidal nanoparticles may exhibit advantageous physical 
properties for implantation, their higher surface area-to-volume ratio compared to respective 
microparticles can also be exploited to expedite material resorption and to modulate the release of 
incorporated bioactive signals. Recently, nanoparticle gelatin colloids were shown to enhance 
rheological properties and prolong delivery of bioactive molecules compared to corresponding 
microparticle gels both in vitro and in vivo.19, 20 While loading and release of bioactive growth 
factors has been a major focus of colloidal technology, a less explored area of research has focused 
on utilizing the bone regenerative potential of colloidal components themselves.    
Shear-responsive HAP formulations represent an intriguing sub-category within colloidal fluid 
designs since this biomolecule closely resembles biological apatite nanoparticles found in native 
bone extracellular matrix (ECM).21, 22 Recently, it was shown that the rheology of pure HAP 
colloidal gels could be modulated with the addition of native glycosaminoglycan (GAG) polymers, 
including hyaluronic acid (HA), to elicit varying degrees of consistency, flow behavior, and 
viscoelastic recovery without compromising the material’s inherent yield stress (Chapter 2).175 
These polymer-particle colloidal gels exhibited synergistic bulk fluid properties likely due to 
physical crosslinking and bridging flocculation, where multivalent GAG polyanions adsorbed 
simultaneously to multiple HAP particles in close proximity. Furthermore, these GAG-HAP 
composites represented the first attempt to exclusively combine native biomolecules in a colloidal 
system for tissue defect filling.  
Native ECM biomaterials have been a key protagonist in the area of bone regeneration since 
they possess both conductive and inductive signaling moieties that are difficult to match with 
synthetic scaffold designs.76-80 Demineralized bone matrix (DBM) from allogeneic sources 
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remains one of the most utilized native ECM biomaterials for bone regeneration5 since it resembles 
portions of the complex composition and structure of healthy bone.65-67, 69, 70 DBM’s osteogenic 
potential has previously been correlated to the relevant concentration of bone morphogenic 
proteins (BMPs).5, 71 However, recent evidence has shown that the structural components of native 
ECM also provide regulatory control on signaling activity of soluble growth factors and modulate 
cell adhesion, proliferation, differentiation, and migration.80, 104 Therefore, the coupling of DBM 
microparticles within a colloidal fluid carrier, such as GAG-HAP, may act to enhance both the 
physical (e.g., rheological) and chemical (e.g., osteoinductive) properties of traditional bone 
pastes. 
An alternative native ECM biomaterial strategy has also recently emerged which relies upon 
mimicking the processes of developmental skeletogenesis involved in native bone healing 
(Chapter 3).177 While traditional ECM biomaterials such as DBM implants aim to mimic the 
composition of healthy bone, it is well understood that the fracture space undergoes extensive 
spatiotemporal ECM changes before bone can be formed.65-67, 69, 70 More specifically, a 
fibrocartilaginous ECM is generated primarily through the process of endochondral (EC) 
ossification, where cartilage precursor tissue is formed prior to bone, as opposed to direct bone 
formation by intramembranous (IM) ossification.65-67, 69, 70 While DBM has been shown to elicit 
both EC and IM ossification in critical-sized defect models85-88, DBM implants may elicit a limited 
bone regenerative response compared to ECM biomaterials mimicking the early inflammatory and 
intermediate fibrocartilaginous ECM observed of fracture repair, commonly referred to as the 
procallus or soft callus.65-67, 69, 70  
To address this underexplored area of bone regeneration, decellularized cartilage (DCC) has 
been proposed as a possible procallus ECM biomimetic.177 DCC has emerged as an ECM 
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biomaterial rich in both chondroinductive and chondroconductive potential.77, 79, 80 Current 
commercially available products utilizing articular cartilage and/or DCC include Biocartilage® 
(Arthrex), De Novo NT® and ET® Live Graft (Zimmer), and Chondrofix® (Zimmer). However, all 
of these products use cartilage ECM for the sole purpose of regenerating cartilage tissue. Exploring 
DCC’s potential for modulating and enhancing EC ossification remains underexplored. However, 
recent evidence from our group suggests that DCC may stimulate bone mesenchymal stem cells 
(BMSCs) to differentiate into hypertrophic chondrocytes [unpublished], a necessary intermediate 
step in the EC ossification pathway. Thus, the incorporation of DCC microparticles with existing 
H-B fluid formulations may be a worthwhile scaffolding strategy to address bone regeneration in 
critical-sized non-load bearing defects.      
In the current study, rheological and viscoelastic performance was assessed in HA-HAP 
colloidal gels combined with micronized native ECM biomaterials. This builds upon previous 
work that mapped and identified GAG-HAP colloidal gel candidates with promising yield stress, 
consistency, flow behavior and recovery properties to explore surgical delivery into non-load 
bearing bone defects (Chapter 2).175 However, the HA used in these previous studies only consisted 
of relatively small molecular weight polymers (20-41 kDa). Since HA is available across a large 
range of molecular weights (MW = 10-1000s kDa), there may be rheological advantages of using 
higher MW polymers in colloidal gels. Initial results in the current study highlighted the effect of 
HA polymer molecular weight (35-1500 kDa) on the resulting fluid parameters in HA-HAP 
colloidal formulations. It was hypothesized that at a given concentration higher molecular weight 
HA formulations could produce superior rheological and viscoelastic performance compared to 
lower molecular weight HA.  
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Additionally, this study represents the first attempt to form colloidal gel composites with 
incorporated native ECM microparticles. More specifically, this study aims to elucidate the 
relationship between bulk fluid properties and relative HA polymer, HAP nanoparticle, and ECM 
microparticle composition. While the addition of ECM microparticles may in the future prove to 
enhance the osteo-regenerative capability of HA-HAP colloids, it was hypothesized that the 
addition of ECM microparticles would disrupt the existing colloidal interactions between HA and 
HAP, leading to inferior rheological and viscoelastic performance. Despite this potential 
weakening of the colloidal network, the primary goal of this assessment was to identify worthwhile 




Hydroxyapatite was purchased as a powder (Davg ≤ 200 nm (BET Analysis); Sigma-Aldrich).  
Hyaluronic acid at various molecular weights (Mw = 21-40 kDa, Mw = 351-600 kDa, Mw = 1200-
1800 kDa) (Lifecore Biomedical; Chaska, MN) was purchased as a sodium salt. 
2.2.Demineralized Bone Matrix and Decellularized Cartilage Procurement 
Human demineralized bone matrix was procured as a course ground powder (Biomet, Irvine, 
CA). DBM particles were cryo-ground into a fine powder with a freezer-mill (SPEX, SamplePrep, 
Metuchen, NJ), and particles were sieved (Spectra/Mesh Woven Filters, Spectrum Laboratories, 
Inc., Rancho Dominguez, CA) to exclude particles measuring above 350 μm to facilitate 
subsequent rheometer experiments. 
Decellularized cartilage procured from porcine knee and hip joints was purchased from a local 
abattoir following sacrifice (120 kg, mixed breed, mixed gender) (Bichelmeyer Meats, Kansas 
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City, KS). Articular cartilage from both the knee and hip joints was carefully removed and 
collected using scalpels. The cartilage was rinsed in phosphate buffered saline (PBS) and stored at 
-20°C. Following freezing, the cartilage was coarsely ground using a cryogenic tissue grinder 
(BioSpec Products, Bartlesville, OK). The coarsely ground tissue was packaged into dialysis 
tubing (3500 MWCO) packets for decellularization.  
An adapted version of our previously established cartilage decellularization method was used 
which included reciprocating osmotic shock, detergent, and enzymatic washes.178 Reagents were 
purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. All steps of 
decellularization were carried out under agitation (200 rpm) at 21°C unless otherwise noted. First, 
the cartilage packets were placed in hypertonic salt solution (HSS) overnight to disrupt membranes 
and lyse the cells. Following HSS treatment, the tissue was subjected to 2 cycles of reciprocating 
triton-X 100 (0.05% v/v) and HSS treatments to further breakdown cellular membranes. The tissue 
was then treated with benzonase (0.0625 KU ml-1) overnight at 37°C to fragment nucleic acids. 
Sodium-lauroyl sarcosine (NLS, 1% v/v) was then used overnight to further solubilize and remove 
cells. Next, the tissue was washed with 40% ethanol, followed with organic exchange resins to 
remove all organic solvents. Lastly, the tissue was removed from the dialysis tubing packages and 
rinsed with deionized water before freezing.  
After decellularization, the tissue was lyophilized for 48 hours and cryo-ground into a fine 
powder with a freezer-mill (SPEX SamplePrep, Metuchen, NJ). Particles were sieved 
(Spectra/Mesh Woven Filters, Spectrum Laboratories, Inc., Rancho Dominguez, CA) to exclude 
particles measuring above 350 μm. Size measurements of micronized DCC and DBM particles 




2.3.Preparation of Colloidal Gels 
HA polymers were combined with HAP nanoparticles according to our previously published 
protocols in PBS solution (pH = 7.4, 150 mM NaCl).175 HA concentrations were varied between 
0-15%, 0-5%, and 0-2% (w/v) in colloidal mixtures containing 35 kDa, 350 kDa and 1500 kDa 
HA polymers, respectively. HA:HAP weight ratio (w:w) was controlled by the incremental 
addition of HAP particles to HA solutions. These mixtures were compared to pure component 
controls (HA and HAP), respectively. Overall volume fraction of HAP (ΦHAP = VHAP/VTOTAL) was 
calculated from particle density and resulting mixture volume measurements. Additional sizing 
and zeta-potential measurements of HAP nanoparticles in the presence of HA polymers at various 
molecular weights (35, 350, and 1500 kDa) were conducted using dynamic light scattering 
(Brookhaven; ZetaPALS) to analyze colloidal particle-polymer interactions.  
Lyophilized DBM and DCC microparticles were formulated as HA-ECM suspensions and HA-
HAP-ECM colloids to elucidate the effect of ECM on rheological and viscoelastic properties 
(Table 4.1 and Table 4.2). This was achieved by maintaining constant media volume (1 ml), HA 
concentration (1-2% w/v) and HAP volume fraction (ΦHAP = 30-32%) in the tested fluids. The 
incremental incorporation of ECM was varied in terms of dry mass fraction (wDCC = 3-9% and 
wDBM = 3-28%) and in terms of volume fraction (ΦDCC = 15-45% and ΦDBM = 5-45%). ECM 
volume fraction was estimated from measured water content and density of respective particles 
following hydration. ECM hydration was assumed to be 100% in all formulations. In reality, the 
incorporated HA polymers likely exhibit some amount of osmotic pressure on nearby ECM 
particles, leading to a hydration equilibrium state slightly below 100%. Although the dynamics of 
this equilibrium were not characterized in this study, the amount of incorporated media was well 
above the hydration limit of DCC and DBM. At this limit, it could be assumed that all available 
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media in the formulation would reside within ECM particles, leaving no free media to solubilize 
the carrier fluid. Homogeneous suspensions and colloid mixtures were prepared by manual stirring 
(5 min) at ambient conditions and stored at 4°C. Samples were allowed to equilibrate to ambient 
conditions (2 hr) before testing. 
2.4.Swelling Characterization 
Relative swelling ratios (S) of colloidal gels were determined by placing 1.0 mL of PBS (pH 
= 7.4, 150 mM NaCl) on top of 0.5 mL of material contained in a 2 mL Eppendorf tube. Tubes 
were then constantly agitated (24 hr, 100 rpm, 37°C) in an incubator shaker (New Brunswick 
Scientific; Excella E24). Swelling ratio (S = (M(swollen)-M(before))/M(before)) was determined from the 
initial (M(before)) and final (M(swollen)) mass of the material as described by Holland et al.
47 The final 
weight was determined by removing excess PBS from tube and drying the surface of gel with 
evaporative paper.   
2.5.Rheological and Viscoelastic Characterization 
The rheological and viscoelastic properties of HA-HAP colloidal formulations (Table 4.1) 
consisting of 35, 350, and 1500 kDa HA were characterized using a controlled stress rheometer 
(TA Instrument; AR2000) and compared to an HAP colloidal control group. In addition, HA-ECM 
microparticle suspensions and HA-HAP-ECM colloidal gel formulations (Table 4.2) were tested 
for rheological and viscoelastic performance compared to respective HA (1500 kDa), HAP, and 
HA-HAP controls. All measurements were performed at a gap distance of 500 µm using a 
roughened stainless steel plate geometry (20 mm diameter) and roughened base plate to minimize 
slip conditions. All samples were tested at 37°C.     
Viscoelastic properties and recovery kinetics following temporary disruption of the colloidal 
gel network were determined by measuring viscoelastic properties as described by Ozbas et al.48 
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Initially, an oscillatory stress sweep (1-10,000 Pa) was performed at a constant frequency (1 Hz) 
to determine several fluid properties, including storage modulus (G′), loss modulus (G″), loss angle 
(δ), and yield stress (τy) within the linear viscoelastic (LVE) region of each fluid, which is 
characterized by G′ and G′′ behaving independent of external stress or strain at a given oscillatory 
frequency.57 Within the LVE, strain measured during small external oscillatory stress is controlled 
by rates of spontaneous rearrangements or relaxations in the fluid, and thus can be assumed to 
represent the resting, or quiescent, state of the fluid.57 The upper boundary limit of the LVE region 
was used to approximate the yield stress, τy [Pa], in the material.
179, 180 To ensure internal 
consistency in estimating this boundary limit, τy was calculated from the external oscillatory stress 
corresponding to a 10% reduction in G′ averaged within the fluid’s LVE region. Above the LVE, 
stress induced deformations cause temporarily disruptions in the fluid microstructure. Subsequent 
gel recovery time sweeps were conducted as four alternating rounds of intense oscillatory 
disruption above the LVE region (30 s, 1000 Pa, 1 Hz) and recovery within the LVE region (5 
min, 10-25 Pa, 1 Hz) at 37°C following pre-shear (1 min, 100 s-1) and equilibration (5 min). 
Recovery was assessed 5 minutes after disruption and expressed as a percentage (G′recovery = 
G′(Final)/G′(Initial) •100%) compared to initial G′ in the mixture.  
2.6. Statistical Analysis 
All measurements were performed in triplicate (n = 3) and depicted as average ± standard 
deviation (SD) unless stated otherwise. Statistical analyses of data were performed using one-way 
analysis of variance (ANOVA) and Tukey’s HSD was used post-hoc to compare differences 






3.1. Colloidal Characterization 
3.1.1. DCC, DBM, and HAP Sizing 
SEM was used to verify particle size of DCC, DBM, and HAP (Figure 4.1A-C). Both DCC 
and DBM dry powders exhibited polydisperse size (Davg ≈ 10-100s μm) and heterogeneous 
morphology. All imaged particles appeared to be below the mesh screen size (< 350 μm), verifying 
effectiveness in sieving particles. HAP nanoparticles appeared to be of spherical particle 
morphology with polydisperse diameters near the supplier’s specified value (Davg ≤ 200 nm (BET); 
Sigma-Aldrich); however, a small fraction of particles were observed to exceed this specification.   
3.1.2. Effective Diameter and Zeta Potential 
Dynamic light scattering was used to measure HAP particle size (nm) and zeta potential (mV) 
in the presence of solubilized 35, 350, and 1500 kDa HA. Dilute suspensions (0.167 mg/ml) of 
pure HAP particles were combined with HA at a 1:1 weight ratio. Both the effective diameter and 
zeta potential magnitude increased with HA molecular weight (Table 4.3). However, only 350 and 
1500 kDa HA resulted in a significant increase in measured particle size and zeta potential (p < 
0.01) compared to pure HAP suspensions.  
3.2. Swelling Characterization 
Relative swelling of HA-HAP colloidal formulations (Figure 4.2) composed of 35, 350, and 
1500 kDa HA increased with a clear dependence on ΦHAP. While sedimentation and swelling 
tolerances were initially set (-20% ≤ S ≤ 20%) in an attempt to identify suitable HA-HAP 
candidates for retention of material at a bone defect surgical site, the most desirable colloidal 
mixtures exhibited the least amount of swelling or sedimentation (S ≈ 0%). Swelling increased 
with increasing HA molecular weight but could be maintained within the swelling tolerances by 
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decreasing polymer concentration. HA-HAP formulations at all tested molecular weights appeared 
to minimize swelling and sedimentation at ΦHAP ≈ 0.30. Therefore, this value was targeted in 
subsequent rheological and viscoelastic characterization studies.   
Pure DCC and DBM water content and density upon hydration was also measured with the 
swelling protocol. Water content in hydrated particles was determined to be 80.5 ± 1.0% (w/w) 
and 39.5 ± 2.1% for DCC and DBM, respectively. The corresponding densities of hydrated DCC 
and DBM were 1.09 and 1.06 g/ml.   
3.3. Rheological and Viscoelastic Characterization 
3.3.1. HA Molecular Weight Studies  
3.3.1.1. Storage Modulus (G′) and Loss Angle (δ) 
Measuring shear strain in response to an increasing external oscillatory shear stress allowed 
for quantification of relevant viscoelastic properties, including G′, G″, δ, and τy, within and above 
the LVE region of tested HA-HAP fluids with varying HA molecular weight (Table 4.1). The 
presence of either HA or HAP resulted in measurable G′ and G″, indicating that all tested fluids 
resided within the viscoelastic spectrum (Figure 4.3). A significant increase in G′ was observed 
when HAP was added to pure HA solutions, regardless of polymer molecular weight, to form HA-
HAP colloidal gels. Furthermore, there was a significant increase (p < 0.01) in G′ for HA(350)-
HAP and HA(1500)-HAP colloids compared to the pure HAP control fluid. This increase in G′ 
appeared to be combinatorial for these colloids, where G′HA-HAP >> G′HA + G′HAP. The measured 
δ in HA-HAP colloids was 18°, 12°, and 13° for HA 35, 350, and 1500 kDa formulations, 
respectively. These values were more similar to the loss angle of pure HAP (δ = 7°) than respective 




3.3.1.2. Yield Stress (τy) 
Yield stress (Figure 4.3) in each tested fluid was approximated at the upper boundary limit of 
the LVE region obtained from the stress sweep profile. Measureable τy amongst pure HA 
solutions was only observed in 1500 kDa HA at 1% w/v. All tested formulations with HAP had a 
measureable τy. In the 1500 kDa HA-HAP colloid where both pure HA and pure HAP controls 
possessed independent τy values, the resulting colloidal τy appeared to be an additive property of 
the fluid, such that τy (HA-HAP) ≈ τy (HA) + τy (HAP).         
3.3.1.3. Viscoelastic Recovery (G′Recovery and δRecovery) 
Following intense oscillatory disruption of the fluid microstructure, all tested colloids 
exhibited near complete recovery of G′ (≥ 98%) within 5 minutes (Figure 4.4C). Repeated 
disruption did not affect the ability of these colloids to recover their resting viscoelastic properties 
(Figure 4.4A). All tested colloidal formulations displayed a shift toward more viscous behavior 
during disruption (δDisruption  90°), and likewise exhibited a shift toward more elastic behavior 
during recovery (δRecovery  0°) (Figure 4.4B).      
3.3.2. HA-ECM and HA-HAP-ECM Viscoelastic Studies 
3.3.2.1. Storage Modulus (G′) and Loss Angle (δ) 
Based on the HA molecular weight rheological results in HA-HAP colloids, 1500 kDa HA was 
chosen for subsequent use in HA-ECM and HA-HAP-ECM studies (Table 4.2). A significant 
increase in G′ was observed (p < 0.01) upon addition of DCC and DBM in HA-ECM microparticle 
suspensions (Figure 4.5). G′ increased with increasing ECM concentration in the suspension. 
While there was no significant difference between HA-DCC and HA-DBM formulations with 
regard to ECM mass fraction, HA-DBM exhibited significantly higher G′ than corresponding HA-
DCC (p < 0.01) at ΦECM = 0.30 and 0.45. No ECM concentration trend was observed in G′ of HA-
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HAP-ECM colloids. However, all HA-HAP-DBM formulations exhibited significantly higher G′ 
values than both HAP (p < 0.01) and HA-HAP (p < 0.05) controls as well as corresponding HA-
HAP-DCC formulations (p < 0.05). HA-HAP-DCC colloids did not have significantly different G′ 
values compared to HA-HAP, but they did exhibit significantly higher G′ than the HAP control. 
Above ΦDBM = 0.30, HA-HAP-DBM colloids appeared to incompletely hydrate during 
reconstitution and fractured upon mixing. Consequently, these samples could not be tested on the 
rheometer.   
While the addition of DCC microparticles to HA suspensions and HA-HAP colloids did not 
significantly change δ values, DBM microparticles exhibited significantly more elastic behavior 
than respective HA (p < 0.01) control. DBM formulations also resulted in more elastic behavior 
than corresponding DCC suspensions (p < 0.01) and colloids (p < 0.01) at a given mass and volume 
fraction. However, both HAP and HA-HAP were observed to have similar elastic behavior to HA-
HAP-DBM formulations. 
3.3.2.2. Yield Stress (τy) 
While measureable τy was observed in all formulations tested (Figure 4.5), no significant 
differences were observed when DCC or DBM was added to HA suspensions, except at ΦDBM = 
0.45 (p < 0.01). HA-HAP-DCC colloids only showed a significant increase in τy at the highest 
tested volume fraction of DCC (ΦDCC = 0.45) compared to HA, HAP, and HA-HAP controls (p < 
0.01). Furthermore, increasing DCC concentration in the colloid appeared to result in an increased 
τy. This trend was not observed in HA-HAP-DBM colloids, where increasing DBM concentration 
in the colloid resulted in a decreased τy. However, all tested HA-HAP-DBM colloids exhibited 




3.3.2.3. Viscoelastic Recovery (G′Recovery and δRecovery) 
All tested HA-ECM and HA-HAP-ECM fluids and corresponding controls exhibited near 
complete recovery of G′ (≥ 87%) within 5 minutes (Figure 4.6C). Recovery experiments with DCC 
and DBM were only run at an equivalent volume fractions (ΦECM = 0.15) since few differences 
were observed in previous ECM viscoelastic stress sweep profiles. Similar to HA-HAP molecular 
weight studies, repeated disruption of HA-ECM and HA-HAP-ECM did not affect the ability of 
these fluids to recover their resting viscoelastic properties (Figure 4.6A). All tested colloidal 
formulations displayed a shift toward more viscous behavior during disruption (δDisruption  90°), 
and likewise exhibited a shift toward more elastic behavior during recovery (δRecovery  0°) (Figure 
4.6B).      
3.3.2.4. Needle and Syringe Fluid Extrusion Study 
All tested formulations from the viscoelastic recovery study above were subsequently tested 
for injectability. All fluids were successfully loaded into 1 ml syringes and readily extruded 
through attached 18-gauge needles (Figure 4.7A). Qualitatively, only HA-HAP and HA-HAP-
ECM colloids appeared to exhibit substantial shape retention following extrusion, while HA, HAP, 
and HA-ECM suspensions appeared to exhibit primarily viscous behavior (Figure 4.7A). 
Furthermore, only HA-HAP and HA-HAP-ECM could be subsequently molded into shapes 
following extrusion (Figure 4.7B) and maintain shape in ambient conditions following handling 
(Figure 4.7C).   
 
4. DISCUSSION 
The effects of molecular weight on polymer solution rheology and viscoelasticity has been 
thoroughly characterized. 37-40 At non-dilute concentrations, these solutions exhibit complex, non-
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Newtonian behavior due to increased intermolecular entanglements and self-associations of 
polymer chains in the solution.37-40 Highly viscous and shear-thinning HA solutions of varying 
molecular weight and concentration have been studied for biomedical applications such as 
synovial fluid supplements and as inert carrier fluids in tissue engineered scaffolds.5, 181, 182 More 
recently, our group studied the effects of HA (35 kDa) in HAP colloidal gels for tissue defect 
filling.175 Rheological and light scattering data from these studies supported the hypothesis that 
multivalent HA polymers adsorbed to surrounding HAP nanoparticles forming ‘bridging’ 
flocculations within the polymer-particle colloidal network. This interaction led to a combinatorial 
increase in corresponding bulk fluid rheology, which was mapped across an extensive array of 
concentrations and particle-polymer ratios to fit potential tissue filling parameters.175      
Initial light scattering experiments in the current study showed similar polymer-particle 
colloidal interactions exist with higher molecular weight HA (350 and 1500 kDa) formulations. 
The inclusion of HA (350 and 1500 kDa) at dilute HAP concentrations significantly increased 
overall effective diameter and zeta potential (p < 0.01) of HAP particles (Table 4.3) compared to 
HA 35 kDa and pure HAP control. While increased zeta potential at dilute concentrations may 
translate to increased attractive strength of bridging flocculations at high colloidal concentrations, 
the resultant increase in particle diameter may act to inhibit particle flocculation via steric 
repulsion183, 184 and compromise beneficial particle-polymer interactions seen with higher 
molecular weight HA. While strengthening inter-particle attraction would hypothetically lead to 
increased elastic behavior in tested viscoelastic colloidal fluids, characterized by a higher G’ and 
τy along with lower δ, increasing steric repulsion between particles would likely lead to an 
opposing viscous shift.  
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Evidence from swelling (Figure 4.2) revealed that even at lower HA concentrations, the higher 
molecular weight HA polymers (350 and 1500 kDa) in HA-HAP formulations exhibited similar 
sample spanning flocculation networks compared to HA(35 kDa)-HAP. Furthermore, 
corresponding viscoelastic studies (Figure 4.3 and 4.4) with these gels showed that higher 
molecular weight HA formulations led to a significant increase in elastic behavior compared to 
HA(35 kDa)-HAP. Collectively, this evidence supports the hypothesis that higher molecular 
weight HA strengthens the resulting bridging flocculations in HA-HAP colloids. While some steric 
repulsive effects may have been present, their contribution to the resulting bulk rheological 
properties was not observed and may have been outweighed by attractive polymer-particle 
interactions.  
Ultimately, these molecular weight studies showed that less HA was needed at 350 and 1500 
kDa to achieve equivalent rheological properties in HA-HAP colloids relevant for surgical 
delivery. The advantages of using 350 and 1500 kDa HA compared to lower molecular weight 
formulations are (i) the potential to achieve wider ranges of rheological properties for surgical 
applications and (ii) lower material requirements, which lead to smaller increases in osmolality of 
the colloid due to the addition of HA polyelectrolytes and associated sodium ions in solution. 
Because of these advantages, HA 1500 kDa was chosen for subsequent studies with ECM 
suspensions and colloids. 
Micronized DBM particles have been used extensively in bone tissue engineering 
applications.5 While DBM has often been formulated with inert polymer carrier fluids such as HA 
and glycerol, combining these particles with colloidal fluids has to date remained underexplored. 
Microparticles suspended in viscous media do not remain in suspension like colloidal 
nanoparticles undergoing Brownian motion.8, 12 This leads to phase separation and heterogeneity 
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over time. As a result, microparticle suspensions must be formulated near or above a critical 
concentration, the percolation threshold (Φp), such that particles are suppressed by the crowding 
or caging effect of neighboring particles and exhibit a randomly packed continuous network that 
spans the sample volume.185 While pure spheres have a geometric Φp threshold around 0.29, 
ellipsoids of various aspect ratios have lower thresholds. SEM images of micronized DCC and 
DBM (Figure 4.1) revealed slight ellipsoid morphology that could be approximated as having 
aspect ratios between 1/3 and 3. The corresponding Φp values for these morphologies were 
reported to be around 0.22.185  
HA-ECM suspensions and HA-HAP-ECM colloids were formulated to elucidate the effect of 
ECM, near ΦP, on rheological and viscoelastic properties during rest and during microstructure 
disruption. Because DCC and DBM exhibit different water contents and densities upon hydration, 
the effect of ECM on bulk fluid properties could be directly compared in terms of both mass and 
volume fraction (Table 4.1 and Table 4.2). It was hypothesized that the addition of ECM 
microparticles would effectively disrupt the continuity of the respective carrier fluid because shear 
stress experienced locally by a polymer confined between particles can be much larger than the 
bulk external shear stress57, 186, leading to inferior viscoelastic properties compared to HA, HAP, 
and HA-HAP controls. The evidence collected in these viscoelastic studies, however, did not 
support this phenomenon. Almost all tested HA-ECM and HA-HAP-ECM fluids exhibited 
equivalent or increased G′ and τy values compared to respective HA, HAP, and HA-HAP controls 
(Figure 4.5).  
A potential explanation of this result might be related to the hydration of the incorporated ECM 
microparticles. As these particles hydrate in the suspending HA solution or HA-HAP colloid, 
available aqueous media becomes scarcer and carrier fluid concentration increases. This 
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concentrating effect may counteract and outweigh the overall destabilizing contributions caused 
by stress localization of ECM microparticles. Although carrier fluid thickening may have occurred 
in both the microparticle suspensions and the colloidal gel formulations, the only identifiable trend 
was observed in the HA-ECM microparticle suspensions, where G′ increased with increasing ECM 
concentration (Figure 4.5). ECM concentration dependency was not observed in HA-HAP 
colloidal formulations, suggesting that competing fluid phenomenon could be occurring in these 
gels. This could be due to the fact that the total volume fraction (ΦTotal = ΦHAP + ΦECM) of these 
colloids resided well above (ΦTotal = 0.36-0.75) the estimated percolation threshold (Φp ≈ 0.22-
0.29). At these high concentrations, localized stress experienced the colloidal fluid may become 
significant compared to the concentrating effect of the ECM microparticles, leading to complex 
viscoelastic behavior.    
In general, it was also observed that DBM suspensions and colloids exhibited higher G′ and τy 
values than corresponding DCC formulations on both a mass and volume fraction basis (Figures 
5 and 6). Not all differences were shown to be significant, especially in HA-ECM suspensions 
where a significant increase in both G′ and τy was only observed at the highest ECM volume 
fraction (ΦECM = 0.45) (p < 0.01). However, HA-HAP-DBM colloids exhibited significantly higher 
G′ and τy than all mass fraction equivalent DCC colloidal formulations (p < 0.01). Some of these 
observed viscoelastic differences between DBM and DCC formulations could have been attributed 
to deviations in sample preparation, including fluid component heterogeneity and shear-history. 
During mixing and reconstitution, samples could have experienced a broad range of shear stresses, 
and strongly flocculated colloids have been shown to be extremely dependent on shear-history.187, 
188 Subsequent recovery studies, however, highlighted the fact that these gels recover viscoelastic 
properties very rapidly following microstructure breakdown. Allowing these samples to 
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equilibrate for multiple hours before testing ensured that shear-history effects were minimized. 
Heterogeneity of suspensions and colloids was also minimized by thoroughly mixing formulations 
as dry powders prior to reconstitution.     
Because the effect of both mass fraction and volume fraction of respective ECM components 
was controlled in these formulations, differences in water content and density of hydrated DBM 
versus DCC were accounted for in viscoelastic studies. However, differences in ECM intra-particle 
properties could have affected overall viscoelastic trends. Pure DBM would likely exhibit 
significantly higher elastic modulus compared to DCC under compression. Although these 
measurements were not directly collected in the current study, referenced values for elastic 
modulus of DBM (130-230 MPa)189 were several orders of magnitude higher than respective DCC 
values (1.9 MPa).153 Since both HA-ECM suspensions and HA-HAP-ECM colloids were 
formulated near or above Φp, ECM particles formed a continuous disordered network throughout 
the sample volume, meaning differences in intra-particle elastic modulus could have played a 
significant role in overall bulk viscoelastic properties.  
Inter-particle interactions between HAP and ECM particles may also have attributed to the 
differences between DBM and DCC formulations. It is possible that HAP interacted differently 
with DBM upon reconstitution compared to DCC since significant increases in G′ and τy were 
predominately observed in colloidal gels instead of microparticle suspensions. During 
demineralization, DBM is stripped of biological apatite, which has dimensions on the order of 
several nanometers.21, 22 The intimate association of apatite nanoparticles in healthy bone with the 
organic osteoid matrix, primarily collagen type 1, lead to a significant increase in the overall elastic 
modulus of the tissue (16-23 GPa).189 It may be possible that HAP nanoparticles present in tested 
colloidal formulations associated with DBM and subsequently increased G′ and τy. The mechanism 
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Overall, the rheological and viscoelastic properties of tested HA-ECM suspensions and HA-
HAP-ECM colloids were observed to be primarily dependent on the fluid properties of the 
respective carrier fluid, either HA or HA-HAP. However, the addition of DCC and DBM resulted 
in equivalent or higher G′, τy and G′Recovery values compared to control fluids, which directly 
contradicted our initial hypothesis. While some differences were observed between DCC loaded 
suspensions and colloids compared to DBM counterparts, the main finding of these studies was 
that HA-ECM and HA-HAP-ECM fluids could be readily formulated for potential surgical 
injection into tissue defects. To date, this represents the first attempt to combine native ECM 
microparticles with colloidal gel fluid carriers. The future work in this space will explore the osteo- 
and chondro- regeneration potential of both HA-ECM suspensions and HA-HAP-ECM colloids.  
Furthermore, the highest HA-DBM suspension explored in this study (ΦDBM = 0.45; WDBM = 
0.28) possessed a similar microparticle concentration compared to DBX® Paste and Putty 
commercial products (DBM 26% and 31% w/w) as reported by the supplier MTF/Synthes. This 
could be used as an external reference point for tested colloidal formulations, where significantly 
higher G′ values were observed in HA-HAP-ECM colloids (Figure 4.5). Although higher τy values 
were observed in the HA-DBM (ΦDBM = 0.45) suspension compared to tested colloidal 
formulations, it is possible for HA-HAP-ECM gels to be further refined by decreasing the relative 
amount of suspending media, leading to increases in both G′ and τy. As such, these studies were 
not designed to cover a comprehensive array of all possible HA, HAP, and ECM fluid 
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combinations. Instead, this study served to highlight the viscoelastic contribution of ECM filled 
HA suspensions and HA-HAP colloidal gels. Future refining work in this space may lead to 
enhanced rheological and viscoelastic features that may suit a wider variety of bone defect 
indications including but not limited to use in cranial, oral/maxillofacial, mandibular, pelvic and 
posterolateral spine reconstruction.   
 
6. LIST OF ABBREVIATIONS  
BMSC – Bone Mesenchymal Stem Cell; BMP – Bone Morphogenic Protein; DBM – 
Demineralized Bone Matrix; DCC – Decellularized Cartilage; ECM – Extracellular Matrix; EC – 
Endochondral Ossification; GAG – glycosaminoglycan; HA – hyaluronic acid; HAP – 
Hydroxyapatite; HHS – hypertonic salt solution; IM – Intramembranous Ossification; LVE – 
linear viscoelastic region; PBS – phosphate buffered saline   
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In vitro and in vivo performance of self-assembling and shear-responsive colloidal gels combined 
with micronized native extracellular matrix (ECM) biomaterials, specifically demineralized bone 
matrix (DBM) and decellularized cartilage (DCC), was assessed for potential bone regenerative 
properties. This builds upon previous work that characterized injectable colloidal formulations 
comprised of hyaluronic acid (HA), hydroxyapatite (HAP) nanoparticles, and ECM 
microparticles. A series of in vitro studies with rat mesenchymal stem cells (rBMSCs) tested cell 
viability and gene expression in an array of colloids combining HA, HAP, DCC, and DBM. While 
the incorporation of DCC in colloids resulted in a temporal gene expression profile that resembled 
the early stages of the endochondral (EC) ossification cascade in native bone fracture healing, the 
inclusion of HAP and DBM into formulations appeared to direct rBMSC differentiation down an 
osteogenic pathway. Colloidal formulations were then implanted in critical-sized rat calvarial 
defects and analyzed 8 weeks post-operation with MicroCT and histology. Despite supportive in 
vitro evidence that colloidal gels could significantly influence gene expression associated with EC 
ossification, incomplete regeneration of critical-sized defects was observed. Furthermore, no 
significant differences were observed in defects treated with colloidal gel formulations compared 
to the sham control. Evidence of EC ossification foci in the central region of the defect space, 
however, were only observed when animals were treated with colloidal gels. This may have been 
evidence of an enhanced EC ossification response, though notably not sufficient enough to 
regenerate the entire defect after 8 weeks. Overall, this study represented the first attempt to 
evaluate the efficacy of HA-ECM and HA-HAP-ECM colloid formulations in vitro and in vivo 
toward bone regeneration. Future studies will aim to reformulate colloidal gels to improve 




Addressing treatment strategies for non-load bearing bone applications is important to victims 
requiring cranial and maxillofacial reconstruction to pelvic and posterolateral spine augmentation. 
Recently, self-assembling and shear-responsive colloidal gels were formulated into complex 
viscoelastic fluids which possessed favorable rheological properties for filling bone tissue defects 
and retaining implanted material at the defect site following surgical placement (Chapter 2).175 
Furthermore, these colloidal gels were formulated exclusively from native extracellular matrix 
(ECM) biomaterials involved in the bone healing process including hyaluronic acid (HA), 
hydroxyapatite (HAP), demineralized bone matrix (DBM), and decellularized cartilage (DCC). 
While native ECM biomaterials have played an essential role in the area of bone regeneration76-80, 
the efficacy of native ECM combined with colloidal gels remains to be determined in both in vitro 
and in vivo bone models.       
Native ECM biomaterials have been implicated in bone regeneration strategies because they 
possess both conductive and inductive bioactive molecules that are difficult to reproduce with 
synthetic tissue engineered designs.76-80 Historically, autologous bone grafting (ABG) has 
remained the gold standard of treatment in bone repair due to autologous bone tissue inherently 
resembling healthy and native bone ECM, which attributes to its osteoconductive, osteoinductive, 
and osteogenic properties.1-3 However, concerns about ABG’s associated donor site morbidity, 
increased risk of infection, graft resorption problems, limited handling capacity and restricted 
tissue availability have led to the emergence of an entire market of alternative bone grafts and 
tissue engineered implants.1-3 Amongst these alternatives, allogeneic bone grafts and DBM have 
remained one of the most utilized native ECM biomaterials for bone regeneration since they 
resemble portions of the complex composition and structure of healthy bone.5 Several non-setting 
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DBM paste formulations are currently commercially available for regenerating bone tissue 
including DBX® (MTF/Synthes), Dynagraft II (Integra Orthobiologics), Grafton® Gel 
(Osteotech), and Puros® DBM (Zimmer).5 Although these formulations incorporate micronized 
DBM particles in a viscous carrier fluid to aid surgical delivery and retention in the defect, they 
can be prone to exhibit undesirable phase-separation upon injection (e.g., filter-pressing) and 
following placement in the tissue defect (e.g., sedimentation).4, 27 Recent studies combining DBM 
in HA-HAP colloidal gels showed that rheological and viscoelastic properties of non-setting 
microparticle pastes could be enhanced to improve surgical delivery and material retention in a 
tissue defect. Prolonged retention of bioactive ECM materials in a bone defect may potentially 
lead to an enhanced regenerative response in the host.  
Although some of DBM’s osteogenic potential has been attributed its relevant concentration 
of inductive bone morphogenic proteins (BMPs)5, 71, it has become increasingly evident that the 
structural components of native ECM also provide regulatory control on signaling activity of 
soluble growth factors and modulate key processes in tissue regeneration including cell adhesion, 
proliferation, differentiation, and migration.80, 104 While traditional ECM biomaterials such as 
DBM implants aim to mimic the composition of healthy bone, it is well understood that the fracture 
space undergoes extensive spatiotemporal ECM changes before bone can be formed.66, 67, 69-71 An 
alternative native ECM biomaterial strategy has recently emerged which relies upon mimicking 
the processes of developmental skeletogenesis involved in native bone healing (Chapter 3).177 
More specifically, a fibrocartilaginous ECM is generated primarily through the process of 
endochondral (EC) ossification, where cartilage precursor tissue is formed prior to bone, as 
opposed to direct bone formation by intramembranous (IM) ossification.66, 67, 69, 70 While DBM has 
been shown to elicit both EC and IM ossification in critical-sized defect models85-88, DBM 
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implants may elicit a limited bone regenerative response compared to ECM biomaterials 
mimicking the early inflammatory and intermediate fibrocartilaginous ECM observed of fracture 
repair, commonly referred to as the procallus or soft callus. To address this underexplored area of 
bone regeneration, decellularized cartilage (DCC) has been proposed as a possible procallus ECM 
biomimetic.177 DCC has emerged as an ECM biomaterial rich in both chondroinductive and 
chondroconductive potential.77, 79, 80 Current commercially available products utilizing articular 
cartilage and/or DCC include Biocartilage® (Arthrex), De Novo NT® and ET® Live Graft 
(Zimmer), and Chondrofix® (Zimmer). However, all of these products use cartilage ECM for the 
sole purpose of regenerating cartilage tissue. Exploring DCC’s potential for modulating and 
enhancing EC ossification remains underexplored.  
In the current study, the in vitro and in vivo performance of HA-HAP colloidal gels combined 
with micronized native ECM biomaterials was assessed for potential bone regenerative properties. 
This builds upon previous work that identified injectable HA-HAP-ECM colloidal gel 
formulations possessing similar or superior viscoelastic properties, including storage modulus 
(G′), yield stress (τy), and gel recovery (G′Recovery), to HAP and HA-HAP control formulations. It 
was hypothesized that enhanced viscoelastic properties would lead to improved retention of 
implanted material at the defect site, possibly translating to enhanced bone regeneration. In 
addition to rheological enhancement, it was hypothesized that both DCC and DBM loaded 
colloidal gels would lead to improved bone regeneration at the defect site compared to control 
formulations. The primary goal of this assessment was to determine whether micronized DBM and 
DCC particles loaded into HA-HAP colloidal gel formulations could significantly direct bone 
mesenchymal stem cell (BMSC) proliferation and differentiation toward bone phenotypes in vitro 




2.1. Colloidal Materials 
Hydroxyapatite was purchased as a powder (Davg ≤ 200 nm (BET Analysis); Sigma-Aldrich).  
Hyaluronic acid at various molecular weights (Mw = 21-40 kDa, Mw = 351-600 kDa, Mw = 1200-
1800 kDa) (Lifecore Biomedical; Chaska, MN) was purchased as a sodium salt. 
2.2. Demineralized Bone Matrix and Decellularized Cartilage Procurement 
Human demineralized bone matrix was procured as a course ground powder (Biomet, Irvine, 
CA). DBM particles were cryo-ground into a fine powder with a freezer-mill (SPEX, SamplePrep, 
Metuchen, NJ), and particles were sieved (Spectra/Mesh Woven Filters, Spectrum Laboratories, 
Inc., Rancho Dominguez, CA) to exclude particles measuring above 350 μm.   
Decellularized cartilage procured from porcine knee and hip joints was purchased from a local 
abattoir following sacrifice (120 kg, mixed breed, mixed gender) (Bichelmeyer Meats, Kansas 
City, KS). Articular cartilage from both the knee and hip joints was carefully removed and 
collected using scalpels. The cartilage was rinsed in phosphate buffered saline (PBS) and stored at 
-20°C. Following freezing, the cartilage was coarsely ground using a cryogenic tissue grinder 
(BioSpec Products, Bartlesville, OK). Following this step, tissue was considered to be devitalized 
cartilage (DVC). The coarsely ground tissue was packaged into dialysis tubing (3500 MWCO) 
packets for decellularization.  
An adapted version of our previously established cartilage decellularization method was used 
which included reciprocating osmotic shock, detergent, and enzymatic washes.178 Reagents were 
purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. All steps of 
decellularization were carried out under agitation (200 rpm) at 21°C unless otherwise noted. First, 
the cartilage packets were placed in hypertonic salt solution (HSS) overnight to disrupt membranes 
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and lyse the cells. Following HSS treatment, the tissue was subjected to 2 cycles of reciprocating 
triton-X 100 (0.05% v/v) and HSS treatments to further breakdown cellular membranes. The tissue 
was then treated with benzonase (0.0625 KU ml-1) overnight at 37°C to fragment nucleic acids. 
Sodium-lauroyl sarcosine (1% v/v) was then used overnight to further solubilize and remove cells. 
Next, the tissue was washed with 40% ethanol, followed with organic exchange resins to remove 
all organic solvents. Lastly, the tissue was removed from the dialysis tubing packages and rinsed 
with deionized water before freezing.  
After decellularization, the tissue was lyophilized for 48 hours and cryo-ground into a fine 
powder with a freezer-mill (SPEX SamplePrep, Metuchen, NJ). Resulting DCC particles were 
sieved (Spectra/Mesh Woven Filters, Spectrum Laboratories, Inc., Rancho Dominguez, CA) to 
exclude particles measuring above 350 μm. Course DVC particles were also micronized with 
cryogrinding, which served as a positive control group for cell viability and gene expression 
studies.    
2.3. Preparation of Colloidal Gels 
HA polymers were combined with HAP nanoparticles according to our previously published 
protocols in PBS solution (pH = 7.4, 150 mM NaCl).175 HA concentrations from 35, 350, and 1500 
kDa batches were varied between 0-15%, 0-5%, and 0-2% (w/v) in colloidal mixtures, 
respectively. HA:HAP weight ratio (w:w) was controlled by the incremental addition of HAP 
particles to HA solutions. These mixtures were compared to pure component controls (HA and 
HAP), respectively. Overall volume fraction of HAP (Φ = VHAP/VMixture) was calculated from 
particle density and resulting mixture volume measurements.  
Lyophilized DBM and DCC microparticles were combined with dry HA-HAP colloidal gel 
formulations before suspension in PBS. DCC and DBM concentrations were varied between 0-
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40% (w/w) in colloidal mixtures. Homogeneous colloid mixtures were prepared by manual stirring 
(5 min) at ambient conditions and stored at 4°C. Samples were allowed to equilibrate to ambient 
conditions (2 hr) before testing. 
2.4. BMSC Harvest, Expansion, and Seeding  
Rat bone marrow mesenchymal stem cells (rBMSC) were harvested from the femurs of male 
Sprague-Dawley rats (200-250 g) following a University of Kansas approved IACUC protocol. 
The BMSCs were cultured in minimum essential medium (MEM) α culture medium with 10% 
fetal bovine serum (FBS) and 1% antibiotic-antimycotic (anti-anti) during expansion. At passage 
4, the cells were suspended in MEM α culture media. In all studies, the medium was changed every 
48 hours.   
Initial studies identifying the effects of pure DCC on cell viability and gene expression seeded 
1x106 cells on 25 mg of non-sieved DCC or DVC microparticles. Results were compared to cells 
seeded with control expansion media (MEM α) and chondrogenic differentiation media composed 
of 10 ng/mL human recombinant transforming growth factor beta-3 (TGF-β3) (PeproTech, Rocky 
Hill, NJ), 50 µg/mL ascorbic acid, 1% Penicillin Streptomycin, 40 µg/mL L-proline, 100 µmol 
sodium pyruvate, 0.1 µm dexamethasone, 1% insulin-transferrin-selenium 100X, and 1% non-
essential amino acids. Cells were suspended in respective wells and centrifuged down (10,000 
RPM, 5 min) to form a pellet culture.  
The initial colloidal in vitro study aimed to identify the effects of HA, HAP, and DCC on cell 
viability over one week. Approximately 250 μL of reconstituted HA, HAP, HA-HAP, HA-DCC 
and HA-HAP-DCC fluid was placed in each well and then centrifuged (2,000 rpm, 1 min) to form 
a thin layer of material on the bottom of each well in 24-well non-treated culture plates. Cells were 
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seeded at 1x105 cells/well, and samples were analyzed for attachment (Day 1) and viability (Day 
7).  
The subsequent three week colloidal in vitro study compared the effects of DCC, DBM, and 
HAP on cell viability and gene expression in HA-ECM and HA-HAP-ECM fluid formulations. 
Thin layers of fluid material were deposited into wells with the same protocol used in the initial 
colloidal study. Treated 24-well plates were used to ensure that control groups exhibited sufficient 
cell viability for RNA isolation and gene expression experiments. Cells were seeded at 1x106 -
cells/well, and samples were analyzed for attachment (Day 1) and viability (Day 7, 14, and 21) 
along with gene expression at each time point.        
2.5. Cell Viability and Gene Expression Analysis 
Overall cell count was determined for each group (n = 6) using previously established 
protocols190 with a high sensitivity double-stranded DNA assay kit (Molecular Probes, Eugene, 
OR). A conversion factor of 8.5 pg DNA/cell may be used to convert DNA mass to cell number.190 
Subsequent gene expression profiles for each group (n = 5) were obtained following RNA isolation 
and purification from cells using the Qiagen RNeasy mini kit (Valencia, CA). All RNA samples 
were reverse transcribed using a high capacity cDNA reverse transcription kit (Invitrogen, 
Carlsbad, CA). Real-time quantitative polymerase chain reaction (RT-qPCR) was performed using 
a RealPlex MasterCycler (Eppendorf, Hauppauge, NY) and TaqMan gene expression assays 
normalizing for equal concentrations of cDNA in each sample. Rat specific commercial primers 
(Invitrogen, Carlsbad, CA) were used to analyze potential progression of cells through the EC 
ossification pathway. Collagen II (Col2A1), Sox9, and Aggrecan (Acan) were used as 
chondrogenic markers. Runx2 and Collagen X (Col10A1) were used as hypertrophic cartilage 
markers. Collagen I (Col1A1) and Bone Sialoprotein (BSP) were used to identify bone lineage. 
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The 2-∆∆Ct method was used to determine the relative expression of each gene with GAPDH used 
as an endogenous control.191, 192  
2.6. Surgical Implantation of Colloidal Gels in Cranial Defects 
Full thickness, critical-sized cranial defects (Diameter = 8 mm) in 7-8 week old Sprague-
Dawley rats were used as the non-load bearing bone defect model in this study. The use of animals 
and the surgical procedures used in this study were approved by the Animal Care and Use 
Committee at the University of Kansas Medical Center (Kansas City, KS). All surgical procedures 
were performed under general anesthesia and sterile conditions. Two intersecting incisions were 
made centered over the mid-sagittal suture of the skull. Following removal of the cranial 
periosteum, a full thickness defect was produced in the parietal bone using a dental burr. The 
wound was carefully rinsed with normal saline to remove any bone debris in the defect, which was 
an important step in this procedure for evaluating the formation of new bone within the cranial 
bone defect. The cranial defects were filled with injectable colloidal gel formulations containing 
HAP, HA-HAP, HA-HAP-DCC, HA-HAP-DBM, or left untreated (sham). The wound was closed 
with a 5-0 nylon suture. The day of surgery was designated as day “0”. Animals were sacrificed 8 
weeks after surgery and operated calvarial bones were harvested for gross anatomical imaging, 
micro-computed tomography (MicroXCT-200, Xradia Inc., Concord, CA) and histological 
analysis. 
2.7. Gross Anatomy and MicroCT Imaging 
After 8 weeks, cranial biopsies of treated rats were dissected for imaging by careful removal 
of dermal tissue (superior to defect) and brain tissue (inferior to defect) near the defect space. 
Gross anatomical images were taken from an inferior view of the calvaria to visualize any signs of 
inflammation and tissue regeneration. Following dissection, MicroCT images of calvaria were 
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taken to assess extent of mineralization and retention of implant material in and around the defect 
space. Images were superior views of the defect space and were virtually rendered using two 
visualization modes to highlight tissue deposits in the defect: shaded surface display (SSD) and 
volume rendering technique (VRT). In SSD, virtual surfaces were generated from a threshold 
density value that was held constant across all samples. Likewise, color and transparency mapping 
of virtual surfaces in VRT was controlled with a density transfer function in the software 
(TXM3DViewer, Xradia), which was held constant across all samples.   
2.8. Histology 
To evaluate the cellular and ECM responses to the implants, implanted materials were retrieved 
with the surrounding host bone, residual periosteum, and underlying brain tissue. Tissue samples 
were fixed in neutral buffered 10% formalin solution (Sigma-Aldrich), decalcified in Cal-riteTM 
solution (Thermo Scientific), embedded in paraffin, sectioned at 10 µm, and stained with either 
hematoxylin and eosin (H&E) or Safranin-O/Fast-green (Saf-O). 
2.9. Statistical Analysis 
All measurements were performed in triplicate (n = 3) and depicted as averages ± 95% 
confidence intervals unless stated otherwise. Statistical analyses of data were performed using one-
way analysis of variance (ANOVA) and Tukey’s HSD was used post-hoc to compare differences 






3.1. Characterizing in vitro Cell Response to Pure DCC 
3.1.1. Cell Viability 
A one week cell attachment (Day 1) and viability (Day 7) study comparing DCC treated cells 
to control media, chondrogenic media (TGF-β), and DVC showed that DCC exhibited significantly 
higher cell attachment than DVC (p < 0.01) and viability compared to control media (p < 0.05) 
and DVC (p < 0.01) (Figure 5.1). No significant differences were observed between DCC and 
TGF-β control. Overall DNA mass significantly increased (p < 0.01) for all treatment groups from 
Day 1 to Day 7 including control media (p < 0.05).   
3.1.2. Gene Expression 
Corresponding endochondral gene expression profiles of BMSCs treated with DCC were 
compared to control media, TGF-β control, and DVC. RT-qPCR data from Day 1, 3, and 7 was 
averaged (n = 15) for analysis (Figure 5.2). DCC exhibited significantly higher gene expression 
for all tested genes compared control media (p < 0.01) and DVC (p < 0.01). In addition, DCC 
exhibited significantly higher expression for Acan (p < 0.05), Sox9 (p < 0.01), Col2A1 (p < 0.01), 
RunX2 (p < 0.01) and Col10A1 (p < 0.01) compared to TGF-β with the exception being Col1A1. 
DCC, DVC, and TGF-β all exhibited significantly higher Sox9 expression relative to RunX2 (p < 
0.01).  
3.2. Characterizing in vitro Cell Response to HA-HAP and HA-HAP-DCC Colloids 
3.2.1. Cell Viability 
A one week cell attachment (Day 1) and viability (Day 7) study comparing the effects of HA, 
HAP, and DCC on rat BMSCs showed that DCC treated groups (HA-DCC and HA-HAP-DCC) 
exhibited significantly higher cell attachment compared to control media (p < 0.01), HA (p < 0.01), 
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HAP (p < 0.01), and HA-HAP (p < 0.01) (Figure 5.3). In addition, DCC treated groups exhibited 
significantly higher DNA mass (Day 7) compared to control media (p < 0.05) and HAP (p < 0.01). 
Only HA and HA-HAP treated cells exhibited significantly higher DNA mass from Day 1 to Day 
7 (p < 0.01). All other groups exhibited statistically equivalent DNA mass over the span of the 
study.   
3.3. Characterizing in vitro Cell Response to Colloids with HAP, DCC, and DBM 
3.3.1.  Cell Viability 
A three week cell attachment (Day 1) and viability (Day 7, 14, and 21) study comparing the 
effects of HAP, DCC, and DBM on rat BMSCs showed that only DBM treated groups (HA-DBM 
and HA-HAP-DBM) exhibited DNA mass increase over the span of the study (Figure 5.4). HA-
DBM treated cells exhibited a significant increase in DNA mass at Day 14 and Day 21 (p < 0.01) 
compared to initial DNA mass on Day 1. Meanwhile, DCC treated groups exhibited a significant 
decrease (p < 0.01) in DNA content over 21 days, which contradicted previous evidence of 
proliferation (Figure 5.3). All groups exhibited significantly DNA mass compared to cells in 
control media on a treated culture plate (p < 0.01) except for HA-DBM at Day 21 which exhibited 
significantly higher DNA mass (p < 0.01).     
3.3.2.  Gene Expression 
Corresponding endochondral gene expression profiles of BMSCs treated with HAP, DCC, and 
DBM were compared to control media. Poor viability and RNA isolation from various groups over 
the span of the study prevented RT-qPCR data from being obtained on days 1, 7, and 21. However, 
sufficient data was obtained on Day 14 to compare treatment groups. HA-DCC exhibited 
significantly higher expression of Sox9 and Runx2 and significantly lower Acan expression 
compared to control media (p < 0.01), suggesting that cells may be undergoing intermediate 
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hypertrophic changes. HA-DBM exhibited significantly higher Col1A1 (p < 0.05) and BSP (p < 
0.01) expression compared to control media, indicating that cells might be osteogenic. The 
presence of HAP in both HA-HAP-DCC and HA-HAP-DBM also appeared to direct cells toward 
an osteogenic lineage compared to control as suggested by significantly higher BSP expression (p 
< 0.05) and (p < 0.01), respectively.   
3.4. Characterizing in vivo Bone Regeneration to Colloids with HAP, DCC, and DBM 
3.4.1. Gross Anatomy 
During 8 weeks of post-operative treatment, no rats were reported to exhibit signs of 
inflammation at or near the calvarial defect site. After 8 weeks, gross anatomical images (Figure 
5.6) of cranial biopsies were taken to visualize signs of tissue response. Proximal brain tissue 
appeared morphologically healthy and undisturbed by the implant materials in all treatment 
groups, and no accumulation of interstitial fluid was observed in or around defect site. In HAP, 
HA-HAP, and HA-HAP-ECM treated animals, small aggregates of white material, presumed to 
be HAP, were observed in and around the defect space on the superior side of the rat calvaria. 
Visualizing the defect space from an inferior view with backlit illumination (Figure 5.6) revealed 
varying levels of opacity in the defect space. While HA-HAP and HA-HAP-ECM groups appeared 
to exhibit less opacity than respective HA and HAP controls, variability in opacity within each 
treatment group was observed. The type of tissue spanning the defect space was indiscernible via 
gross anatomical imaging.     
3.4.2. MicroCT Imaging 
MicroCT images of rat calvaria were obtained to visualize retention of implant material and 
extent of mineralization in the defect (Figure 5.7 and Figure 5.8). An estimate of the initial defect 
location (dotted lines, Diameter = 8 mm) was made to aid qualitative assessment of the tissue 
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response. Mineralized tissue was observed growing radially inward from the defect borders in all 
tested groups including sham. In addition, bony spicules dispersed through the defect were 
observed more in HA-HAP and HA-HAP-ECM colloids than HAP and sham controls. Retention 
of colloidal material in the defect could be tracked with HAP, which appeared pink in MicroCT 
images using VRT visualization (Figure 5.8). More HAP was retained in the colloidal treatment 
groups containing HA compared to pure HAP. Migration of HAP outside the defect space was 
observed in some cases, which corresponded to the appearance of small white aggregates observed 
in gross anatomical imaging.  
Relative differences in mineralization were assessed (Table 5.1) through scoring of MicroCT 
images (n = 3), as defined by Spicer et al.193 HA-HAP exhibited the highest mineralization score 
(average ± SD) (2.67 ± 0.58) followed by HA-HAP and sham (2.33 ± 0.58). HAP and HA-HAP-
DBM exhibited the lowest mineralization score (1.67 ± 0.58), but no significant differences were 
found between the tested groups. The presence of HAP from implanted material was not factored 
into defect scoring.   
3.4.3. Histology 
H&E and Saf-O/Fast Green histological images of rat calvarial defects revealed most bone 
formation directly appositional to native bone regions, but bony spicules were observed in the 
middle of the defect space (Figure 5.9). This corresponded to previous MicroCT observations of 
regionalized mineralization in the healing defect. All treatment groups including sham exhibited 
areas of newly ossified bone, but no relative comparisons were made with histological analysis. 
No evidence of cartilaginous regions, hypertrophic cartilage, or ongoing EC ossification was 
observed across all tested groups. However, retention of colloidal material in the defect was 
observed in all implant groups. In some cases, active ossification was observed directly adjacent 
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to implanted colloidal material. Images were sagittal cross-sections of the border between the 
defect space and the native bone tissue with left-to-right orientation representing inferior-to-
superior direction (Figure AD). Fibrous connective tissue was observed spanning the defect space 
interspersed with colloidal implant material. Blood vessels were also identified in the defect space. 
Loose connective tissue was observed anterior to the defect space.     
 
4. DISCUSSION 
The current study utilized colloidal technology to make HA-HAP gels loaded with ECM 
microparticles. This was the first study to evaluate the in vitro cellular and genetic response of 
rBMSCs to various components of HA-HAP-ECM colloidal gels. In addition, this was the first 
study to assess potential in vivo bone regeneration of HA-HAP-ECM colloids in critical-sized rat 
calvarial defects. While micronized DBM has previously been shown to elicit bone regeneration 
in critical-sized defects85-88, DCC has remained underexplored as a potential ECM biomaterial for 
regenerating bone despite its physical and chemical resemblance to the intermediate procallus 
microstructure involved in native bone fracture healing.66, 67, 69, 70 
Initial in vitro studies revealed that pure DCC microparticles significantly increased rBMSC 
viability over one week compared to negative control (p < 0.05) and DVC microparticles (p < 
0.01). Coupling this result with significant up-regulation (p < 0.01) of chondrogenic genes Acan, 
Sox9, and Col2A1 in response to DCC treatment suggests that the novel decellularization method 
utilized in this study may be worthwhile for future cartilage tissue engineering endeavors. 
However, a significant increase in both hypertrophic cartilage markers Runx2 and Col10A1 was 
also observed in DCC treated rBMSCs compared to negative control media (p < 0.01), DVC (p < 
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0.01), and TGF-β positive chondrogenic media (p < 0.01). This result suggests that DCC may be 
better suited for tissue engineering applications requiring EC ossification for bone regeneration.  
The relative expression of Sox9:Runx2 can be used as an indicator of cartilage progression 
toward a hypertrophic phenotype.93 While the former key transcription factor is involved in initial 
chondrogenesis, the latter is associated primarily with cartilage hypertrophy.92, 93, 100, 137 
Furthermore, a study by Hattori et al.138 showed that murine Sox9 was a major antagonistic 
regulator of cartilage vascularization, bone marrow formation, and EC ossification. In their study, 
newborn transgenic mice misexpressing Sox9 exhibited an extreme lack of bone marrow due to 
retardation of vascular invasion into hypertrophic cartilage and delayed cartilage ECM 
remodeling. Cartilage hypertrophy is a critical maturation stage of EC ossification. Chondrocytes 
experience a large increase in volume (~5 to 10 fold), and downstream proteins activated by Runx2 
transcription factor begin to remodel the surrounding ECM.92, 93, 100, 137 These targets include 
matrix metalloproteinases (MMPs) that degrade cartilaginous ECM65-70, 72, 73, Indian Hedgehog 
(Ihh) that induces proliferation of non-hypertrophic chondrocytes92, 93, 100, 137, angiogenic factors 
like vascular endothelial growth factor (VEGF) to promote neo-vascularization93, 94, 131, 136, 137 
along with collagen type X, alkaline phosphatase (ALP), and matrix vesicles for ECM 
mineralization.145-147  
In the current study, rBMSCs treated with DCC microparticles exhibited significantly higher 
expression levels of Sox9 compared to Runx2 (p < 0.01) over the first week (Figure 5.2). This ratio 
was reversed during the subsequent gene expression study (Day 14) where DCC was formulated 
as an HA-DCC suspension and HA-HAP-DCC colloid (Figure 5.5). In these studies, Runx2 
expression was significantly higher than Sox9 when DCC was present, (p < 0.05) and (p < 0.01) 
respectively. This temporal shift in expression levels corresponds well with previous observations 
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of the spatiotemporal change in growth factors and ECM molecules involved in EC ossification 
and native bone healing.66, 71 The presence of DBM in HA-DBM and HA-HAP-DBM formulations 
also resulted in elevated, albeit insignificant, Runx2 expression relative to Sox9. Meanwhile HA-
DBM and HA-HAP-DBM exhibited significantly higher BSP levels compared to control (p < 
0.01), which may be an indication of osteogenic differentiation. This result corresponds with 
previous evidence showing that DBM can elicit both IM and EC ossification in critical-sized bone 
defects.85-88 Furthermore, the temporal expression of BSP at Day 14 corresponds well with 
previous observations of the spatiotemporal change in BSP expression involved in native bone 
healing.66, 71 A similar significant increase in BSP expression was observed in HA-HAP-DCC 
treated cells compared to control media (p < 0.05) and HA-DCC (p < 0.05) groups. Taken together, 
these results suggest that the presence of DCC may have directed cell differentiation down the EC 
ossification pathway while the presence of DBM or HAP may have directed cell differentiation 
down an osteogenic pathway or accelerated EC ossification into an osteogenic phase.  
Meanwhile, the two cell attachment and viability studies with various HA-HAP-ECM colloids 
provided contradicting evidence on the suitability of DCC and nanocrystalline HAP as a 
compatible biomaterial with rBMSCs in the proposed application. While the preliminary one week 
study (Figure 5.3) provided evidence of elevated cell attachment and sustained viability in DCC 
and HAP treated groups, the subsequent 21-day viability study showed significant depletion of 
cell population in similar treated DCC and HAP groups over the course of study. The latter result 
was hypothesized to be attributed to the presence of undesirable excipients in HAP powder, which 
were introduced during the manufacturer’s crystallization protocol of HAP nanoparticles, and the 
residual presence of decellularization reagents in the batch of DCC used for the 21-day study, 
which may have caused cytotoxicity in seeded rBMSCs. As a result, subsequent in vivo cranial 
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defect studies incorporated an additional dialysis step before colloids were formulated. This 
involved dialyzing HAP nanoparticles and DCC microparticles in PBS solution (pH = 7.4, 150 
mM NaCl) for 72 hours followed by lyophilization. No evidence of necrosis or prolonged 
inflammation was observed in vivo when colloids incorporated dialyzed HAP and DCC particles. 
Collectively, these preliminary in vitro cell viability results provided limited evidence to support 
or reject the use of HAP or DCC in colloidal formulations. However, coupling these results with 
the corresponding gene expression studies showing positive signs of chondrogenic, hypertrophic, 
and osteogenic differentiation did provide evidence to support the hypothesis that HA-HAP-ECM 
colloidal formulations could influence EC ossification and potentially facilitate bone regeneration.  
The rat calvarial critical-sized defect model used in the current study was chosen because its 
non-load bearing nature was suitable for colloidal gel implantation. In fetal development, the 
calvaria is formed by IM ossification rather than EC ossification103, suggesting that only implants 
directed toward IM ossification will possess regenerative potential. However, evidence from Rabie 
et al. 87, 89, 90 showed that IM and EC ossification pathways can be utilized, exclusively or in 
combination, to regenerate critical-sized calvarial defects with DBM implants. This was supported 
by evidence that both IM and EC ossification occur in the native process of bone fracture healing.66, 
67, 69-71 In the current study, implantation of various colloidal gel formulations (Table 5.1) into 
critical-sized rat calvarial defects yielded MicroCT and histological evidence of both IM and EC 
ossification in the defect space (Figure 5.7, Figure 5.8, and Figure 5.9).  
A primary aim of the current in vivo study was to assess 1) the retention of colloidal implant 
material and 2) the extent of bone regeneration at the defect site. With regard to the first aim, 
retention was qualitatively assessed by observing gross anatomy, MicroCT, and histological 
sections. The collective evidence from these analyses confirmed that delivered colloidal material 
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was retained in all tested animals to varying extents. MicroCT imaging (Figure 5.7 and Figure 5.8) 
especially highlighted the presence of HAP material in and around the defect site. It was clear that 
the presence of HA in colloidal formulations increased the retention of HAP material within the 
defect. However, it was also evident from these images that some colloidal material in all treatment 
groups was displaced around the defect in a superior orientation to the calvaria. This undesirable 
migration from the defect site may have been due to various operative and post-operative 
conditions including unintentional disruption of the material by the surgeon during wound closure, 
wound-site mechanical disruption by the animal during recovery, or even swelling of the exposed 
inferior brain tissue. Regardless, a favorable colloidal material in the future should be designed to 
resist migration from these external mechanical perturbations. This could possibly be 
accomplished by increasing concentration of colloidal components which would increase yield 
stress and storage modulus of the colloidal implant.  
The extent of ossification in the defect space was also qualitatively assessed by observing gross 
anatomy, MicroCT, and histological sections. All tested animals, including the negative control 
sham groups, exhibited some evidence of ossification at the border of the defect. Both H&E and 
Saf-O/Fast-green stains revealed bone morphology at these sites without the presence of nearby 
cartilage tissue (Figure 5.9). This likely meant that bone formation observed at the borders of the 
defect were formed via IM ossification. IM ossification has previous been observed in defect 
spaces occurring adjacent to existing healthy bone because this pathway requires angiogenesis and 
permanent vasculature to occur before bone can be formed.66, 67, 69, 70 Meanwhile, EC ossification 
does not require angiogenesis to occur since precursor chondrocytes can arise in lower oxygen 
tension environments compared to osteoblasts.66, 67, 69, 70 This results in EC ossification occurring 
in the bulk of the defect space, where oxygen tension in the tissue is low due to absence of 
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established vasculature.66, 67, 69, 70 In the current study, some evidence of regionalized ossification 
in the center of the defect space was observed with MicroCT and histological analysis. Although 
no cartilage tissue was identified in histological sections, active EC ossification may have ceased 
in the bulk of the defect space 8 weeks after implantation. This result was not desirable since full 
regeneration of the defect was incomplete.  
Relative comparisons of the extent of bone regeneration in the defect space could be made by 
scoring MicroCT images (Table 5.1) according to a methodology reported by Spicer et al.193 
Although no significant differences were observed between tested groups, qualitatively it was 
evident that the colloidal formulations incorporating HA polymer exhibited more ossification in 
the defect. This could be due to increased retention of colloidal material at the defect site which 
builds upon previous work that identified injectable HA-HAP-ECM colloidal gel formulations 
possessing similar or superior viscoelastic properties, including G′, τy, and G′Recovery, compared to 
HAP formulations. Although this result supported our initial hypothesis, the primary goal of this 
assessment was to determine the efficacy of DCC and DBM in colloidal formulations. The 
presence of DCC and DBM did not result in a significantly higher ossification score compared to 
sham, HAP, or HA-HAP treatment groups. There was also no qualitative evidence that DCC or 
DBM contributed to active EC ossification in vivo, though evidence of ossification foci in the 
central, avascular portion of the defect space was present.  
 
5. CONCLUSION 
Despite supportive in vitro evidence that HA-HAP-DCC and HA-HAP-DBM colloidal gels 
could significantly influence gene expression associated with EC ossification and osteogenesis, 
incomplete regeneration of critical-sized rat calvarial defects was observed in animals treated with 
104 
 
colloidal implants. Furthermore, no significant differences were observed in defects treated with 
colloidal gel formulations compared to the negative sham control group. Evidence of ossification 
foci in the central region of the defect space, however, were only observed when animals were 
treated with colloidal gels. This may have been evidence of an enhanced EC ossification response, 
though notably not sufficient enough to regenerate the entire defect at 8 weeks post-implantation. 
This means that future HA-HAP and HA-HAP-ECM colloidal gels could be reformulated with 
increased viscoelastic properties, such as G′ and τy, to increase retention of colloidal material in 
the tissue defect and to increase regenerative capacity of the implant. Additionally, many sources 
of cartilage ECM exist in the body including hyaline cartilage (e.g., femoral condyles and tibial 
plateau), fibrocartilage (e.g., temporomandibular joint disc and knee meniscus), elastic cartilage 
(e.g., nose and ear), and even hypertrophic cartilage (e.g., fetal bones and growth plates).68 
Fibrocartilage may provide an even better procallus mimetic tissue than hyaline cartilage since the 
procallus is fibrocartilaginous in nature. Additionally, fetal bones undergoing EC ossification 
during skeletogenesis may provide a primed hypertrophic cartilage template that could facilitate 
rapid ossification in a bone defect. Thus, there exists a range of DCC-derived tissues that may be 
explored in relation to EC ossification.  
 
6. ABBREVIATIONS 
ABG – Autologous Bone Grafting; Acan – Aggrecan; BMSC – Bone Mesenchymal Stem Cell; 
BMP – Bone Morphogenic Protein; BSP – Bone Sialoprotein; Col1A1 – Collagen Type 1; 
Col2A1 – Collagen Type 2; Col10A1 – Collagen Type 10; DBM – Demineralized Bone Matrix; 
DCC – Decellularized Cartilage; ECM – Extracellular Matrix; EC – Endochondral Ossification; 
FBS – Fetal Bovine Serum; GAG – glycosaminoglycan; HA – hyaluronic acid; HAP – 
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Hydroxyapatite; H&E – Hematoxylin and Eosin; HSS – hypertonic salt solution; IM – 
Intramembranous Ossification; LVE – linear viscoelastic region; MEM – Minimum Essential 
Medium; MicroCT – Micro Computed Tomography; PBS – phosphate buffered saline; Runx2 – 
Runt related transcription factor 2; RT-qPCR – reverse transcriptase quantitative polymerase 
chain reaction; SSD – shaded surface display; Saf-O – Safranin O; VRT – volume rendering 
display    
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CHAPTER 6: Conclusion 
Predecessors to this work developed methods of creating self-assembling and shear-
responsive colloidal gels from oppositely charged PLGA nanoparticles and demonstrated 
feasibility of the concept for tissue defect filling, controlled drug release, and in vivo stimulation 
of bone regeneration in rat calvarial defects.10, 11 Within this thesis, colloidal gel materials were 
derived exclusively from native ECM components found in the bone healing environment. The 
majority of this work focused on the feasibility of combining these components, including HA, 
HAP, DCC, and DBM, to meet standards for surgical delivery and retention of material at the 
defect site. Pilot in vitro and in vivo studies furthermore characterized the regenerative potential 
of these viscoelastic materials within bone defects.   
Extensive rheological and viscoelastic profiling of initial GAG-HAP colloids along with 
subsequent HA-ECM suspensions and HA-HAP-ECM colloids demonstrated that fluid parameters 
including G′, τy, and G′Recovery could be readily modified by changing composition of colloidal 
formulations. The combination of GAG polymers and HAP particles led to a synergistic increase 
in both consistency index and storage modulus of fluids that was dependent on polymer 
concentration and molecular weight. This corresponded to changes in physical association of GAG 
and HAP observed during light scattering zeta potential measurements. Although GAGs increased 
electrostatic stability of HAP at dilute concentrations, it was hypothesized that at high 
concentrations, similar to those tested in rheological experiments, bridging flocculation occurred 
due to multivalent GAG polymers adsorbing simultaneously to multiple HAP particles in close 
proximity. The additional loading of ECM microparticles to HA-HAP colloidal formulations did 
not compromise the physical crosslinking or the viscoelastic properties of colloidal gels. Instead, 
all tested HA-ECM microparticle suspensions and HA-HAP-ECM colloidal gels exhibited either 
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equivalent or substantially higher storage modulus (G′ ≈ 100-10,000 Pa), yield stress (τy ≈ 100-
1000 Pa), and viscoelastic recovery (G′Recovery ≥ 87%) kinetics compared to HA, HAP, and HA-
HAP control fluids. Most importantly, these colloidal formulations could be modified to facilitate 
injectability and retention of implant material in critical-sized bone tissue defects.  
Preliminary in vitro evidence revealed that DCC could positively influence cell viability 
and direct gene expression profile of seeded rBMSCs toward hypertrophic chondrogenesis while 
both DBM and HAP colloidal formulations appeared to direct cell lineage down an osteogenic 
pathway in a temporal manner similar to expression profiles observed in native bone fracture 
healing.66, 71 Meanwhile, two preliminary cell viability studies with DCC and HAP loaded colloidal 
gels provided conflicting evidence to support or reject their use in formulations. However, 
coupling these results with the corresponding gene expression studies showing positive signs of 
chondrogenic, hypertrophic, and osteogenic differentiation did provide evidence to support the 
hypothesis that HA-HAP-ECM colloidal formulations could influence EC ossification and 
potentially facilitate bone regeneration.  
In vivo evidence revealed the presence of both EC and IM ossification foci in critical-sized 
calvarial defects treated with HA-HAP, HA-HAP-DCC and HA-HAP-DBM. Incomplete 
regeneration of the defect, however, was observed in all tested formulations 8 weeks following 
implantation. Furthermore, no significant differences were observed in defects treated with 
colloidal formulations compared to the negative sham control group. Qualitatively it was evident 
that the incorporation of HA into colloidal gels led to higher retention of implant material at the 
defect site and increased ossification, though notably not sufficient enough to regenerate the entire 
critical-sized defect space. Thus, definite advantages of using colloidal gel technology were 
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observed in these preliminary studies, but future iterations of the implant design may yield 
enhanced bone tissue regeneration.      
The evidence presented in this thesis readily demonstrates that using native ECM colloidal 
gels to facilitate bone regeneration in non-load bearing calvarial defects is feasible and potentially 
efficacious. Improving the regenerative capacity of these injectable colloids may reside in 
exploring alternative native ECM sources and strategies that better resemble the bone healing 
microenvironment along with reformulation approaches to enhance retention of material at the 
defect site. Many sources of specialized cartilage ECM exist in the body that may provide a primed 
hypertrophic cartilage template to facilitate rapid ossification in a bone defect. Therefore, future 
HA-HAP and HA-HAP-ECM colloidal gels could be reformulated with enhanced regenerative 
capacity. The viscoelastic properties of colloidal gels, such as G′ and τy, may also be increased by 
altering the physicochemical properties of individual components of the colloids. This could 
include modifying HAP morphology or surface chemistry along with changing GAG molecular 
weight. GAG polymers may also be chemically modified to possess dendritic structure or cross-
linking moieties to yield desirable rheological properties for surgical delivery. Improving 
viscoelastic properties of colloidal formulations could improve retention of the implant at the tissue 
defect and ultimately improve implant efficacy. Although a wide array of colloidal gel 
formulations were evaluated in this thesis, there remain largely underexplored design spaces within 
colloidal technology that combine elements of the traditional tissue engineering triad (i.e., cells, 
signal, and scaffolds). The future of this scaffolding technology, however, may reside in adjacent 
tissue engineering applications outside of orthopedics. Self-assembling and shear-responsive 
colloidal gels may prove advantageous in many soft-tissue regeneration strategies. Ultimately, the 
idea of colloidal-based tissue implants has been taken from concept to practice, produced 
109 
 
promising results for the treatment of non-load bearing bone defects, and has precipitated 







APPENDIX A: TABLES 
Table 2.1: HAP Dynamic Light Scattering data  
 
Significant differences between groups compared to pure HAP (ANOVA, post-hoc Tukey’s HSD; 
n = 15; p < 0.05*; p < 0.01**). 
  
Weight Ratio (GAG:HAP)
Pure HAP 430 ± 73 -26.3 ± 5.5
CS:HAP (1:1) 524 ± 72 -49.5 ± 8.3 **
CS:HAP (10:1) 545 ± 113 * -56.6 ± 6.2 **
Pure HAP 430 ± 73 -26.3 ± 5.5
HA:HAP (1:1) 489 ± 96 -39.4 ± 7.4 **
HA:HAP (10:1) 475 ± 46 -45.8 ± 6.1 **
Size (nm) Zeta Potential (mV)
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Table 2.2: CS-HAP rheological properties estimated by H-B fluid model  
 
Individual points are reported (average ± 95% CI) from triplicate studies and overall model fit 
reported as root-mean-squared error (RMSE).   
  
[CS] RMSE
(% w/v) (% w/v) φ (% v/v) Average ± 95% CI Average ± 95% CI Average ± 95% CI ―
0% 0.0% 0.01 ± 0.07 0.04 ± 0.01 0.93 ± 0.02 0.06
5% 3.1% 0.05 ± 0.10 0.14 ± 0.01 0.86 ± 0.01 0.10
10% 6.1% 0.52 ± 0.55 0.11 ± 0.03 0.93 ± 0.04 0.57
20% 12.3% 0.96 ± 0.61 0.24 ± 0.05 0.85 ± 0.03 0.61
40% 24.6% 10.46 ± 2.39 0.87 ± 0.28 0.77 ± 0.05 2.20
80% 49.2% 1403.00 ± 1193.00 38.34 ± 52.66 0.28 ± 2.84 286.60
0% 0.0% -0.23 ± 0.24 0.34 ± 0.03 0.81 ± 0.02 0.20
7.5% 4.6% 0.24 ± 0.54 0.30 ± 0.04 0.86 ± 0.02 0.53
15% 9.2% 0.31 ± 0.61 0.51 ± 0.06 0.81 ± 0.02 0.59
30% 18.4% 2.33 ± 0.72 1.52 ± 0.10 0.73 ± 0.01 0.63
60% 36.9% 218.50 ± 21.10 2.69 ± 1.23 0.80 ± 0.06 3.51
― ― ― ― ― ― ― ― ―
0% 0.0% 0.13 ± 0.16 0.43 ± 0.02 0.85 ± 0.01 0.14
10% 6.1% -0.65 ± 0.65 1.08 ± 0.07 0.78 ± 0.01 0.60
20% 12.3% -0.72 ± 0.84 2.23 ± 0.13 0.71 ± 0.01 0.73
40% 24.6% 11.66 ± 3.67 4.06 ± 0.55 0.72 ± 0.02 3.22
80% 49.2% 1350.00 ± 68.00 3.14 ± 2.49 0.93 ± 0.11 31.10
― ― ― ― ― ― ― ― ―
0% 0.0% 0.15 ± 1.48 1.34 ± 0.13 0.83 ± 0.01 1.44
15% 9.2% -2.23 ± 1.27 4.02 ± 0.19 0.73 ± 0.01 1.11
30% 18.4% -2.06 ± 3.67 7.97 ± 0.56 0.72 ± 0.01 3.18
60% 36.9% 134.70 ± 25.70 20.20 ± 3.77 0.73 ± 0.03 22.56
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
0% 0.0% -1.86 ± 1.26 3.19 ± 0.13 0.80 ± 0.01 1.19
20% 12.3% -11.56 ± 8.84 10.39 ± 1.37 0.71 ± 0.02 7.65
40% 24.6% 3.09 ± 13.97 16.55 ± 1.69 0.77 ± 0.02 12.82
80% 49.2% 958.80 ± 368.20 382.40 ± 205.90 0.52 ± 0.10 125.80
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
0% 0.0% -7.96 ± 3.28 10.47 ± 0.36 0.78 ± 0.01 3.06
30% 18.4% -65.26 ± 83.57 44.58 ± 12.56 0.72 ± 0.04 72.90
60% 36.9% 112.60 ± 47.50 199.30 ± 17.20 0.68 ± 0.02 24.16
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
0% 0.0% -81.25 ± 101.09 48.17 ± 18.46 0.74 ± 0.06 79.21
40% 24.6% 11.33 ± 55.17 111.00 ± 14.80 0.78 ± 0.03 33.02
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―








K (Consistency Index) (Pa-sn) n (Flow Behavior Index)[HAP] τy  (Yield Stress) (Pa)
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Table 2.3: HA-HAP rheological properties estimated by H-B fluid model   
 
Individual points are reported (Average ± 95% CI) from triplicate studies and overall model fit 
reported as root-mean-squared error (RMSE).  
[HA] RMSE
(% w/v) (% w/v) φ (% v/v) Average ± 95% CI Average ± 95% CI Average ± 95% CI ―
0% 0.0% 0.26 ± 0.21 0.11 ± 0.01 0.98 ± 0.02 0.21
5% 3.1% 0.39 ± 0.35 0.10 ± 0.01 0.99 ± 0.03 0.38
10% 6.1% 0.52 ± 0.50 0.06 ± 0.01 1.05 ± 0.04 0.56
20% 12.3% 0.37 ± 1.68 0.55 ± 0.15 0.83 ± 0.04 1.64
40% 24.6% 7.24 ± 2.94 0.85 ± 0.22 0.86 ± 0.04 2.94
80% 49.2% 912.40 ± 266.60 105.90 ± 133.20 0.37 ± 0.16 53.06
0% 0.0% 1.04 ± 1.41 0.17 ± 0.04 1.01 ± 0.09 1.59
7.5% 4.6% 1.41 ± 1.31 0.34 ± 0.05 1.01 ± 0.02 1.43
15% 9.2% 2.97 ± 1.93 0.63 ± 0.09 0.97 ± 0.02 2.07
30% 18.4% 7.41 ± 0.09 2.32 ± 0.09 0.87 ± 0.01 1.18
60% 36.9% 132.60 ± 17.80 46.66 ± 4.10 0.63 ± 0.01 13.50
― ― ― ― ― ― ― ― ―
0% 0.0% 1.10 ± 1.44 0.49 ± 0.05 1.03 ± 0.01 1.59
10% 6.1% 0.46 ± 0.36 1.15 ± 0.02 0.96 ± 0.00 0.38
20% 12.3% -0.24 ± 2.32 3.07 ± 0.15 0.89 ± 0.01 2.37
40% 24.6% -4.49 ± 23.44 14.81 ± 2.76 0.77 ± 0.03 21.64
80% 49.2% 263.00 ± 521.90 759.90 ± 373.10 0.39 ± 0.08 113.10
― ― ― ― ― ― ― ― ―
0% 0.0% -5.02 ± 6.54 3.40 ± 0.32 0.95 ± 0.01 6.93
15% 9.2% -32.50 ± 44.75 12.94 ± 4.32 0.81 ± 0.05 43.00
30% 18.4% -17.48 ± 28.59 22.31 ± 3.69 0.82 ± 0.03 24.54
60% 36.9% -22.98 ± 111.90 234.10 ± 44.40 0.65 ± 0.04 53.53
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
0% 0.0% -37.25 ± 49.85 15.06 ± 5.34 0.86 ± 0.06 44.50
20% 12.3% -33.06 ± 43.35 30.27 ± 6.78 0.85 ± 0.04 33.44
40% 24.6% -221.30 ± 376.60 223.10 ± 151.80 0.65 ± 0.13 178.20
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
― ― ― ― ― ― ― ― ―
[HAP] τy  (Yield Stress) (Pa) K (Consistency Index) (Pa-s








Table 2.4: Pure HAP rheological properties estimated by H-B fluid model  
 
Individual points are reported (Average ± 95% CI) from triplicate studies and overall model 





(% w/v) φ (% v/v) Average ± 95% CI Average ± 95% CI Average ± 95% CI ―
0% 0.0% 0.00 ± 0.00 0.001 ± 0.00 0.95 ± 0.18 0.01
5% 3.1% -0.04 ± 0.13 0.002 ± 0.05 1.05 ± 0.24 0.07
7.5% 4.6% 0.00 ± 0.10 0.001 ± 0.05 1.07 ± 0.20 0.02
10% 6.1% 0.00 ± 0.20 0.002 ± 0.05 1.05 ± 0.25 0.21
15% 9.2% -0.06 ± 0.18 0.01 ± 0.02 0.90 ± 0.19 0.16
20% 12.3% -0.15 ± 0.28 0.03 ± 0.05 0.81 ± 0.17 0.24
30% 18.4% -9.57 ± 18.69 0.97 ± 18.05 0.91 ± 0.15 0.92
40% 24.6% -11.07 ± 23.76 2.78 ± 21.94 0.90 ± 0.18 1.89
60% 36.9% 12.68 ± 122.42 35.29 ± 86.47 0.85 ± 0.43 29.42
80% 49.2% 1124.87 ± 1245.02 21.98 ± 53.86 0.56 ± 0.83 384.31
[HAP] τy  (Yield Stress) (Pa) K (Consistency Index) (Pa-s
n) n (Flow Behavior Index)
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Table 2.5: Viscoelastic recovery of GAG (15%) – HAP (60%) mixtures compared to pure 




G' (kPa) G" (kPa) δ (°) G' (kPa) G" (kPa) δ (°) G' (kPa) G" (kPa) δ (°)
Pure CS 15% — 8.00E-05 1.88E-03 88 2.40E-04 1.57E-03 81 8.00E-05 1.90E-03 88 100%
Mixture 15% 60% 7.8 1.9 14 9.75E-04 2.34E-02 88 4.95 1.42 16 64%
Pure HAP — 60% 878 86.7 6 1.10E-03 1.12E-02 84 810 82.8 6 92%
Pure HA 15% — 1.40E-04 1.70E-03 85 2.30E-04 1.79E-03 83 1.40E-04 1.73E-03 85 100%
Mixture 15% 60% 175 20.2 7 1.58E-03 1.39E-01 89 149 16.8 6 85%
Pure HAP — 60% 878 86.7 6 1.10E-03 1.12E-02 84 810 82.8 6 92%
[HAP]





Table 3.1: Modulators of Chondrocyte Hypertrophy  
Differentiation 
Pathway 




Low Oxygen Tension 
Lower stiffness and 
Adhesion, Intermittent 





Vitamin D3, Retinoic 
Acid, Leptin, Insulin, 
Thyroxine, β-
glycerophosphate, 




Higher stiffness and 
adhesion, Lower 
magnitude and higher 














In Vitro Priming Method Animal Model Highlighted Results 







Isolated rat BMSCs were 
chondrogenically primed on 
b-TCP blocks and implanted 




EC ossification was only seen in primed 
rBMSC constructs.  Non-cellular and 








Isolated rat BMSCs were 
chondrogenically primed and 
implanted with dual growth 





Significantly higher amount of EC 
ossification was seen in scaffolds with dual 
GF compared to single GF and non-loaded 
controls. 
Pelttari, K. et 
al.131 
2006 BMSCs Fibrin Matrix 
Isolated human BMSCs were 
primed in chondrogenic 
medium for 4 to 7 weeks. 
Human ACs were isolated for 
implantation and a portion of 





hBMSCs exhibited extensive EC 
ossification, while hACs remained stable 
cartilage. Chondrogenically expanded hACs 
did not undergo EC ossification, suggesting 
that they are locked into a stable cartilage 
phase. 






Isolated human BMSCs were 
cultured for 21 days in 
chondrogenic medium.  Three 
groups were cultured for 14 
extra days in a) the same 
medium, b) mineralizing 
chondrogenic medium, or c) 
osteogenic medium. 
Unprimed control medium 




Chondrogenic priming led to collagen II and 
X production along with vessel ingrowth in 
vivo while osteogenic priming led to 
mineralized matrix, no vascularization, and 
poor cell viability. Unprimed control 
conditions yielded no bone. Mineralized 
chondrogenic priming severely diminished 
production of inductive growth factors. 








Isolated human BMSCs were 
primed in chondrogenic 
medium (6 weeks), in 
osteogenic medium, or 




Osteogenic priming led to poor bone 
formation. Unprimed hBMSCs on betaTCP 
exhibited IM ossification. With 
chondrogenic priming, hBMSCs formed 
bone via EC ossification, while 
hematopoietic marrow formed from murine 
origin.  This was hypothesized to be result 
of direct osteogenesis of cartilage-resident 
hBMSCs or transdifferentiation from 
chondrocytes to osteoblasts. 






Isolated human BMSCs were 
primed to prechondrogenic, 
early hypertrophic, and late 




Hypertrophic cartilage templates were 
required to form bone trabeculae. Pre-
hypertrophic hBMSCs resorbed quickly and 
did not form bone. Results indicate that no 
external scaffolding was required to undergo 
EC ossification. 






Isolated human BMSCs and 
rat BMSCs were cultured in 
osteogenic, chondrogenic, or 
control medium (28 days). In 
some cases, induced 
mineralization in 







Bone and bone marrow was observed in 
chondrogenic primed constructs but not in 
unprimed control and osteogenic primed 
constructs. Late switching (last 7 days) to 
osteogenic medium prevented bone 
formation, but beta-glycophosphate induced 
mineralization did not prevent bone 
formation in chondrogenic primed 
constructs. Osteoblasts in formed bone were 
almost entirely of host origin, but osteocytes 











In Vitro Priming Method Animal Model Highlighted Results 
Scotti, C. et 
al.132 
2013 BMSCs 
Collagen Type I 
Meshes 
Isolated human BMSCs were 
primed to hypertrophic stage 
and seeded onto collagen type 
I meshes.  
Implanted 
subcutaneously in 
nude mice.  
Functional bone was formed heterotopically 
with cortical-like bone originating from host 
murine cells, and inner trabecular-like bone 
from EC ossification and originating from 
hBMSC primed hypertrophic cartilage 
constructs.  
Sheehy, E.J. et 
al.119 
2013 BMSCs Agarose 
Isolated porcine chondrocytes 
and BMSCs were cultured and 
chondrogenically primed prior 
to seeding on bilayer 
osteochondral scaffolds.  
Implanted 
subcutaneously in 
nude mice.  
EC ossification was restricted to the BMSC 
primed layer of the scaffold in vivo, while 
primed chondrocytes maintained 
chondrogenic phenotype. This led to a 
bilayer osteochondral construct. 






Isolated porcine BMSCs were 
chondrogenically primed for 5 
weeks followed by 
hypertrophic priming for an 
additional week.  
Implanted 
subcutaneously in 
nude mice.  
EC ossification was observed in 
hypertrophic primed pBMSCs encapsulated 
in agarose gel. Additionally, channeled 
agarose gels with pBMSCs showed 
increased vascularization and mineralization 
compared to solid agarose counterparts, 
which indicated that EC ossification may be 
enhanced with improved vascular support.  






Isolated human BMSCs were 
chondrogenically primed for 
three weeks. Additionally, 
cartilage grafts were isolated 
from healing callus 7 days 
after fracture and re-implanted 
in vivo. Implants were 
compared to living isografts, 
devitalized allografts, and 
sham groups.  
Implanted into 
mid-tibia diaphysis 
osteotomy in nude 
mice. 
Cartilage grafts and primed hBMSC pellets 
produce well vascularized and integrated 
bone regenerate via EC ossification; 
however, hBMSC pellets did not integrate 
with each other in vivo. Cartilage graft was 
equally likely to integrate with adjacent bone 
as bone isografts and outperformed 
devitalized allografts. Osteocytes in 
regenerated bone were primarily of donor 
origin rather than host recruited cells.       






Isolated human BMSCs were 
chondrogenically primed for 
three weeks and compared to 
hBMSCs cultured in 
chondrogenic media for only 3 
days. 
Implanted in 6mm 
mid-femur 
diaphysis defects 
in RNU rats. 
Significantly higher EC ossification was 
observed in 21 day chondrogenically primed 
hBMSC pellets compared to 3 day 
undifferentiated hBMSC controls. Primed 
hBMSC can result in complete bridging of 
the 6 mm defect; however, the effect was 
donor dependent.   






Isolated rat BMSCS were 
chondrogenically primed for 
21 days and compared to 
rBMSCS that were cultured in 
standard medium. Implants 
were also compared to cell-
free scaffolds and contralateral 
femur controls. 
Implanted into 
5mm and 15mm 
mid-femur 
diaphysis defects 
in Fischer 344 rats.  
Significantly higher EC ossification was 
observed in chondrogenically primed 
rBMSCs seeded onto PLGA scaffolds 
compared to undifferentiated rBMSC 
controls. Histological, micro-CT, and 
mechanical analysis of primed cell scaffolds 
revealed functionalized bone regeneration as 
early as 2 weeks following implantation in 
both 5 and 15 mm defect models. By 8 
weeks, mechanical strength of primed cell 
scaffolds were statistically equivalent to 
contralateral femur controls in 5 mm defects 
while scaffolds implanted in 15 mm defects 













In Vitro Priming Method Animal Model Highlighted Results 
Montufar-





Isolated murine ESC constructs 
were chondrogenically primed 
for 3 weeks. 
Implanted 
adjacent to and 
within murine 
skull defects of 
same lineage. 
Implants placed both adjacently and directly 
into skull defects exhibited EC ossification 
while control groups without primed implants 
did not. 






Isolated murine ESC constructs 
were chondrogenically primed 
for 3 weeks. 
Implanted into 
murine skull 
defects of same 
lineage. 
EC Ossification was only seen in rBMSC 
primed cartilage implants. 
Shoji, T. et 
al.163 
2010 ADSCs Collagen 
Isolated human ADSCs 
expanded from SVF 
Implanted in 
nude rat femurs 
hADSCs exhibited greater EC ossification 
than PBS and hFB (fibroblast) implant 
controls in collagen matrix. 





Isolated rabbit chondrocytes 
from patellar groove and 
femoral condyles were 
chondrogenically primed on 






Cell loaded constructs exhibited EC 
ossification and led to increased bone 
formation compared to devitalized constructs. 
Thus, cells had significant impact on 
outcome. 
Oliveira, S.M. 
et al.129, 130 
2009 ACs Chitosan Sponge 
Isolated chondrocytes from 
chicken embryo sterna 
expanded on chitosan sponge 
and hypertrophically primed for 
3 weeks. Control chondrocytes 
taken from caudal region of 
sternum while transient 
chondrocytes taken from 
cephalic region of sternum. 
Implanted 
subcutaneously 
in nude mice. 
Maturation and hypertrophy seen in treated 
chondrocyte-chitosan scaffolds. EC 
ossification was only seen in transient 
cartilage templates compared to permanent 
cartilage scaffold (control). 






Induced chondrocytes (iChons) 
were directly reprogrammed 
from murine dermal fibroblasts 
by two methods iChon(Con) 
and iChon(Ind). Following 
induction, cells were 
chondrogenically primed for 7 
days, and hypertrophically 
primed for 14 days. 
Implanted 
subcutaneously 
in nude mice. 
Both induced cell sources underwent 
chondrogenic differentiation in vitro, but 
hypertrophic differentiation was only seen in 
iChon(Ind) cells. In vivo, iChon(Con) cells 
formed stable cartilage, while iChon(Ind) 
cells exhibited EC ossification markers. 
Osteoblasts in formed bone were of host 
origin, while chondrocytes were of both donor 











In Vitro Priming Method Animal Model Highlighted Results 










Isolated human BMSCs, 
ADSCs, SDSCs, and ACs were 
cultured in chondrogenic 
medium (5 weeks).  
Implanted 
subcutaneously 
in nude mice.  
Chondrogenic priming led to similar collagen 
type II vs. type I levels and were positive for 
type X in all cells. SDSCs and ACs had 
significantly lower levels of ALP activity 
after priming, which correlated with poor EC 
ossification after implantation. While primed 
BMSCs and ADSCs exhibited EC ossification 
in vivo, SDSCs and ACs exhibited fibrous 
dedifferentiation and degradation.   








Isolated goat and human 
BMSCs were osteogenically 
primed for 7 or 21 days. 
Additionally, these cells along 
with murine ESCs and goat 
ACs were chondrogenically 




Osteogenic priming led only to direct IM 
ossification. Chondrogenic priming was 
necessary for EC ossification, but not 
sufficient since only mESCs underwent EC 
ossification.  Goat and human BMSCs 
underwent only marginal EC ossification and 
goat ACs didn't exhibit any EC ossification 
when cultured in similar fashion.  







Isolated rate BMSCs and OBs 




in nude mice.  
The capacity to recruit host cells and the 
ossification pathway were dependent on 
donor cell commitment. rBMSC implants led 
to formation of bone from host cells through 
the EC ossification pathway, and donor rOBs 
exhibited direct IM ossification. No studies 
were conducted with chondrogenically primed 
cells. 










Isolated human BMSCs, rat 
ESCs, and human ESCs were 
cultured in a series of 
differentiation mediums 
including chondrogenic 
priming followed by osteogenic 




in nude mice.  
ESCs were indistinguishable from BMSCs 
following in vitro osteogenic priming. 
Osteogenic priming of BMSCs led to direct 
(IM) osteogenesis and extensive bone 
formation. Both rESCs and hESCs did not 
form substantial bone but did exhibit signs of 
limited EC ossification. 








Isolated porcine BMSCs, 
SDSCs, FPSCs, and ACs were 
chondrogenically primed (3 
weeks). An additional group 
was primed in hypertrophic 
medium for 4 weeks.   
Implanted 
subcutaneously 
in nude mice.  
Only BMSCs exhibited EC ossification. 
SDSCs and FPSCs underwent fibrous 
dedifferentiation and resorption, and ACs 









Group HA HA HAP DCC DBM Media HAP DCC DBM Media
HA(35)-HAP 10% 8% 41% 51% 32% 68%
HA(350)-HAP 3% 3% 43% 54% 32% 68%
HA(1500)-HAP 1% 1% 44% 55% 32% 68%
Mass Fraction (%) Volume Fraction (%)
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Group HA HA HAP DCC DBM Media HAP DCC DBM Media
HA(1500) 2% 2% 98% 100%
HAP 44% 56% 32% 68%
HA(1500)-HAP 1% 2% 44% 55% 32% 68%
HA(1500)-HAP-DCC (Φ = 0.15) 1% 1% 43% 3% 53% 32% 15% 53%
HA(1500)-HAP-DCC (Φ = 0.30) 1% 1% 42% 5% 52% 31% 30% 39%
HA(1500)-HAP-DCC (Φ = 0.45) 1% 1% 41% 8% 51% 30% 45% 25%
HA(1500)-DCC (Φ = 0.15) 2% 2% 3% 95% 15% 85%
HA(1500)-DCC (Φ = 0.30) 2% 2% 6% 92% 30% 70%
HA(1500)-DCC (Φ = 0.45) 2% 2% 9% 89% 45% 55%
HA(1500)-HAP-DBM (Φ = 0.05) 1% 1% 43% 3% 53% 31% 5% 64%
HA(1500)-HAP-DBM (Φ = 0.10) 1% 1% 42% 5% 52% 31% 10% 60%
HA(1500)-HAP-DBM (Φ = 0.15) 1% 1% 41% 8% 51% 30% 15% 55%
HA(1500)-DBM (Φ = 0.05) 2% 2% 3% 95% 5% 95%
HA(1500)-DBM (Φ = 0.10) 2% 2% 6% 92% 10% 90%
HA(1500)-DBM (Φ = 0.15) 2% 2% 9% 89% 15% 85%
HA(1500)-DBM (Φ = 0.30) 2% 2% 19% 80% 30% 70%
HA(1500)-DBM (Φ = 0.45) 2% 2% 28% 70% 45% 55%
Volume Fraction (%)Mass Fraction (%)
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Table 4.3: HAP Size and Zeta Potential  
 
Significant differences between individual groups compared to pure HAP (ANOVA with post-
hoc Tukey’s HSD test) (n = 15; p < 0.05*; p < 0.01**). 
  
Pure HAP 476.7 ± 106.6 -26.7 ± 6.8
HA (35) - HAP (1:1) 537.6 ± 103.0 -31.1 ± 7.3
HA (350) - HAP (1:1) 639.4 ± 106.3 ** -42.9 ± 7.3 **











Group HA HAP DCC DBM Media HAP DCC DBM Media Average ± SD
SHAM 2.33 ± 0.58
HAP 44% 56% 32% 68% 1.67 ± 0.58
HA-HAP 2% 44% 55% 32% 68% 2.67 ± 0.58
HA-DCC (Φ = 0.15) 2% 3% 95% 15% 85%
HA-HAP-DCC (Φ = 0.15) 1% 43% 3% 53% 32% 15% 53% 2.33 ± 0.58
HA-DBM (Φ = 0.05) 2% 3% 95% 5% 95%
HA-HAP-DBM (Φ = 0.05) 1% 43% 3% 53% 31% 5% 64% 1.67 ± 0.58
Cranial Defect ScoreVolume Fraction (%)Mass Fraction (%)
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APPENDIX B: FIGURES 
  







Figure 2.2A-C: SEM images of A) HAP particles (60% w/v), B) CS-HAP (15%-60% w/v), and 






































    
Figure 2.6A-B: Swelling ratio of A) CS-HAP and B) HA-HAP gels plotted versus HAP Φ.  Data 
sets represent GAG:HAP ratios (w:w) compared to pure HAP. No swelling change was desired (S 
≈ 0), and success criteria for the gels were established by setting swelling tolerances (dashed lines; 
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Figure 2.7A-F: Trends in modeled H-B fluid parameters for K (A, B), n (C, D), and τy (E, F) plotted 







Figure 2.8A-D: Examples of shear stress and viscosity profiles of CS 15% - HAP 60% (A, C) and 
HA 15% - HAP 60% (B, D) colloidal gels (circles) compared to pure components GAG 15% 
(squares) and HAP 60% (triangles). Displayed solid trend lines were calculated using a three-
parameter fit to the H-B fluid model, and individual data points represent experimental average ± 
SD from triplicate studies. Dashed lines represent the H-B fit of experimental data from the 






Figure 2.9A-B: Ternary diagrams (weight %) for A) CS-HAP and B) HA-HAP colloidal mixtures 
identifying overlay of desirable regions of rheological yield (dotted line), shear-response (dashed 
line), and swelling properties (dot-dashed line). Images of extruded mixtures (via 21-gauge needle) 
of C) Pure CS (15%), D) CS-HAP (15-60%), E) Pure HAP (60%), F) HA-HAP (15-60%), and G) 






Figure 2.10A-D: Viscoelastic recovery profiles of CS 15% - HAP 60% (A, C) and HA 15% - HAP 
60% (B, D) gels (circles) were compared to pure components, GAG 15% (squares) and HAP 
(triangles) 60%. G′ (solid symbols), G″ (not shown), and δ (open symbols) were measured every 
3 seconds (n = 5) following a high oscillatory disruption phase. Recovery was assessed relative to 
a baseline low oscillatory stress profile for each group (dashed lines).  
























































Figure 2.11: Schematic depicting the formulation parameters and rheological fluid properties of 






Figure 3.1: Both IM and EC ossification occur during the bone healing process in three overlapping 
regeneration phases. Critical-sized bone defects favor EC ossification over direct IM ossification 
primarily due to the large, avascular nature of these defects. Four ECM based biomaterial strategies 
(boxes) are highlighted with regard to bone regeneration. The intermediate fibrocartilaginous ECM 
remains underexplored (**) as a strategy to potentially enhance quality and extent of EC 







Figure 3.2: Current landscape of EC ossification strategies (blue boxes) along with underexplored 
design space (dashed outlines) highlighted in this review. Some combined cell and material 
strategies are not shown explicitly (dashed arrows). This includes several in vitro priming studies 
that utilized cell and material approaches (**) and is further explored elsewhere (Table 3.2-3.4). 
All strategies will be critically evaluated with regard to technical, regulatory, and commercial 
challenges. ABG = Autologous Bone Grafting; ADSCs = Adipose Derived Stem Cells; BMA = 
Bone Marrow Aspirate; DBM = Demineralized Bone Matrix; DCC = Decellularized Cartilage; 





Figure 3.3: Top-down approaches to mimic native ECM tissue require less processing before 
implantation and retain more of the ECM’s physicochemical composition, structure and function 















































Figure 4: Schematic depicting the formulation parameters and rheological fluid properties of HA-




































Figure 4.1: SEM images of sieved (< 350 µm) ECM microparticles A) DBM and B) DCC as 
well as C) HAP nanoparticles. Scale bars for images A and B were (100 μm) and for image C 
(500 nm). 
 




Figure 4.2: Swelling ratio (S) of HA-HAP gels plotted versus HAP Φ. Data sets represent colloids 
comprised of different molecular weight HA (35, 350, and 1500 kDa) compared to pure HAP. No 
swelling change was desired (S-ratio ≈ 0), and success criteria for the gels were established by 
setting S-ratio tolerances (dashed lines; 0 ± 20%). Individual points are reported (average ± SD) 







































Figure 4.3: LVE region viscoelastic properties from controlled stress sweeps (1-10,000 Pa) at 
constant frequency (1 Hz) of HA-HAP colloids composed of 35 kDa (10% w/v), 350 kDa (3% 
w/v), and 1500 kDa (1% w/v) HA polymers and compared to HAP and HA control fluids, 
respectively. Averaged values for G′, G″, and τy (Pa) are displayed from triplicate studies. Error 





Figure 4.4 A-C: A) Viscoelastic G′Recovery profiles of HA-HAP colloids composed of 35 kDa 
(10% w/v), 350 kDa (3% w/v), and 1500 kDa (1% w/v) HA polymers and compared to HAP and 
HA control fluids, respectively. Measurements were made every 10 seconds during four 
alternating rounds of intense disruption (30 s, 1000 Pa, 1 Hz) and recovery (5 min, low stress in 
LVE regime, 1 Hz) oscillatory time sweeps at 37°C. B) Average δ (°) value of oscillatory 
recovery and disruption sweeps, and C) average G′Recovery (%) following 5 minutes of recovery 



































































Figure 4.5: LVE region viscoelastic properties from controlled stress sweeps (1-10,000 Pa) at 
constant frequency (1 Hz) of HA-ECM suspensions and HA-HAP-ECM colloids compared to 
HA, HAP, and HA-HAP control fluids, respectively. HA-HAP-DBM colloids (ΦDBM ≥ 30%) 
exhibited incomplete hydration, fractured when tested with the rheometer, and thus could not be 
measured. Averaged values for G′, G″, and τy (Pa) are displayed from triplicate studies. Error 












Figure 4.6 A-C: A) Viscoelastic G′Recovery profiles of HA-ECM suspensions and HA-HAP-ECM 
colloids compared to HA, HAP, and HA-HAP control fluids, respectively. Measurements were 
made every 10 seconds during four alternating rounds of intense disruption (30 s, 1000 Pa, 1 Hz) 
and recovery (5 min, low stress in LVE regime, 1 Hz) oscillatory time sweeps at 37°C. B) Average 
δ (°) value of oscillatory recovery and disruption sweeps, and C) average G′Recovery (%) following 




















HA-DCC (Φ = 0.15)
HA-DBM (Φ = 0.15)
HA-HAP (Control)
















































Figure 4.7 A-C: A) All tested HA-ECM and HA-HAP-ECM fluids could readily be loaded into 1 
ml syringes and subsequently be extruded through 18-gauge needles. Colloidal ECM formulations 
could be shaped B) during extrusion and C) maintained form following handling. HA-HAP-DBM 








Figure 5.1: One week cell attachment (Day 1) and viability (Day 7) study comparing DCC treated 
cells to control media, chondrogenic media (TGF-β), and DVC. Initial seeding density was 
500,000 cells/well. Overall DNA mass significantly increased for all groups from day 1 to day 7 
(* = p < 0.05; ** = p < 0.01) (n = 6). DCC exhibited significantly higher DNA than DVC (Day 1) 
(d = p < 0.05; D = p < 0.01) and compared to control (Day 7) (a = p < 0.05; A = p < 0.01) and 
DVC groups. No significant difference was observed between DCC and TGF-β (b = p < 0.05; B = 





























Figure 5.2: Endochondral gene expression profiles of BMSCs treated with DCC compared to 
control media, chondrogenic media (TGF-β), and DVC averaged over a one week span (Day 1, 3, 
and 7) (n = 15). DCC exhibited significantly higher expression for all tested genes compared to 
control media (a = p < 0.05; A = p < 0.01), TGF-β (b = p < 0.05; B = p < 0.01), and DVC (d = p < 
0.05; D = p < 0.01) with the exception of Col1A1 expression compared to TGF-β. DCC, DVC, and 
TGF-β all exhibited significantly higher Sox9 expression relative to RunX2 (p < 0.01).      Values 










































Figure 5.3: One week cell attachment (Day 1) and viability (Day 7) study comparing the effects of 
HA, HAP, and DCC compared to control media. Initial seeding density was 95,000 cells/well. 
Overall DNA mass was statistically equivalent or significantly higher for all groups from day 1 to 
day 7 (* = p < 0.05; ** = p < 0.01) (n = 6). DCC treated groups exhibited significantly higher DNA 
mass at Day 1 and Day 7 compared to control media (a = p < 0.05; A = p < 0.01), HA (b = p < 
0.05; B = p < 0.01), HAP (d = p < 0.05; D = p < 0.01), and HA-HAP (e = p < 0.05; E = p < 0.01). 





























Figure 5.4: Three week cell attachment (Day 1) and viability (Day 7, 14, and 21) study comparing 
the effects of HAP, DCC, and DBM compared to control media. Initial seeding density was 1x106 
cells/well (n = 6). Overall DNA mass for each group was compared to Day 1 (* = p < 0.05; ** = 
p < 0.01). Only DBM loaded groups exhibited DNA increase over 21 days. All groups exhibited 
significantly lower DNA mass compared to control media on a treated culture plate (a = p < 0.05; 
A = p < 0.01) except for HA-DBM at day 21. Values represent averages ± 95% confidence 












































Figure 5.5: Endochondral gene expression profiles comparing the effects of DCC, DBM, and HAP 
to control media. Values represent averages ± 95% confidence intervals taken two weeks (Day 14) 
after initial cell seeding (n = 5). Poor RNA isolation from various groups prevented RT-qPCR data 
from being obtained on days 1, 7, and 21. HA-DCC exhibited significantly higher expression of 
Sox9 and Runx2 and significantly lower Acan expression compared to control media (a = p < 0.05; 
A = p < 0.01), suggesting that cells may be undergoing intermediate hypertrophic changes. HA-
DBM exhibited significantly higher Col1A1 and BSP expression compared to control media, 
indicating that cells might be osteogenic. The presence of HAP in both HA-HAP-DCC and HA-
HAP-DBM also appeared to direct cells toward an osteogenic lineage compared to control.  
 
 

































Figure 5.6: Gross anatomy images of rat calvarial defects harvested 8 weeks post-operation 
performed with a trephine (D = 8 mm). Images are inferior views of the defect space following 
dermal tissue (superior to defect) and brain tissue (inferior to defect) removal. Images are backlit 
to aid visualization of the defect site, and the resulting visual image was mirrored to match the 
superior view MicroCT images. The dotted line represents an estimation of the original defect site 





Figure 5.7: MicroCT images of rat calvarial defects performed with a trephine (D = 8 mm) and 
harvested 8 weeks post-operation. Images are superior views of the defect space and are virtually 
rendered using a shaded surface display (SSD) visualization mode. Threshold values for virtual 
surfaces were constant across all samples. The dotted line represents an estimation of the original 
defect site (D = 8 mm). The scale bar for all images was 5 mm. 




Figure 5.8: MicroCT images of rat calvarial defects performed with a trephine (D = 8 mm) and 
harvested 8 weeks post-operation. Images are superior views of the defect space and are virtually 
rendered using a volume rendering technique (VRT) visualization mode. Color and transparency 
mapping of virtual surfaces was controlled with a transfer function in the software (Xradia 
TXM3DViewer), which was held constant across all samples. The dotted line represents an 





Figure 5.9: H&E and Saf-O/Fast Green histological images of rat calvarial defects corresponding 
to previous gross anatomy and MicroCT images (Trial 1). Images are sagittal cross-sections of the 
border between the defect space and native bone with left-to-right orientation representing inferior-
to-superior direction. All treatment groups including sham exhibited areas of newly ossified bone, 
but no relative comparisons were made with histological analysis. B = native bone, C = colloidal 
implant material, CT = connective tissue, F = fibrous tissue, NB = new bone. The scale bar for all 
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